Note: Descriptions are shown in the official language in which they were submitted.
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
NOTCH PATHWAY INHIBITION
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of priority of US Provisional Application
No.
62/089,425, filed December 9, 2014, and US Provisional Application No.
62/023,554, filed
July 11, 2014, each of which is incorporated by reference herein in its
entirety for any purpose.
SEQUENCE LISTING
This application contains a Sequence Listing which has been submitted via EFS-
Web
and is hereby incorporated by reference in its entirety. Said ASCII copy,
created July 8, 2015,
is named 2015-07-09_01146-0036-00PCT_seq_listing.txt and is 370,446 bytes in
size.
FIELD OF THE INVENTION
The present invention relates to Notch pathway inhibition.
BACKGROUND
The Notch signaling pathway regulates a diverse array of cell functions (Kopan
et al.,
Cell 137, 216-233 (2009)). Four Notch receptors have been identified in
mammals, i.e., Notch
1-4, that share basic structural elements that include an extracellular
domain, a trans membrane
domain, and an intracellular domain. Similarly, the canonical ligands of Notch
share certain
structural similarities but a number of non-canonical ligands of Notch have
also been identified
(Kopan et al., Cell 137, 216-233 (2009)). The five canonical ligands in
mammals are Delta-
like 1, Delta-like 3, Delta-like 4, Jaggedl and Jagged2. Binding of a Notch
ligand to the
extracellular domain of a Notch receptor sets a signaling cascade in motion
that begins with
proteolytic cleavage at the extracellular S2 site by an alpha secretase of the
ADAM (a
disintegrin and metalloprotease) family. Cleavage at S2 is followed by
proteolytic cleavage by
a gamma secretase at the intracellular S3 site, which results in release of
the intracellular
domain and downstream events that ultimately activate Notch-dependent
transcription factors
such as Hes 1 and Hey.
Because aberrant Notch expression and signaling has been implicated in a
number of
diseases, including cancer (Koch et al., Cell. Mol. Life Sci. 64, 2746-2762
(2007)), modulators
of Notch signaling have been investigated as possible therapeutic agents for
such diseases. For
1
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
example, gamma secretase inhibitors have been tested in clinical trials for
their effectiveness in
treating various malignancies (Shih et al, Cancer Res.67 , 1879-1882 (2007)).
Gamma
secretase inhibitors prevent cleavage at S3 and thereby prevent signaling
through Notch
receptors. However, gamma secretase inhibitors do not distinguish individual
Notch family
members and therefore inhibit signaling through multiple receptors at once, as
well as through
unrelated pathways (Bed l et al., Cell. Mol. Life Sci. 65,1311-1334 (2008)).
Moreover,
administration of gamma secretase inhibitors is associated with intestinal
toxicity marked by
weight loss and intestinal goblet cell metaplasia, indicative of a role for
Notch in determining
cell fate by maintaining proliferation of intestinal crypt progenitor cells
and prohibiting
differentiation to a secretory cell fate (see van Es et al., Nature 435:959-
963 (2005)).
Similarly, inhibition of both Notchl and Notch2 signaling via conditional
Notch gene knockout
(Riccio et al., EMBO Rep. 9:377-383 (2008)) or via antagonist antibody
inhibition (US Patent
Application Publication No. 2010/0080808) also causes intestinal goblet cell
metaplasia.
The mouse intestinal epithelium provides an important model for studying
tissue
regeneration. Continuous turnover of the epithelium is supported by intestinal
stem cells (IS Cs)
located near the base of the crypts. Genetic lineage tracing studies have led
to the identification
of distinct ISC populations, including crypt base columnar cells (CBCs) that
are marked by
Lgr5 expression, a Wnt target gene (Barker, van Es et al. 2007). CBCs reside
at the bottom of
crypts, occupying cell positions +1 through +5 from the base, where they are
intercalated
between post-mitotic Paneth cells, which constitute the stem cell niche (Sato,
van Es et al.
2011). CBCs contribute to all intestinal cell types, including the secretory
and absorptive
lineages, through a population of rapidly proliferating intermediates known as
transit-
amplifying (TA) cells (Barker, van Es et al. 2007). Continuous replacement and
sloughing of
old cells leads the intestinal epithelium to renew approximately every 5 days.
Development of the small intestine and adult intestinal homeostasis requires
canonical
Wnt signaling. LefITcf4, the transcription factor that mediates canonical Wnt
signaling, is
essential for the formation of proliferative compartments in prospective crypt
regions of
neonatal mice (Korinek, Barker et al. 1998). Lef/Tcf4 is also required for
adult intestinal
homeostasis (van Es, Haegebarth et al. 2012), as is the Wnt effector P-catenin
(Fevr, Robine et
al. 2007). Conversely, administration of the Wnt signaling agonist R-spondinl
leads to
expansion of the ISC compartment (Yan, Chia et al. 2012), which can mitigate
loss of ISCs
during chemoradiation (Zhou, Geng et al. 2013). In adult animals, the central
role of Wnt
signaling is highlighted by the Wnt-dependent expression of numerous ISC
markers, including
Lgr5. (de Lau, Barker et al. 2011). In addition to its role in maintaining
ISCs, Wnt signaling
2
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
confers competence for the secretory fate decision. Wnt signaling plays
specific roles in Paneth
cell differentiation (Andreu, Colnot et al. 2005; van Es, Jay et al. 2005;
Andreu, Peignon et al.
2008; van Es, Haegebarth et al. 2012), whereas overexpression of the Wnt
inhibitor DKK1
leads to loss of all secretory cells (Pinto, Gregorieff et al. 2003).
The Notch pathway affects intestinal homeostasis by regulating CBCs and by
promoting the absorptive cell fate. Compromising Notch signaling in adult mice
with the 7-
secretase inhibitor DAPT, which blocks the conversion of the Notch receptor
into its
transcriptionally active state, causes a loss of proliferating Lgr5-positive
CBCs and an overall
increase in secretory cells (VanDussen, Carulli et al. 2012). Secretory cell
hyperplasia in the
gut also occurs with deletion of the Notch effector Rbp-j (van Es, van Gijn et
al. 2005;
VanDussen, Carulli et al. 2012). Conversely, the activation of constitutive
Notch signaling in
the small intestine of perinatal mice causes an expansion of the proliferative
compartment as
well as a decrease in the number of secretory cells (Fre, Huyghe et al. 2005;
Stanger, Datar et
al. 2005). Genetic evidence suggests that Notch signaling exerts its negative
regulatory effect
on secretory cell differentiation entirely through repression of Mathl/Atohl ,
a transcription
factor required for the formation of secretory cells (Yang, Bermingham et al.
2001), as
conditional deletion of Math] rescues the Rbp-j loss of function phenotype
(Kim and
Shivdasani 2011). However, while Math] is up-regulated in the absence of Notch
(VanDussen,
Carulli et al. 2012), the signal(s) required for positively maintaining normal
levels of Math] in
the small intestine are unknown.
There is a need in the art for anti-Notch pathway therapeutic regimens that
lack the
toxicity associated with inhibition of Notch receptors.
SUMMARY
In some embodiments, methods of alleviating toxicity associated with Notch
pathway
inhibition are provided. In some embodiments, a method comprises administering
to an
individual being treated with a Notch pathway inhibitor an effective amount of
at least one Wnt
pathway inhibitor. In some embodiments, the Wnt pathway inhibitor is
administered after the
individual has been administered at least one dose of a Notch pathway
inhibitor. In some
embodiments, the Wnt pathway inhibitor is administered at the same time that
the individual is
administered a Notch pathway inhibitor. In some embodiments, the Wnt pathway
inhibitor is
administered before the individual is administered a Notch pathway inhibitor.
In some
embodiments, the toxicity comprises one or more of secretory metaplasia, liver
toxicity, lung
toxicity, heart toxicity, subcutaneous tumors, and thymic atrophy. In some
embodiments, the
3
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
toxicity comprises diarrhea or gastrointestinal bleeding or both. In some
embodiments,
administration of at least one Wnt pathway inhibitor alleviates the diarrhea
or gastrointestinal
bleeding or both. In some embodiments, the liver toxicity comprises one or
more of sinusoidal
dilation, centrilobular hepatocyte atrophy, bile ductula proliferation, and
elevated alanine
aminotransferase. In some embodiments, the heart toxicity and/or lung toxicity
comprises
necrotic lesions.
In some embodiments, methods of treating cancer are provided, comprising
administering to an individual with cancer an effective amount of at least one
Notch pathway
inhibitor and an effective amount of at least one Wnt pathway inhibitor. In
some
embodiments, the method results in reduced toxicity compared to toxicity
observed with the at
least one Notch pathway inhibitor alone. In some embodiments, the cancer is
selected from
breast cancer, lung cancer, brain cancer, cervical cancer, colon cancer, liver
cancer, bile duct
cancer, pancreatic cancer, skin cancer, B-cell malignancies, and T-cell
malignancies.
In some embodiments, the Notch pathway inhibitor is a gamma-secretase
inhibitor. In
some embodiments, the Notch pathway inhibitor inhibits at least one protein
selected from
Notchl, Notch2, Notch3, Notch4, DLL1, DLL4, Jaggedl, and Jagged2.
In some embodiments, the Notch pathway inhibitor inhibits at last two proteins
selected
from Notch 1, Notch2, Notch 3, and Notch 4. In some embodiments, the Notch
pathway
inhibitor inhibits Notchl and Notch2. In some embodiments, the Notch pathway
inhibitor
inhibits Notch 2 and Notch 3. In some embodiments, the Notch pathway inhibitor
is an anti-
Notch antibody. In some embodiments, the anti-Notch antibody is an anti-Notch
NRR
antibody. In some embodiments, the anti-Notch antibody binds to the EGF-like
repeat domain
of Notch. In some embodiments, the anti-Notch antibody is selected from:
a) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 35 to 40, respectively;
b) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 33 and 34, respectively;
c) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 27 to 32, respectively;
d) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 25 and 26, respectively;
e) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 43, 46, 48, 49, 50, and 53, respectively;
4
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
f) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 41 and 42, respectively;
g) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 58 to 60, 64, 67, and 71, respectively;
h) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 55 and 56, respectively;
i) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 74, 75, 77, and 79-81, respectively; and
j) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 72 and 73, respectively
k) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 243 to 248, respectively; and
1) an antibody comprising a heavy chain variable region and a
light chain variable
region shown in SEQ ID NOs: 241 and 242, respectively.
In some embodiments, the antibody is a monoclonal antibody. In some
embodiments, the
antibody is a human, humanized, or chimeric antibody.
In some embodiments, the Notch pathway inhibitor inhibits at least one protein
selected
from Jaggedl and Jagged2. In some embodiments, the Notch pathway inhibitor
inhibits
Jaggedl and Jagged2. In some embodiments, the Notch pathway inhibitor is an
anti-Jagged
antibody. In some embodiments, the anti-Jagged antibody is selected from:
a) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 108-113, respectively;
b) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 106 and 107, respectively;
c) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 116-121, respectively;
d) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 114 and 115, respectively;
e) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 124-129, respectively;
f) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 122 and 123, respectively;
g) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 130 and 131, respectively;
5
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
h) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 134-139, respectively;
i) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 132 and 133, respectively;
j) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 142-147, respectively;
k) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 140 and 141, respectively;
1) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 150-155, respectively;
m) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 148 and 149, respectively;
n) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 158-163, respectively;
o) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 156 and 157, respectively;
p) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 166-171, respectively;
q) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 164 and 165, respectively;
r) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 174-179, respectively;
s) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 172 and 173, respectively;
t) an antibody comprising an HVR-H1 of SEQ ID NO: 258, and HVR-H2 selected
from SEQ ID NOs: 259 and 260, and HVR-H3 of SEQ ID NO: 261, and HVR-
Ll of SEQ ID NO: 262, and HVR-L2 selected from SEQ ID NOs: 263 to 266;
and an HVR-L3 of SEQ ID NO: 267;
u) an antibody comprising a heavy chain variable region selected from SEQ ID
NOs: 273 to 277 and a light chain variable region selected from SEQ ID NOs:
268 to 272;
v) an antibody comprising an HVR-H1 of SEQ ID NO: 278, and HVR-H2 selected
from SEQ ID NOs: 279 to 281, and HVR-H3 of SEQ ID NO: 282, and HVR-L1
6
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
selected from SEQ ID NOs: 283 ad 284, and HVR-L2 selected from SEQ ID
NOs: 285 to 287; and an HVR-L3 selected from SEQ ID NOs: 288 and 289; and
w) an antibody comprising a heavy chain variable region selected from SEQ ID
NOs: 295 to 299 and a light chain variable region selected from SEQ ID NOs:
290 to 294.
In some embodiments, the antibody is a monoclonal antibody. In some
embodiments, the
antibody is a human, humanized, or chimeric antibody.
In some embodiments, the Notch pathway inhibitor inhibits at least one protein
selected
from DLL1 and DLL4. In some embodiments, the Notch pathway inhibitor is an
anti-DLL
antibody. In some embodiments, the anti-DLL antibody is an anti-DLL4 antibody.
In some
embodiments, the anti-DLL antibody is an antibody selected from:
a) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 182-187, respectively;
b) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 180 and 181, respectively;
c) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 190-195, respectively;
d) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 188 and 189, respectively;
e) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 251-256, respectively; and
f) an antibody comprising a heavy chain variable region and a
light chain variable
region shown in SEQ ID NOs: 249 and 250, respectively.
In some embodiments, the antibody is a monoclonal antibody. In some
embodiments, the
antibody is a human, humanized, or chimeric antibody. In some embodiments, the
anti-DLL
antibody is a bispecific antibody. In some embodiments, the anti-DLL antibody
binds to DLL4
and VEGF.
In some embodiments, the Wnt pathway inhibitor inhibits at least one protein
selected
from a Wnt, an LRP, and a Fzd. In some embodiments, the Wnt pathway inhibitor
inhibits
LRP5, LRP6, or both LRP5 and LRP6. In some embodiments, the Wnt pathway
inhibitor is an
anti-LRP antibody. In some embodiments, the anti-LRP antibody is selected
from:
a) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 198-203, respectively;
7
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
b) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 196 and 197, respectively;
c) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 206-211, respectively;
d) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 204 and 205, respectively;
e) a bispecific antibody comprising a first half antibody comprising HVR-H1,
HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 shown in SEQ ID NOs:
198-203, respectively, and a second half antibody comprising HVR-H1, HVR-
H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 shown in SEQ ID NOs: 206-
211, respectively;
f) a bispecific antibody comprising a first half antibody comprising a
heavy chain
variable region and a light chain variable region shown in SEQ ID NOs: 196
and 197, respectively, and a second half antibody comprising a heavy chain
variable region and a light chain variable region shown in SEQ ID NOs: 204
and 205, respectively;
g) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 220 and 221, respectively;
h) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 214-219, respectively; and
i) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 212 and 213, respectively.
In some embodiments, the antibody is a monoclonal antibody. In some
embodiments, the
antibody is a human, humanized, or chimeric antibody.
In some embodiments, the Wnt pathway inhibitor inhibits at least one Fzd. In
some
embodiments, the Wnt pathway inhibitor is an anti-Fzd antibody. In some
embodiments, the
anti-Fzd antibody is an antibody selected from:
a) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 224-229, respectively;
b) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 222 and 223, respectively
c) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 232-237, respectively; and
8
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
d) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 230 and 231, respectively.
In some embodiments, the antibody is a monoclonal antibody. In some
embodiments, the
antibody is a human, humanized, or chimeric antibody.
In some embodiments, the Wnt pathway inhibitor inhibits at least one R-spondin
(RSPO). In some embodiments, the Wnt pathway inhibitor is an anti-RSPO
antibody. In some
embodiments, the anti-RSPO antibody is selected from:
a) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 300-305, respectively;
b) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 306 and 307, respectively;
c) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 308-313, respectively;
d) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 314 and 315, respectively;
e) an antibody comprising HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and
HVR-L3 shown in SEQ ID NOs: 316-321, respectively; and
f) an antibody comprising a heavy chain variable region and a light chain
variable
region shown in SEQ ID NOs: 322 and 323, respectively.
In some embodiments, the antibody is a monoclonal antibody. In some
embodiments, the
antibody is a human, humanized, or chimeric antibody.
In some embodiments, the Wnt pathway inhibitor is a soluble Fzd. In some
embodiments, the soluble Fzd comprises an Fzd extracellular domain and an Fc.
In some
embodiments, the soluble Fzd is a soluble Fzd8. In some embodiments, the
soluble Fzd8
comprises the sequence of SEQ ID NO: 240 or SEQ ID NO: 257. In some
embodiments, the
soluble Fzd consists the sequence of SEQ ID NO: 240 or SEQ ID NO: 257.
In some embodiments, the Wnt pathway inhibitor inhibits at least one Wnt. In
some
embodiments, the Wnt pathway inhibitor is an anti-Wnt antibody. In some
embodiments, the
antibody is a monoclonal antibody. In some embodiments, the antibody is a
human,
humanized, or chimeric antibody.
In some embodiments, the Wnt pathway inhibitor is a small molecule. In some
embodiments, the Wnt pathway inhibitor is selected from LGK974 (2-(2',3-
dimethy142,4'-
bipyridin1-5-y1)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide), AVN316 (Avalon
Pharmaceuticals), and PRI-724 (Prism Pharma Co.).
9
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1A-F. Distribution of Wnt and Notch signaling in crypts of the mouse
small
intestine. (A) Wnt signaling is active in crypt base columnar cells (CBCs).
Lgr5GFP (green)
and Axin2Lacz (red) expression are co-incident in CBCs (arrows). (B) Wnt
signaling is present
in proliferating CBCs and transit amplifying (TA) cells. Axin2Lacz (red)
expression overlaps
with EdU incorporation (green) in cells at the base of the crypt (arrows) and
in TA cells
(asterisks) adjacent to CBCs. (C) Wnt signaling is present in secretory cell
progenitors.
Axin2Lacz expression (red) overlaps with secretory cell progenitors marked by
Math1GFP (green,
arrowheads). (D) Notch signaling is also present in CBCs as the active form of
Notchl (NICD,
red) is localized to the nuclei of CBCs (green, arrows). (E) Notch signaling
is present in
proliferating CBCs and TA cells. NICD (red) overlaps with Ki67 staining
(green) in CBCs
(arrows) and TA cells. (F) Notch signaling (red) is absent from secretory
progenitor cells
(green).
FIG. 2A-0. Loss of Notch signaling perturbs the function of Lgr5-positive stem
cells.
(A) Control crypts show a normal distribution of NICD staining in CBCs and TA
cells. (B)
Combined treatment with anti-Notchl and anti-Notch2 blocking antibodies
(aN1/N2)
effectively down-regulates Notch signaling. NICD immunostaining is absent from
crypts that
were treated with aN1/N2 over 6 days. (C) Control crypts show a normal
distribution of
Lgr5GFP expression in proliferating CBCs and a subset of TA cells (arrows).
(D) Notch
blockade causes an increase in Lgr5GFP expression (green) and a decrease in
proliferating cells
(red) in the TA zone. (E) Lgr5-positive CBCs (green) are largely non-
overlapping with
lysozyme-positive Paneth cells (red). (F) Notch blockade causes secretory cell
hyperplasia.
Increased Lysozyme expressing cells (red) are present after 6 days aN1/N2
treatment. (G)
Control crypts showing distribution of Wnt signaling (Axin2Lacz, red) and
secretory cell
progenitors (Math1GFP , green). (H) Wnt attenuation with anti-LRP6 (aLRP6)
blocking
antibody inhibits secretory cell differentiation. aLRP6 treatment down-
regulates Axin2Lacz (red)
and Math1GFP (green). (I) Control crypts showing Lgr5GFP expression (green)
and proliferating
Ki67-positive cells (red). (J) Wnt attenuation with aLRP6 blocking antibody
down-regulates
Lgr5GFP expression (absence of green staining) without affecting proliferating
CBCs (red,
arrows). (K) Lineage tracing experiments using Lgr5c"ER4;RosaRFP/ mice show
widespread
labeling of crypts and villi 7 days post induction with Tamoxifen (TAM). (L)
Treatment with
aN1/N2 before and after induction with TAM causes decreased lineage tracing
from Lgr5-
positive cells. (M) Lgr5-positive stem cells were first induced to undergo
recombination with
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
TAM and then treated with aN1/N2 on days 1 and 4. (N) aLRP6 treatment causes a
loss of
lineage tracing from Lgr5-positive cells if provided before induction with
TAM. (0) aLRP6
treatment does not affect lineage tracing if provided after induction with
TAM.
FIG. 3A-H. Lgr5 expression is initially suppressed by Notch blockade and is re-
established over time. (A) In situ hybridization showing Lgr5 mRNA
distribution in control
intestine. (B) Lgr5GFP (green) expression in control intestine. (C) Lgr5 mRNA
is absent 7
hours post Notch blockade. (D) Lgr5GFP is absent 7 hours post Notch blockade.
(E) Lgr5
mRNA is absent 24 hours post Notch blockade. (F) Lgr5GFP is absent 24 hours
post Notch
blockade. (G) Lgr5 mRNA in crypts recovers 3 days post Notch blockade. (H)
Lgr5GFP in
crypts recovers 3 days post Notch blockade.
FIG. 4A-E. The Notch target gene and ISC marker Olfm4 is sensitive to Notch
blockade but not Wnt signaling attenuation. (A) In situ hybridization showing
Olftn4 mRNA
distribution in control intestine. (B-D) Olfm4 gene expression is repressed by
Notch blockade.
(E) Olfm4 mRNA is unaffected by LRP6 blockade. (F) Olfm4 mRNA is repressed in
crypts
treated with combined Notch/LRP6 blockade.
FIG. 5A-Z-1. Notch blockade leads to Wnt signaling up-regulation. (A) Fold
changes
in gene expression relative to controls after antibody treatments. mRNA was
purified from
isolated crypts. Results are mean SEM. (B) Control crypts showing Axin2Lacz
staining (red).
(C) Combined Axin2Lacz (red) and MathIGFP (green) staining. (D) Control crypts
showing
expression of Lgr5GFP (green) and proliferating cells (Ki67, red). (E) Control
crypts showing
antibody staining of the Wnt targets SOX9 (red) and EPHB3 (green) at the base
of the crypt.
(F) 7 hour timepoint during Notch blockade shows an increase in the Wnt
reporter Axin2Lacz .
(G) 7 hour timepoint shows a normal distribution of MathIGFP relative to
controls. (H) At 7
hour timepoint during Notch blockade, Lgr5 positiveCBCs are still present
but have
stopped proliferating (arrows). (I) 7 hour timepoint during Notch blockade
shows increasing
intensity of SOX9-positive nuclei at the base of the crypt (red). (J) 24 hour
timepoint during
Notch blockade shows an increased in Axin2Lacz staining. (K) 24 hour timepoint
during Notch
blockade shows an increased distribution of MathIGFP staining (green). (L) At
24 hour
timepoint during Notch blockade, Lgr5GFP (green) and proliferating cells (red)
are largely
absent from the base of the crypt. (M) 24 hour timepoint during Notch blockade
shows
increased staining and distribution of the Wnt targets SOX9 and EPHB3. (N,O)
24 hour
timepoint during LRP6 blockade shows absence of Axin2Lacz (M, red) and loss of
MathIGFP
expression (N) in treated crypts. Arrows in (N) point to residual MathIGFP
expression at base
of crypt. (P) 24 hour timepoint during LRP6 blockade shows an absence of
Lgr5GFP (green)
11
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
and a normal distribution of Ki67 staining in CBCs (arrows). (Q) 24 hour
timepoint during
LRP6 blockade shows near complete down-regulation of the Wnt targets SOX9 and
EPHB3.
(R) 7 hour timepoint during combined Notch/LRP6 blockade shows a reduced
distribution of
Axin2Lacz relative to Notch blockade alone (E). (S) 7 hour timepoint during
combined
Notch/LRP6 blockade shows rescued of Math1GFP expression pattern. (T) 7 hour
timepoint
during combined Notch/LRP6 blockade shows a loss of Lgr5GFP expression and a
rescued
distribution of Ki67-positive cells at the base of the crypt. (U) 7 hour
timepoint during
combined Notch/LRP6 blockade shows the Wnt target genes Sox9 and EphB3 remain
down-
regulated. (V) 24 hour timepoint during combined Notch/LRP6 blockade shows
that Axin2Lacz
expression is reduced relative to (I). (W) 24 hour timepoint during combined
Notch/LRP6
blockade shows that Math1GFP expression is reduced relative to (J). (X) 24
hour timepoint
during combined Notch/LRP6 blockade shows a rescued distribution of Ki67-
positive cells
including CBCs (arrows). (Y) 24 hour timepoint during combined Notch/LRP6
blockade
shows the Wnt target genes Sox9 and EphB3 remain down-regulated. (Z) Relative
levels of
Wnt target gene expression in Villin Cre;Mathlfvfl mice treated with Notch
blocking antibodies.
(Z-1) Levels of Wnt5a, Wnt9b, and Rspo4 increase in Villin Cre;Mathlfvfl mice
treated with
Notch blocking antibodies.
FIG. 6A-D. CBCs convert to secretory cells during Notch blockade. (A) RFP-
positive
cells derived from Lgr5 expressing cells during Notch blockade. (B) Overlap of
RFP-positive
cells and Lysozyme expressing secretory cells (green) merged panels) when
aN1/N2 is injected
before induction with Tamoxifen. (C) RFP-positive cells derived from Lgr5
expressing cells
during Notch blockade. (D) Overlap of RFP-positive cells and Lysozyme
expressing secretory
cells (green) merged panels) when aN1/N2 is injected after induction with
Tamoxifen.
FIG. 7A-I. Co-treatment with Notch and Wnt blocking antibodies rescues
secretory cell
metaplasia and ISC activity. (A) Control ileum showing proliferating cells
(Ki67, brown) and
Alcian Blue stained Goblet cells. (B) Notch blockade causes goblet cell
metaplasia. Increased
presence of Alcian Blue stained goblet cells in the crypts is coincident with
a loss of
proliferating cells. (C) aLRP6 treatment leads to no significant changes in
the distribution of
Goblet cells or proliferating cells. (D) Combined aN1/N2 and aLRP6 treatment
rescues the
proliferation defects and Goblet cell metaplasia associated with Notch
blockade alone. (E)
Lineage tracing experiments using Lgr5C"ER/ ;RosaRFP/ mice with fully
labeled crypts and
villi 7 days post induction with Tamoxifen (TAM). Inset shows expression of
Lgr5GFP at crypt
base. (F) Combined aN1/N2 and aLRP6 treatment rescues stem cell activity, as
indicated by a
recovery of lineage tracing events from Lgr5-positive stem cells. Inset shows
representative
12
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
fully labeled crypt with suppressed Lgr5GFP expression. (G) Notch blockade
causes goblet cell
metaplasia. (H) Combined aN1/N2 and FZD8CRD treatment rescues the
proliferation defects
and Goblet cell metaplasia. (I) Survival curve for aN1/N2 animals (brown line)
and aN1/N2 +
FZD8CRD animals (green line).
FIG. 8A-R. Treatment with FZD8CRD represses Wnt signaling and secretory cell
differentiation, and D114 expression correlates with increased secretory cell
differentiation. (A)
Control crypts showing normal distribution of Axin2Lacz. (B) Control crypts
showing normal
distribution of Math1GFP. (C) Notch blockade at the 24 hour timepoint shows an
increase in
Axin2Lacz. (D) Notch blockade at the 24 hour timepoint shows an increase in
Math1GFP(merged channels). (E) FZD8CRD treatment represses Axin2Lacz and Mathl
expression. (F) FZD8CRD treatment represses Math1GFP(merged panels). (G) Co-
treatment
with aN1/N2 and FZD8CRD restores Axin2Lacz (merged panels) to patterns
approximating
controls. (H) Co-treatment with aN1/N2 and FZD8CRD restores and Math1GFP
(merged
panels) to patterns approximating controls. (I) Control crypts showing D114
(green) and Mathl
(red) in secretory progenitor cells. (J) Control crypts showing D114 (green)
and Axin2Lacz (Wnt
signaling, red) are co-expressed. (K) Notch blockade at the 7 hour timepoint
shows an increase
in Mathl that extends beyond the crypt/villus junction (red, asterisks). (L)
Notch blockade at
the 7 hour timepoint shows an increase in Axin2Lacz (Wnt signaling, red) that
is co-incident
with D114 staining (green). (M) Notch/LRP6 blockade at the 7 hour timepoint
shows increased
staining distribution of Mathl (red) and D114 (green). (N) Notch/LRP6 blockade
at the 7 hour
timepoint shows elevated levels of Axin2Lacz (red) co-incident with D114
(green). (0) Notch
blockade at the 24 hour timepoint shows a substantial increase in Mathl (red)
co-incident with
D114. (P) Axin2Lacz expression correlates with D114 and Mathl (shown in G).
(Q) Notch/LRP6
blockade rescues Mathl (red) and D114 expression (green) to normal levels by
24 hours (R)
Notch/LRP6 blockade rescues Axin2Lacz (red) and D114 (green) expression to
normal levels by
24 hours.
FIG. 9A-M. Wnt signaling up-regulation in Villin Cre;Mathl" mice. (A,B)
Lysozyme staining in WT duodenum (A) and WT duodenum treated with Notch
antibodies for 24 hours (B). (C) Defal levels in duodenum from treated (3 day
Notch antibody-
treated) and control Villin Cre;Mathl" mice relative to WT.
(D-F) SOX9 staining in duodenum from WT, untreated Villin Cre;Mathl" mice, and
Villin
Cre;Mathl" mice treated with Notch antibodies for 3 days. (H-J) Ki67 staining
in duodenum
from WT, untreated Villin Cre;Mathl" mice, and Villin Cre;Mathl" mice treated
with Notch
antibodies for 3 days. (K) Wnt isoform levels in Notch 3 day treated Villin
Cre;Mathl" mice
13
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
relative to untreated. (L) Rspondin1-3 levels Notch 3 day treated Villin
Cre;Mathlfvfl mice
relative to untreated. (M) Wnt5a, Wnt9b, and Rspo4 levels in Notch 3 day
treated WT mice
relative to WT untreated.
DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION
I. DEFINITIONS
An "acceptor human framework" for the purposes herein is a framework
comprising the
amino acid sequence of a light chain variable domain (VL) framework or a heavy
chain
variable domain (VH) framework derived from a human immunoglobulin framework
or a
human consensus framework, as defined below. An acceptor human framework
"derived
from" a human immunoglobulin framework or a human consensus framework may
comprise
the same amino acid sequence thereof, or it may contain amino acid sequence
changes. In
some embodiments, the number of amino acid changes are 10 or less, 9 or less,
8 or less, 7 or
less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some
embodiments, the VL acceptor
human framework is identical in sequence to the VL human immunoglobulin
framework
sequence or human consensus framework sequence.
"Affinity" refers to the strength of the sum total of noncovalent interactions
between a
single binding site of a molecule (e.g., an antibody) and its binding partner
(e.g., an antigen).
Unless indicated otherwise, as used herein, "binding affinity" refers to
intrinsic binding affinity
which reflects a 1:1 interaction between members of a binding pair (e.g.,
antibody and antigen).
The affinity of a molecule X for its partner Y can generally be represented by
the dissociation
constant (Kd). Affinity can be measured by common methods known in the art,
including
those described herein. Specific illustrative and exemplary embodiments for
measuring
binding affinity are described in the following.
An "affinity matured" antibody refers to an antibody with one or more
alterations in one
or more hypervariable regions (HVRs), compared to a parent antibody which does
not possess
such alterations, such alterations resulting in an improvement in the affinity
of the antibody for
antigen.
The term "alleviates" or "alleviation" as used herein, refers to a reduction
in a
condition, such as an adverse event or toxicity associated with Notch pathway
inhibition. A
condition is considered to be alleviated if the incidence or severity of the
condition is reduced
by at least 10%. In some embodiments, the incidence or severity of the
condition is reduced by
at least 15%, or at least 20%, or at least 25%, or at least 30%, or attest
35%, or at least 40%, or
at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least
90%.
14
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
The term "anti-Delta-like (DLL) antibody" and "antibody that binds Delta-like
(DLL)"
refer to an antibody that is capable of binding DLL1, DLL4, or DLL1 and DLL4
(DLL1/4) with
sufficient affinity such that the antibody is useful as a diagnostic and/or
therapeutic agent in
targeting DLL. In one embodiment, the extent of binding of an anti-DLL
antibody to an
unrelated, non-DLL protein is less than about 10% of the binding of the
antibody to DLL as
measured, e.g., by a radioimmunoassay (RIA). In certain embodiments, an
antibody that binds
to DLL has a dissociation constant (Kd) of < 1 ,M, < 100 nM, < 10 nM, < 1 nM,
< 0.1 nM,
<0.01 nM, or < 0.001 nM (e.g. 10-8M or less, e.g. from 10-8M to 10-13M, e.g.,
from 10-9M to
10-13 M). In certain embodiments, an anti-DLL antibody binds to an epitope of
Jagged that is
conserved among DLL from different species. The terms "anti-DLL1 antibody" and
"an
antibody that binds to DLL1" refer to an antibody that is capable of binding
DLL1 with
sufficient affinity such that the antibody is useful as a diagnostic and/or
therapeutic agent in
targeting DLL1. The terms "anti-DLL4 antibody" and "an antibody that binds to
DLL4" refer
to an antibody that is capable of binding DLL4 with sufficient affinity such
that the antibody is
useful as a diagnostic and/or therapeutic agent in targeting DLL4. The terms
"anti-DLL1/4
antibody" and "an antibody that binds to DLL1/4" refer to an antibody that is
capable of
binding DLL1 and DLL4 with sufficient affinity such that the antibody is
useful as a diagnostic
and/or therapeutic agent in targeting DLL1 and DLL4. In some embodiments, an
anti-DLL
antibody inhibits DLL activity. In some such embodiments, an anti-DLL antibody
may be
referred to as an antagonist anti-DLL antibody. Nonlimiting exemplary anti-DLL
antibodies
are described, e.g., in U.S. Patent No. 7,803,377; U.S. Publication No.
2010/0196385;
2014/0093521; 2013/0323248; and 2013/0164295.
The terms "anti-Jagged antibody" and "an antibody that binds to Jagged" refer
to an
antibody that is capable of binding Jagged 1, Jagged2, or Jaggedl and Jagged2
("Jagged1/2")
with sufficient affinity such that the antibody is useful as a diagnostic
and/or therapeutic agent
in targeting Jagged. In one embodiment, the extent of binding of an anti-
Jagged antibody to an
unrelated, non-Jagged protein is less than about 10% of the binding of the
antibody to Jagged
as measured, e.g., by a radioimmunoassay (RIA). In certain embodiments, an
antibody that
binds to Jagged has a dissociation constant (Kd) of < 1 ,M, < 100 nM, < 10 nM,
< 1 nM, < 0.1
nM, < 0.01 nM, or < 0.001 nM (e.g. 10-8M or less, e.g. from 10-8M to 10-13M,
e.g., from 10-9
M to 10-13 M). In certain embodiments, an anti-Jagged antibody binds to an
epitope of Jagged
that is conserved among Jagged from different species. The terms "anti-Jaggedl
antibody" and
"an antibody that binds to Jagged 1" refer to an antibody that is capable of
binding Jaggedl with
sufficient affinity such that the antibody is useful as a diagnostic and/or
therapeutic agent in
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
targeting Jaggedl. The terms "anti-Jagged2 antibody" and "an antibody that
binds to Jagged2"
refer to an antibody that is capable of binding Jagged2 with sufficient
affinity such that the
antibody is useful as a diagnostic and/or therapeutic agent in targeting
Jagged2. The terms
"anti-Jagged1/2 antibody" and "an antibody that binds to Jagged1/2" refer to
an antibody that is
capable of binding Jaggedl and Jagged2 with sufficient affinity such that the
antibody is useful
as a diagnostic and/or therapeutic agent in targeting Jaggedl and Jagged2. In
some
embodiments, an anti-Jagged antibody inhibits Jagged activity. In some such
embodiments, an
anti-Jagged antibody may be referred to as an antagonist anti-Jagged antibody.
Nonlimiting
exemplary anti-Jagged antibodies are described, e.g., in U.S. Publication No.
20140010810
(anti-Jagged1/2 antibodies); 2012/0301489; 2008/0317760; and PCT Publication
No.
2014/028446.
The term "anti-Notch antibody" or "an antibody that binds to Notch" refers to
an
antibody that is capable of binding one or more of Notch 1, Notch 2, Notch3,
and Notch4 with
sufficient affinity such that the antibody is useful as a diagnostic and/or
therapeutic agent in
targeting Notch. Preferably, the extent of binding of an anti-Notch antibody
to an unrelated,
non-Notch protein is less than about 10% of the binding of the antibody to
Notch as measured,
e.g., by a radioimmunoassay (RIA). In certain embodiments, an antibody that
binds to Notch
has a dissociation constant (Kd) of < 1 M, < 100 nM, < 10 nM, < 1 nM, or < 0.1
nM. In
certain embodiments, an anti-Notch antibody binds to an epitope of Notch that
is conserved
among Notch from different species, e.g., rodents (mice, rats) and primates.
The term "anti-
Notch antibody" includes anti-Notch NRR antibodies and antibodies that bind to
other regions
of Notch, such as the EGF-like repeat domain. In some embodiments, an anti-
Notch antibody
inhibits Notch activity. In some such embodiments, an anti-Notch antibody may
be referred to
as an antagonist anti-Notch antibody. The term "anti-Notch antibody" includes
anti-Notchl
antibodies, anti-Notch2 antibodies, anti-Notch3 antibody, and anti-Notch4
antibodies,
including antibodies that bind to more than one Notch.
The term "anti-Notchl antibody" or "an antibody that binds to Notch 1" refers
to an
antibody that is capable of binding Notchl with sufficient affinity such that
the antibody is
useful as a diagnostic and/or therapeutic agent in targeting Notchl.
Preferably, the extent of
binding of an anti-Notchl antibody to an unrelated, non-Notch protein is less
than about 10%
of the binding of the antibody to Notchl as measured, e.g., by a
radioimmunoassay (RIA). In
certain embodiments, an antibody that binds to Notchl has a dissociation
constant (Kd) of
<100 nM, < 10 nM, < 1 nM, or <0.1 nM. In certain embodiments, an anti-Notchl
antibody binds to an epitope of Notch that is conserved among Notch from
different species,
16
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
e.g., rodents (mice, rats) and primates. The term "anti-Notchl antibody"
includes anti-Notchl
NRR antibodies and antibodies that bind to other regions of Notch 1, such as
the EGF-like
repeat domain. In some embodiments, an anti-Notchl antibody inhibits Notch
activity. In
some such embodiments, an anti-Notchl antibody may be referred to as an
antagonist anti-
Notchl antibody. In some embodiments, an anti-Notchl antibody binds to Notchl
and at least
one other Notch, such as Notch2 and/or Notch3. Nonlimiting exemplary
antagonist anti-
Notchl antibodies are described, e.g., in U.S. Patent Nos. 8,404,237;
8,088,617; 8,435,513;
8,460,661; U.S. Publication Nos. 2013/0266594; 2012/0213786; 2011/0311552;
2009/0258026; 2012/0093813. Nonlimiting exemplary anti-Notchl antibodies that
bind the
EGF-like repeat domain are described, e.g., in U.S. Patent Nos. 8,088,617;
8,460,661;
8,404,237.
The term "anti-Notchl NRR antibody" or "an antibody that binds to Notchl NRR"
refers to an anti-Notchl antibody that is capable of binding Notchl NRR with
sufficient
affinity such that the antibody is useful as a diagnostic and/or therapeutic
agent in targeting
Notch 1. Preferably, the extent of binding of an anti-Notchl NRR antibody to
an unrelated,
non-Notch protein is less than about 10% of the binding of the antibody to
Notchl NRR as
measured, e.g., by a radioimmunoassay (RIA). In certain embodiments, an
antibody that binds
to Notchl NRR has a dissociation constant (Kd) of < 1 M, < 100 nM, < 10 nM, <
1 nM, or
< 0.1 nM. In certain embodiments, an anti-Notchl NRR antibody binds to an
epitope of Notch
that is conserved among Notch from different species, e.g., rodents (mice,
rats) and primates.
In some embodiments, an anti-Notchl NRR antibody inhibits Notch activity. In
some such
embodiments, an anti-Notchl NRR antibody may be referred to as an antagonist
anti-Notchl
NRR antibody. Nonlimiting exemplary antagonist anti-Notchl NRR antibodies are
described,
e.g., in U.S. 8,435,513; and U.S. Publication Nos. 2013/0266594; 2012/0213786;
2009/0258026; 2012/0093813.
The term "anti-Notch2 antibody" or "an antibody that binds to Notch2" refers
to an
antibody that is capable of binding Notch2 with sufficient affinity such that
the antibody is
useful as a diagnostic and/or therapeutic agent in targeting Notch2.
Preferably, the extent of
binding of an anti-Notch2 antibody to an unrelated, non-Notch protein is less
than about 10%
of the binding of the antibody to Notch2 as measured, e.g., by a
radioimmunoassay (RIA). In
certain embodiments, an antibody that binds to Notch2 has a dissociation
constant (Kd) of
<100 nM, < 10 nM, < 1 nM, or < 0.1 nM. In certain embodiments, an anti-Notch2
antibody binds to an epitope of Notch that is conserved among Notch from
different species,
e.g., rodents (mice, rats) and primates. The term "anti-Notch2 antibody"
includes anti-Notch2
17
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
NRR antibodies and antibodies that bind to other regions of Notch2, such as
the EGF-like
repeat domain. In some embodiments, an anti-Notch2 antibody inhibits Notch
activity. In
some such embodiments, an anti-Notch2 antibody may be referred to as an
antagonist anti-
Notch2 antibody. In some embodiments, an anti-Notch2 antibody binds to Notch2
and at least
one other Notch, such as Notchl and/or Notch3. Nonlimiting exemplary
antagonist anti-
Notch2 antibodies are described, e.g., in U.S. Patent Nos. 8,425,903 and
8,226,943 (anti-Notch
2/3 antibodies), 8,404,239; 8,206,713; 7,919,092; and U.S. Publication Nos.
2013/0323266
(anti-Notch 2/3 antibodies). Nonlimiting exemplary anti-Notch2 antibodies that
bind the EGF-
like repeat domain are described, e.g., in U.S. Patent Nos. 8,425,903 and
8,226,943 (anti-Notch
2/3 antibodies); 8,206,713; 7,919,092; 8,404,239; and U.S. Publication Nos.
2013/0323266
(anti-Notch 2/3 antibodies); 2010/0080808.
The term "anti-Notch2 NRR antibody" or "an antibody that binds to Notch2 NRR"
refers to an antibody that is capable of binding Notch2 NRR with sufficient
affinity such that
the antibody is useful as a diagnostic and/or therapeutic agent in targeting
Notch2. Preferably,
the extent of binding of an anti-Notch2 NRR antibody antibody to an unrelated,
non-Notch
protein is less than about 10% of the binding of the antibody to Notch2 NRR as
measured, e.g.,
by a radioimmunoassay (RIA). In certain embodiments, an antibody that binds to
Notch2 NRR
has a dissociation constant (Kd) of < 1 M, < 100 nM, < 10 nM, < 1 nM, or < 0.1
nM. In
certain embodiments, an anti-Notch2 NRR antibody binds to an epitope of Notch
that is
conserved among Notch from different species, e.g., rodents (mice, rats) and
primates. In some
embodiments, an anti-Notch2 NRR antibody inhibits Notch activity. In some such
embodiments, an anti-Notch2 NRR antibody may be referred to as an antagonist
anti-Notch2
NRR antibody. Nonlimiting exemplary antagonist anti-Notch2 NRR antibodies are
described,
e.g., in U.S. 8,404,239; and U.S. Publication No. 2010/0080808.
The term "anti-Notch3 antibody" or "an antibody that binds to Notch3" refers
to an
antibody that is capable of binding Notch3 with sufficient affinity such that
the antibody is
useful as a diagnostic and/or therapeutic agent in targeting Notch3.
Preferably, the extent of
binding of an anti-Notch3 antibody to an unrelated, non-Notch protein is less
than about 10%
of the binding of the antibody to Notch3 as measured, e.g., by a
radioimmunoassay (RIA). In
certain embodiments, an antibody that binds to Notch3 has a dissociation
constant (Kd) of
<100 nM, < 10 nM, < 1 nM, or < 0.1 nM. In certain embodiments, an anti-Notch3
antibody binds to an epitope of Notch that is conserved among Notch from
different species,
e.g., rodents (mice, rats) and primates. The term "anti-Notch3 antibody"
includes anti-Notch3
NRR antibodies and antibodies that bind to other regions of Notch3, such as
the EGF-like
18
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
repeat domain. In some embodiments, an anti-Notch3 antibody inhibits Notch
activity. In
some such embodiments, an anti-Notch3 antibody may be referred to as an
antagonist anti-
Notch3 antibody. In some embodiments, an anti-Notch3 antibody binds to Notch3
and at least
one other Notch, such as Notchl and/or Notch2. Nonlimiting exemplary
antagonist anti-
Notch3 antibodies are described, e.g., in U.S. Patent Nos. 7,994,285;
7,935,791; 8,513,388;
8,329,868; 8,148,106; 8,425,903 and 8,226,943 (anti-Notch 2/3 antibodies);
U.S. Publication
Nos. 2012/0328608; 2013/0323266 (anti-Notch 2/3 antibodies); 2013/0323257.
Nonlimiting
exemplary anti-Notch3 antibodies that bind the EGF-like repeat domain are
described, e.g., in
U.S. Patent No. 8,513,388; 8,425,903 and 8,226,943 (anti-Notch 2/3
antibodies); and U.S.
Publication Nos. 2013/0323266 (anti-Notch 2/3 antibodies); 2013/0323257.
The term "anti-Notch3 NRR antibody" or "an antibody that binds to Notch3 NRR"
refers to an antibody that is capable of binding Notch3 NRR with sufficient
affinity such that
the antibody is useful as a diagnostic and/or therapeutic agent in targeting
Notch3. Preferably,
the extent of binding of an anti-Notch3 NRR antibody antibody to an unrelated,
non-Notch
protein is less than about 10% of the binding of the antibody to Notch3 NRR as
measured, e.g.,
by a radioimmunoassay (RIA). In certain embodiments, an antibody that binds to
Notch3 NRR
has a dissociation constant (Kd) of < 1[tM, < 100 nM, < 10 nM, < 1 nM, or <
0.1 nM. In
certain embodiments, an anti-Notch3 NRR antibody binds to an epitope of Notch
that is
conserved among Notch from different species, e.g., rodents (mice, rats) and
primates. In some
embodiments, an anti-Notch3 NRR antibody inhibits Notch activity. In some such
embodiments, an anti-Notch3 NRR antibody may be referred to as an antagonist
anti-Notch3
NRR antibody. Nonlimiting exemplary antagonist anti-Notch3 NRR antibodies are
described,
e.g., in U.S. Patent No. 7,935,791; U.S. Publication No. 2012/0328608.
The term "anti-Notch4 antibody" or "an antibody that binds to Notch4" refers
to an
antibody that is capable of binding Notch4 with sufficient affinity such that
the antibody is
useful as a diagnostic and/or therapeutic agent in targeting Notch4.
Preferably, the extent of
binding of an anti-Notch4 antibody to an unrelated, non-Notch protein is less
than about 10%
of the binding of the antibody to Notch4 as measured, e.g., by a
radioimmunoassay (RIA). In
certain embodiments, an antibody that binds to Notch4 has a dissociation
constant (Kd) of
< 1 ,M, < 100 nM, < 10 nM, < 1 nM, or <0.1 nM. In certain embodiments, an
anti-Notch4
antibody binds to an epitope of Notch that is conserved among Notch from
different species,
e.g., rodents (mice, rats) and primates. In some embodiments, an anti-Notch4
antibody inhibits
Notch activity. In some such embodiments, an anti-Notch4 antibody may be
referred to as an
19
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
antagonist anti-Notch4 antibody. In some embodiments, an anti-Notch4 antibody
binds to
Notch4 and at least one other Notch.
The term "anti-LRP antibody" or "an antibody that binds to LRP" refers to an
antibody
that is capable of binding a low-density lipoprotein receptor-related protein
(LRP) with
sufficient affinity such that the antibody is useful as a diagnostic and/or
therapeutic agent in
targeting LRP. Preferably, the extent of binding of an anti-LRP antibody to an
unrelated, non-
LRP protein is less than about 10% of the binding of the antibody to LRP as
measured, e.g., by
a radioimmunoassay (RIA). In certain embodiments, an antibody that binds to
LRP has a
dissociation constant (Kd) of < 1 M, < 100 nM, < 10 nM, < 1 nM, or < 0.1 nM.
In certain
embodiments, an anti-LRP antibody binds to an epitope of LRP that is conserved
among LRP
from different species, e.g., rodents (mice, rats) and primates. In some
embodiments, an anti-
LRP antibody inhibits LRP activity. In some such embodiments, an anti-LRP
antibody may be
referred to as an antagonist anti-LRP antibody. The term "anti-LRP antibody"
includes, but is
not limited to, anti-LRP5 antibodies and anti-LRP6 antibodies, and antibodies
that bind both
LRP5 and LRP6 (anti-LRP5/6 antibodies). Nonlimiting exemplary antagonist anti-
LRP
antibodies are described, e.g., in U.S. Publication Nos. 2013/0183320;
2011/0256127;
2011/0243963; 2013/0064823; and 2012/0276089 (anti-LRP5/6 antibodies).
The term "anti-LRP5 antibody" or "an antibody that binds to LRP5" refers to an
antibody that is capable of binding a low-density lipoprotein receptor-related
protein (LRP) 5
with sufficient affinity such that the antibody is useful as a diagnostic
and/or therapeutic agent
in targeting LRP5. Preferably, the extent of binding of an anti-LRP5 antibody
to an unrelated,
non-LRP protein is less than about 10% of the binding of the antibody to LRP5
as measured,
e.g., by a radioimmunoassay (RIA). In certain embodiments, an antibody that
binds to LRP5
has a dissociation constant (Kd) of < 1 M, < 100 nM, < 10 nM, < 1 nM, or < 0.1
nM. In
certain embodiments, an anti-LRP5 antibody binds to an epitope of LRP that is
conserved
among LRP5 from different species, e.g., rodents (mice, rats) and primates. In
some
embodiments, an anti-LRP5 antibody inhibits LRP5 activity. In some such
embodiments, an
anti-LRP5 antibody may be referred to as an antagonist anti-LRP5 antibody.
Nonlimiting
exemplary antagonist anti-LRP5 antibodies are described, e.g., in U.S.
Publication No.
2013/0183320.
The term "anti-LRP6 antibody" or "an antibody that binds to LRP6" refers to an
antibody that is capable of binding a low-density lipoprotein receptor-related
protein (LRP) 6
with sufficient affinity such that the antibody is useful as a diagnostic
and/or therapeutic agent
in targeting LRP6. Preferably, the extent of binding of an anti-LRP6 antibody
to an unrelated,
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
non-LRP protein is less than about 10% of the binding of the antibody to LRP6
as measured,
e.g., by a radioimmunoassay (RIA). In certain embodiments, an antibody that
binds to LRP6
has a dissociation constant (Kd) of < 1 M, < 100 nM, < 10 nM, < 1 nM, or < 0.1
nM. In
certain embodiments, an anti-LRP6 antibody binds to an epitope of LRP6 that is
conserved
among LRP6 from different species, e.g., rodents (mice, rats) and primates. In
some
embodiments, an anti-LRP6 antibody inhibits LRP6 activity. In some such
embodiments, an
anti-LRP6 antibody may be referred to as an antagonist anti-LRP6 antibody. In
some
embodiments, an anti-LRP6 antibody is a bispecific antibody. Nonlimiting
exemplary
antagonist anti-LRP6 antibodies are described, e.g., in U.S. Publication Nos.
2011/0256127;
2011/0243963.
The term "anti-Wnt antibody" or "an antibody that binds to Wnt" refers to an
antibody
that is capable of binding Wnt with sufficient affinity such that the antibody
is useful as a
diagnostic and/or therapeutic agent in targeting Wnt. Preferably, the extent
of binding of an
anti-Wnt antibody to an unrelated, non-Wnt protein is less than about 10% of
the binding of the
antibody to Wnt as measured, e.g., by a radioimmunoassay (RIA). In certain
embodiments, an
antibody that binds to Wnt has a dissociation constant (Kd) of < 1 M, < 100
nM, < 10 nM, < 1
nM, or < 0.1 nM. In certain embodiments, an anti-Wnt antibody binds to an
epitope of Wnt
that is conserved among Wnt from different species, e.g., rodents (mice, rats)
and primates. In
some embodiments, an anti-Wnt antibody inhibits Wnt activity. In some such
embodiments,
an anti-Wnt antibody may be referred to as an antagonist anti-Wnt antibody. In
some
embodiments, an anti-Wnt antibody binds to one or more Wnt proteins selected
from Wntl,
Wnt2, Wnt2B, Wnt3, Wnt3A, Wnt4, Wnt5A, Wnt5B, Wnt6, Wnt7A, Wnt7B, Wnt8A,
Wnt8B,
Wnt9A, Wnt9B, Wntl0A, Wntl OB, Wntl 1, and Wnt16. In some embodiments, an anti-
Wnt
antibody binds to one or more Wnt proteins selected from Wntl, Wnt2, Wnt2B,
Wnt3, Wnt3A,
Wnt7A, Wnt7B, Wnt8A, Wnt8B, Wntl OA, and Wntl OB. In some embodiments, an anti-
Wnt
antibody binds to one or more Wnt proteins selected from Wnt3, Wnt3A, Wnt5A,
Wnt5B, and
Wnt9B. Nonlimiting exemplary anti-Wnt antibodies are described, e.g., in U.S.
Publication
No. 2013/0045209.
The term "anti-Frizzled antibody" or "an antibody that binds to Frizzled" or
"anti-Fzd
antibody" or "antibody that binds Fzd" refers to an antibody that is capable
of binding Frizzled
(or Fzd) with sufficient affinity such that the antibody is useful as a
diagnostic and/or
therapeutic agent in targeting Frizzled. Preferably, the extent of binding of
an anti-Frizzled
antibody to an unrelated, non-Frizzled protein is less than about 10% of the
binding of the
antibody to Frizzled as measured, e.g., by a radioimmunoassay (RIA). In
certain embodiments,
21
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
an antibody that binds to Frizzled has a dissociation constant (Kd) of < 1 M,
< 100 nM, < 10
nM, < 1 nM, or < 0.1 nM. In certain embodiments, an anti-Frizzled antibody
binds to an
epitope of Frizzled that is conserved among Frizzled from different species,
e.g., rodents (mice,
rats) and primates. In some embodiments, an anti-Frizzled antibody inhibits
Frizzled activity.
In some such embodiments, an anti-Frizzled antibody may be referred to as an
antagonist anti-
Frizzled antibody. In some embodiments, an anti-Frizzled antibody binds to one
or more
Frizzled proteins selected from Fzdl, Fzd2, Fzd3, Fzd4, Fzd5, Fzd6, Fzd7,
Fzd8, Fzd9, and
Fzdl O. In some embodiments, an anti-Frizzled antibody binds to Fzd7 and/or
Fzd8. In some
embodiments, an anti-Frizzled antibody binds to Fzdl, Fzd2, Fzd5, Fzd7, and/or
Fzd8.
Nonlimiting exemplary antagonist anti-Frizzled antibodies are described, e.g.,
in U.S. Patent
Nos. 7,982,013; 8,507,442 (Fzdl, Fzd2, Fzd5, Fzd7, and Fzd8); and U.S.
Publication No.
2013/0295106; 2012/0027778; 2013/0095104 (Fzd10).
The term "anti-RSPO antibody" or "an antibody that binds to RSPO" refers to an
antibody that is capable of binding an R-spondin protein (RSPO) with
sufficient affinity such
that the antibody is useful as a diagnostic and/or therapeutic agent in
targeting an RSPO.
Preferably, the extent of binding of an anti-RSPO antibody to an unrelated,
non-RSPO protein
is less than about 10% of the binding of the antibody to RSPO as measured,
e.g., by a
radioimmunoassay (RIA). In certain embodiments, an antibody that binds to an
RSPO has a
dissociation constant (Kd) of < 1 M, < 100 nM, < 10 nM, < 1 nM, or < 0.1 nM.
In certain
embodiments, an anti-RSPO antibody binds to an epitope of RSPO that is
conserved among
RSPO from different species, e.g., rodents (mice, rats) and primates. In some
embodiments, an
anti-RSPO antibody inhibits RSPO activity. In some such embodiments, an anti-
RSPO
antibody may be referred to as an antagonist anti-RSPO antibody. In some
embodiments, an
anti-RSPO antibody binds at least one RSPO selected from RSP01, RSP02, and
RSP03. In
some embodiments, an anti-RSPO antibody binds RSP01. In some embodiments, an
anti-
RSPO antibody binds RSPO2 and RSP03. In some embodiments, an anti-RSPO
antibody is a
bispecific antibody. Nonlimiting exemplary antagonist anti-RSPO antibodies are
described,
e.g., in U.S. Publication No. 2013/0209473; PCT Publication No. WO
2014/012007; U.S.
Patent No. 8,802,097.
The term "antibody" herein is used in the broadest sense and encompasses
various
antibody structures, including but not limited to monoclonal antibodies,
polyclonal antibodies,
multispecific antibodies (e.g., bispecific antibodies), and antibody fragments
so long as they
exhibit the desired antigen-binding activity.
22
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
A "blocking" antibody or an "antagonist" antibody is one which significantly
inhibits
(either partially or completely) a biological activity of the antigen it
binds.
An "antibody fragment" refers to a molecule other than an intact antibody that
comprises a portion of an intact antibody that binds the antigen to which the
intact antibody
binds. Examples of antibody fragments include but are not limited to Fv, Fab,
Fab', Fab'-SH,
F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g.
scFv); and
multispecific antibodies formed from antibody fragments.
An "antibody that binds to the same epitope" as a reference antibody refers to
an
antibody that blocks binding of the reference antibody to its antigen in a
competition assay by
50% or more, and conversely, the reference antibody blocks binding of the
antibody to its
antigen in a competition assay by 50% or more. An exemplary competition assay
is provided
herein.
The term "chimeric" antibody refers to an antibody in which a portion of the
heavy
and/or light chain is derived from a particular source or species, while the
remainder of the
heavy and/or light chain is derived from a different source or species.
The "class" of an antibody refers to the type of constant domain or constant
region
possessed by its heavy chain. There are five major classes of antibodies: IgA,
IgD, IgE, IgG,
and IgM, and several of these may be further divided into subclasses
(isotypes), e.g., IgGi,
IgG2, IgG3, Igat, IgAi, and IgA2. The heavy chain constant domains that
correspond to the
different classes of immunoglobulins are called a, 8, e, y, and la,
respectively.
The term "cytotoxic agent" as used herein refers to a substance that inhibits
or prevents
a cellular function and/or causes cell death or destruction. Cytotoxic agents
include, but are not
limited to, radioactive isotopes (e.g., At211, 1131, 1125, y90, Re186, Re188,
sm153, Bi212, p 32 ,
Pb212 and radioactive isotopes of Lu); chemotherapeutic agents or drugs (e.g.,
methotrexate,
adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide),
doxorubicin, melphalan,
mitomycin C, chlorambucil, daunorubicin or other intercalating agents); growth
inhibitory
agents; enzymes and fragments thereof such as nucleolytic enzymes;
antibiotics; toxins such as
small molecule toxins or enzymatically active toxins of bacterial, fungal,
plant or animal
origin, including fragments and/or variants thereof; and the various antitumor
or anticancer
agents disclosed below.
The term "Delta-like" or "DLL" as used herein, refers to any native DLL from
any
vertebrate source, including mammals such as primates (e.g. humans) and
rodents (e.g., mice
and rats), unless otherwise indicated. The term encompasses "full-length,"
unprocessed DLL
23
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
as well as any form of DLL that results from processing in the cell. The term
also encompasses
naturally occurring variants of DLL, e.g., splice variants or allelic
variants. A nonlimiting
exemplary human DLL1 is shown in SEQ ID NO: 17 (precursor; exemplary mature
form is
amino acids 18-723 of SEQ ID NO: 17). A nonlimiting exemplary human DLL4 is
shown in
SEQ ID NO: 18 (precursor; exemplary mature form is amino acids 27-685 of SEQ
ID NO: 18).
"Effector functions" refer to those biological activities attributable to the
Fc region of
an antibody, which vary with the antibody isotype. Examples of antibody
effector functions
include: C lq binding and complement dependent cytotoxicity (CDC); Fc receptor
binding;
antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down
regulation of cell
surface receptors (e.g. B cell receptor); and B cell activation.
An "effective amount" of an agent, e.g., a pharmaceutical formulation, refers
to an
amount effective, at dosages and for periods of time necessary, to achieve the
desired
therapeutic or prophylactic result.
The term "Fc region" herein is used to define a C-terminal region of an
immunoglobulin heavy chain that contains at least a portion of the constant
region. The term
includes native sequence Fc regions and variant Fc regions. In one embodiment,
a human IgG
heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-
terminus of the
heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or
may not be
present. Unless otherwise specified herein, numbering of amino acid residues
in the Fc region
or constant region is according to the EU numbering system, also called the EU
index, as
described in Kabat et al., Sequences of Proteins of Immunological Interest,
5th Ed. Public
Health Service, National Institutes of Health, Bethesda, MD, 1991.
"Framework" or "FR" refers to variable domain residues other than
hypervariable
region (HVR) residues. The FR of a variable domain generally consists of four
FR domains:
FRE FR2, FR3, and FR4. Accordingly, the HVR and FR sequences generally appear
in the
following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
The term "Frizzled" or "Fzd" as used herein, refers to any native Fzd from any
vertebrate source, including mammals such as primates (e.g. humans) and
rodents (e.g., mice
and rats), unless otherwise indicated. The term encompasses "full-length,"
unprocessed Fzd as
well as any form of Fzd that results from processing in the cell. The term
also encompasses
naturally occurring variants of Fzd, e.g., splice variants or allelic
variants. A nonlimiting
exemplary human Fzd7 is shown in SEQ ID NO: 19 (precursor; exemplary mature
form is
amino acids 33-574 of SEQ ID NO: 19). A nonlimiting exemplary human Fzd8 is
shown in
SEQ ID NO: 20 (precursor; exemplary mature form is amino acids 28-694 of SEQ
ID NO: 20).
24
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
The term "soluble Frizzled," "Frizzled ECD," "Frizzled trap," and "Frizzled
decoy" are
used interchangeably herein to refer to a fragment of a Fzd protein that lacks
a transmembrane
domain and an intracellular domain, and which retains the ability to bind Wnt.
In some
embodiments, a soluble Fzd is capable of binding one or more, two or more,
three or more, or
four or more human Wnt proteins selected from Wntl, Wnt2, Wnt2b, Wnt3, Wnt3a,
Wnt7a,
Wnt7b, Wnt8a, Wnt8b, Wntl0a, and Wntl0b. In some embodiments, a soluble Fzd is
capable
of binding Wntl, Wnt2, Wnt3, Wnt3a, and Wnt7b. A soluble Fzd may be fused to a
heterologous moiety, such as an Fc. In some embodiments, a soluble Fzd7
comprises amino
acids 33 to 257 of SEQ ID NO: 19, or a fragment thereof that is capable of
binding Wnt. In
some embodiments, a soluble Fzd7 comprises amino acids 45 to 167 of SEQ ID NO:
19. In
some embodiments, a soluble Fzd8 comprises amino acids 28 to 275 of SEQ ID NO:
20, or a
fragment thereof that is capable of binding Wnt. In some embodiments, a
soluble Fzd8
comprises amino acids 31 to 155 of SEQ ID NO: 20. Nonlimiting exemplary
soluble Fzds
include 54F28 Fzd8-Fc and FZD8CRD. See U.S. Patent No. 7,723,477; 7,947,277;
Publication
No. 2013/0034551; 2010/0317098.
The terms "full length antibody," "intact antibody," and "whole antibody" are
used
herein interchangeably to refer to an antibody having a structure
substantially similar to a
native antibody structure or having heavy chains that contain an Fc region as
defined herein.
The terms "gamma-secretase inhibitor" or "7-secretase inhibitor" are used
interchangeably to refer to inhibitors of gamma secretase, a protease complex
involved in
processing of certain type I integral membrane proteins, such as Notch.
Nonlimiting exemplary
gamma-secretase inhibitors include tarenflurbil (Flurizan), semagacestat
(LY450139),
avagacestat, MK-0752 (3-((1r,4s)-4-(4-chlorophenylsulfony1)-4-(2,5-
difluorophenyl)cyclohexyl)propanoic acid), N-lN-(3,5-Difluorophenacety1)-L-
alanyll-S-
phenylglycine t-butyl ester (DAPT), (2S)-2-{ 11(3,5-
Difluorophenyl)acetyllamino} -N-R3S)-1-
methy1-2-oxo-5-pheny1-2,3-dihydro-1H-1,4-benzodiazepin-3-yllpropanamide
(compound E),
and N=-[(15)-2- I I 75) - 6,7 - dro.-5 --methyl.-6-oxo- 51-/-dibenzl b.d
aaTin.-7--yll amino I
I 110thyl-2-0X0edly ] , 5 -(1 ifiuorobentonea4.-etanl ide (I Nonlimiting
exemplary gamma-
secretase inhibitors include those described, for example, in U.S. Patent Nos.
6,756,511;
6,890,956; 6,984,626; 7,049,296; 7,101,895; 7,138,400; 7,144,910; 7,183,303;
8,377,886.
The terms "host cell," "host cell line," and "host cell culture" are used
interchangeably
and refer to cells into which exogenous nucleic acid has been introduced,
including the progeny
of such cells. Host cells include "transformants" and "transformed cells,"
which include the
primary transformed cell and progeny derived therefrom without regard to the
number of
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
passages. Progeny may not be completely identical in nucleic acid content to a
parent cell, but
may contain mutations. Mutant progeny that have the same function or
biological activity as
screened or selected for in the originally transformed cell are included
herein.
A "human antibody" is one which possesses an amino acid sequence which
corresponds
to that of an antibody produced by a human or a human cell or derived from a
non-human
source that utilizes human antibody repertoires or other human antibody-
encoding sequences.
This definition of a human antibody specifically excludes a humanized antibody
comprising
non-human antigen-binding residues.
A "human consensus framework" is a framework which represents the most
commonly
occurring amino acid residues in a selection of human immunoglobulin VL or VH
framework
sequences. Generally, the selection of human immunoglobulin VL or VH sequences
is from a
subgroup of variable domain sequences. Generally, the subgroup of sequences is
a subgroup as
in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth
Edition, NIH
Publication 91-3242, Bethesda MD (1991), vols. 1-3. In one embodiment, for the
VL, the
subgroup is subgroup kappa I as in Kabat et al., supra. In one embodiment, for
the VH, the
subgroup is subgroup III as in Kabat et al., supra.
A "humanized" antibody refers to a chimeric antibody comprising amino acid
residues
from non-human HVRs and amino acid residues from human FRs. In certain
embodiments, a
humanized antibody will comprise substantially all of at least one, and
typically two, variable
domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond
to those of a
non-human antibody, and all or substantially all of the FRs correspond to
those of a human
antibody. A humanized antibody optionally may comprise at least a portion of
an antibody
constant region derived from a human antibody. A "humanized form" of an
antibody, e.g., a
non-human antibody, refers to an antibody that has undergone humanization.
The term "hypervariable region" or "HVR" as used herein refers to each of the
regions
of an antibody variable domain which are hypervariable in sequence
("complementarity
determining regions" or "CDRs") and/or form structurally defined loops
("hypervariable
loops") and/or contain the antigen-contacting residues ("antigen contacts").
Generally,
antibodies comprise six HVRs: three in the VH (H1, H2, H3), and three in the
VL (L1, L2,
L3). Exemplary HVRs herein include:
(a) hypervariable loops occurring at amino acid residues 26-32 (L1), 50-52
(L2), 91-96
(L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol.
196:901-917
(1987));
26
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
(b) CDRs occurring at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3),
31-35b
(H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of
Immunological
Interest, 5th Ed. Public Health Service, National Institutes of Health,
Bethesda, MD (1991));
(c) antigen contacts occurring at amino acid residues 27c-36 (L1), 46-55 (L2),
89-96
(L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al. J. Mol. Biol.
262: 732-745
(1996)); and
(d) combinations of (a), (b), and/or (c), including HVR amino acid residues 46-
56
(L2), 47-56 (L2), 48-56 (L2), 49-56 (L2), 26-35 (H1), 26-35b (H1), 49-65 (H2),
93-102 (H3),
and 94-102 (H3).
Unless otherwise indicated, HVR residues and other residues in the variable
domain
(e.g., FR residues) are numbered herein according to Kabat et al., supra.
An "immunoconjugate" is an antibody conjugated to one or more heterologous
molecule(s), including but not limited to a cytotoxic agent.
An "individual" or "subject" is a mammal. Mammals include, but are not limited
to,
domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates
(e.g., humans and
non-human primates such as monkeys), rabbits, and rodents (e.g., mice and
rats). In certain
embodiments, the individual or subject is a human.
An "isolated" antibody is one which has been separated from a component of its
natural
environment. In some embodiments, an antibody is purified to greater than 95%
or 99% purity
as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric
focusing (IEF),
capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse
phase HPLC). For
review of methods for assessment of antibody purity, see, e.g., Flatman et
al., J. Chromatogr. B
848:79-87 (2007).
An "isolated" nucleic acid refers to a nucleic acid molecule that has been
separated
from a component of its natural environment. An isolated nucleic acid includes
a nucleic acid
molecule contained in cells that ordinarily contain the nucleic acid molecule,
but the nucleic
acid molecule is present extrachromosomally or at a chromosomal location that
is different
from its natural chromosomal location.
"Isolated nucleic acid encoding an anti4target1 antibody" refers to one or
more nucleic
acid molecules encoding antibody heavy and light chains (or fragments
thereof), including such
nucleic acid molecule(s) in a single vector or separate vectors, and such
nucleic acid
molecule(s) present at one or more locations in a host cell.
The term "Jagged" or "Jag," as used herein, refers to any native Jagged from
any
vertebrate source, including mammals such as primates (e.g. humans) and
rodents (e.g., mice
27
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
and rats), unless otherwise indicated. The term encompasses "full-length,"
unprocessed Jagged
as well as any form of Jagged that results from processing in the cell. The
term also
encompasses naturally occurring variants of Jagged, e.g., splice variants or
allelic variants. The
amino acid sequence of exemplary human and murine Jaggedl and Jagged2 are
shown in SEQ
ID NOS: 1-4. A nonlimiting exemplary human Jaggedl is shown in SEQ ID NO: 1
(precursor;
exemplary mature form is amino acids 34-1218 of SEQ ID NO: 1). A nonlimiting
exemplary
human Jagged2 is shown in SEQ ID NO: 3 (precursor; exemplary mature form is
amino acids
24-1238 of SEQ ID NO: 3).
The term "low-density lipoprotein receptor-related protein" or "LRP," as used
herein,
refers to any native LRP from any vertebrate source, including mammals such as
primates (e.g.
humans) and rodents (e.g., mice and rats), unless otherwise indicated. The
term encompasses
"full-length," unprocessed LRP as well as any form of LRP that results from
processing in the
cell. The term also encompasses naturally occurring variants of LRP, e.g.,
splice variants or
allelic variants. A nonlimiting exemplary human LRP5 is shown in SEQ ID NO: 21
(precursor; exemplary mature form is amino acids 32-1615 of SEQ ID NO: 21). A
nonlimiting
exemplary human LRP6 is shown in SEQ ID NO: 22 (precursor; exemplary mature
form is
amino acids 20-1613 of SEQ ID NO: 22).
The term "monoclonal antibody" as used herein refers to an antibody obtained
from a
population of substantially homogeneous antibodies, i.e., the individual
antibodies comprising
the population are identical and/or bind the same epitope, except for possible
variant
antibodies, e.g., containing naturally occurring mutations or arising during
production of a
monoclonal antibody preparation, such variants generally being present in
minor amounts. In
contrast to polyclonal antibody preparations, which typically include
different antibodies
directed against different determinants (epitopes), each monoclonal antibody
of a monoclonal
antibody preparation is directed against a single determinant on an antigen.
Thus, the modifier
"monoclonal" indicates the character of the antibody as being obtained from a
substantially
homogeneous population of antibodies, and is not to be construed as requiring
production of
the antibody by any particular method. For example, the monoclonal antibodies
to be used in
accordance with the present invention may be made by a variety of techniques,
including but
not limited to the hybridoma method, recombinant DNA methods, phage-display
methods, and
methods utilizing transgenic animals containing all or part of the human
immunoglobulin loci,
such methods and other exemplary methods for making monoclonal antibodies
being described
herein.
28
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
A "naked antibody" refers to an antibody that is not conjugated to a
heterologous
moiety (e.g., a cytotoxic moiety) or radiolabel. The naked antibody may be
present in a
pharmaceutical formulation.
"Native antibodies" refer to naturally occurring immunoglobulin molecules with
varying structures. For example, native IgG antibodies are heterotetrameric
glycoproteins of
about 150,000 daltons, composed of two identical light chains and two
identical heavy chains
that are disulfide-bonded. From N- to C-terminus, each heavy chain has a
variable region
(VH), also called a variable heavy domain or a heavy chain variable domain,
followed by three
constant domains (CHE CH2, and CH3). Similarly, from N- to C-terminus, each
light chain
has a variable region (VL), also called a variable light domain or a light
chain variable domain,
followed by a constant light (CL) domain. The light chain of an antibody may
be assigned to
one of two types, called kappa (x) and lambda (4 based on the amino acid
sequence of its
constant domain.
The term "Notch," as used herein, refers to any native Notch (Notch1-4) from
any
vertebrate source, including mammals such as primates (e.g. humans) and
rodents (e.g., mice
and rats), unless otherwise indicated. The term encompasses "full-length,"
unprocessed Notch
as well as any form of Notch that results from processing in the cell. The
term also
encompasses naturally occurring variants of Notch, e.g., splice variants or
allelic variants. The
term Notch encompasses Notchl, Notch2, Notch3, and Notch4.
The term "Notchl," as used herein, refers to any native Notchl from any
vertebrate
source, including mammals such as primates (e.g. humans) and rodents (e.g.,
mice and rats),
unless otherwise indicated. The term encompasses "full-length," unprocessed
Notchl as well
as any form of Notchl that results from processing in the cell. The term also
encompasses
naturally occurring variants of Notchl, e.g., splice variants or allelic
variants. A nonlimiting
exemplary human Notchl amino acid sequence is shown in SEQ ID NO: 9
(precursor;
exemplary mature form is amino acids 19-2555 of SEQ ID NO: 9).
The term "Notch2," as used herein, refers to any native Notch2 from any
vertebrate
source, including mammals such as primates (e.g. humans) and rodents (e.g.,
mice and rats),
unless otherwise indicated. The term encompasses "full-length," unprocessed
Notch2 as well
as any form of Notch2 that results from processing in the cell. The term also
encompasses
naturally occurring variants of Notch2, e.g., splice variants or allelic
variants. A nonlimiting
exemplary human Notch2 amino acid sequence is shown in SEQ ID NO: 10
(precursor;
exemplary mature form is amino acids 26-2471 of SEQ ID NO: 10).
29
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
The term "Notch3," as used herein, refers to any native Notch3 from any
vertebrate
source, including mammals such as primates (e.g. humans) and rodents (e.g.,
mice and rats),
unless otherwise indicated. The term encompasses "full-length," unprocessed
Notchl as well
as any form of Notch3 that results from processing in the cell. The term also
encompasses
naturally occurring variants of Notch3, e.g., splice variants or allelic
variants. A nonlimiting
exemplary human Notch3 amino acid sequence is shown in SEQ ID NO: 11
(precursor;
exemplary mature form is amino acids 40-2321 of SEQ ID NO: 11).
The term "Notch4," as used herein, refers to any native Notch4 from any
vertebrate
source, including mammals such as primates (e.g. humans) and rodents (e.g.,
mice and rats),
unless otherwise indicated. The term encompasses "full-length," unprocessed
Notchl as well
as any form of Notch4 that results from processing in the cell. The term also
encompasses
naturally occurring variants of Notch4, e.g., splice variants or allelic
variants. A nonlimiting
exemplary human Notch4 amino acid sequence is shown in SEQ ID NO: 12
(precursor;
exemplary mature form is amino acids 24-2003 of SEQ ID NO: 12).
The term "Notchl activity" refers to Notchl signaling. An agent (e.g., an
antibody) that
"inhibits Notchl activity" significantly decreases Notchl signaling relative
to the level of
Notchl signaling observed in an appropriate control under substantially
identical conditions.
In certain embodiments, Notchl activity may be assessed by a suitable reporter
assay, as
described, e.g., in U.S. Publication No. 2009/0258026. In certain embodiments,
Notchl activity
may be assessed by measuring vascular network density in a corneal pocket
assay or mouse
retinal model of angiogenesis, as described, e.g., in U.S. Publication No.
2009/0258026. In
certain embodiments, the decrease in Notchl signaling is at least 2-, 3-, 4-,
5-, or 10-fold below
the level observed in the control.
The term "Notchl NRR" refers to a region of Notchl consisting of the three LNR
modules (LNR-A, LNR-B, and LNR-C) and the HD domain (HD-N and HD-C). Exemplary
human and mouse Notchl NRR sequences are shown in SEQ ID NOs: 13 and 14,
respectively.
A further exemplary human Notchl NRR has the sequence of amino acids 1307-
1732 of SEQ
ID NO: 9. The Notchl NRR may consist of non-covalently linked fragments, e.g.,
that result
from the processing of Notchl at 51, as well as a single contiguous
polypeptide sequence. By
way of example, human Notchl NRR may consist of amino acids 1307-1732 of human
Notchl
(SEQ ID NO: 9).
The term "Notch2 activity" refers to Notch2 signaling. An agent (e.g., an
antibody) that
"inhibits Notch2 activity" significantly decreases Notch2 signaling relative
to the level of
Notch2 signaling observed in an appropriate control under substantially
identical conditions.
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
In certain embodiments, Notch2 activity may be assessed by a suitable reporter
assay, as
described, e.g., in U.S. Patent No. 8,404,239. In certain embodiments, Notch2
activity may be
assessed by measuring generation of marginal B zone cells, as described, e.g.,
in U.S. Patent
No. 8,404,239. In certain embodiments, the decrease in Notch2 signaling is at
least 2-, 3-, 4-,
5-, or 10-fold below the level observed in the control.
The term "Notch2 NRR" refers to a region of Notch2 consisting of the three LNR
modules (LNR-A, LNR-B, and LNR-C) and the HD domain (HD-N and HD-C). Exemplary
human and mouse Notch2 NRR sequences are shown in SEQ ID NOs: 15 and 16,
respectively.
The Notch2 NRR may consist of non-covalently linked fragments, e.g., that
result from the
processing of Notch2 at 51, as well as a single contiguous polypeptide
sequence. By way of
example, human Notch2 NRR may consist of amino acids 1422-1677 of human Notch2
(SEQ
ID NO: 10), or alternatively, amino acids 1422-1608 of SEQ ID NO: 10
noncovalently linked
to amino acids 1609-1677 of SEQ ID NO: 10.
The term "Notch3 activity" refers to Notch3 signaling. An agent (e.g., an
antibody) that
"inhibits Notch3 activity" significantly decreases Notch3 signaling relative
to the level of
Notch3 signaling observed in an appropriate control under substantially
identical conditions.
In certain embodiments, Notch3 activity may be assessed by a suitable reporter
assay, as
described, e.g., in U.S. Publication No. 2013/0144040. In certain embodiments,
Notch3
activity may be assessed using an apoptosis assay, cell migration assay,
invasion assay, and/or
morphology assay, as described, e.g., in U.S. Publication No. 2013/0144040. In
certain
embodiments, the decrease in Notch3 signaling is at least 2-, 3-, 4-, 5-, or
10-fold below the
level observed in the control.
The term "Notch3 NRR" refers to a region of Notch3 consisting of the three LNR
modules (LNR-A, LNR-B, and LNR-C) and the HD domain (HD-N and HD-C). Exemplary
human and mouse Notch3 NRR sequences are shown in SEQ ID NOs: 15 and 16,
respectively.
The Notch3 NRR may consist of non-covalently linked fragments, e.g., that
result from the
processing of Notch3 at 51, as well as a single contiguous polypeptide
sequence. By way of
example, human Notch3 NRR may consist of amino acids 1378-1640 of human Notch3
(SEQ
ID NO: 11).
The term "Notch4 activity" refers to Notch4 signaling. An agent (e.g., an
antibody) that
"inhibits Notch4 activity" significantly decreases Notch4 signaling relative
to the level of
Notch4 signaling observed in an appropriate control under substantially
identical conditions.
In certain embodiments, the decrease in Notch4 signaling is at least 2-, 3-, 4-
, 5-, or 10-fold
below the level observed in the control.
31
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
As used herein, the term "Notch-mediated disorder" means a condition or
disease
which is characterized by the overexpression and/or hypersensitivity of one or
more Notch
receptors. Specifically it includes conditions associated with cancers such as
non-small cell
lung cancer, ovarian cancer, and T-cell acute lymphoblastic leukemia. Other
cancers including
pancreatic, prostate cancer, plasma cell neoplasms (e.g., multiple myeloma,
plasma cell
leukemia and extramedullary plasmacytoma), neuroblastoma and extramedullary
plasmacytoma are also encompassed by this term. Other types of Notch-mediated
disorders
include lymphoma, Alagille syndrome, liver disease involving aberrant
vascularization,
neurologic diseases, diabetes, diseases involving vascular cell fate, and
rheumatoid arthritis.
The term "Notch pathway inhibitor" or "inhibitor of Notch pathway" as used
herein
refers to an agent that inhibits Notch activity. A Notch pathway inhibitor may
be an antibody,
a soluble receptor, a small molecule, or the like. Nonlimiting exemplary Notch
pathway
inhibitors include anti-Notch antibodies (including, but not limited to, anti-
Notchl antibodies,
anti-Notch2 antibodies, anti-Notch3 antibodies, and anti-Notch4 antibodies,
and antibodies that
bind to more than one Notch), anti-Jagged antibodies (including, but not
limited to, anti-
Jaggedl antibodies, anti-Jagged2 antibodies, and antibodies that bind to more
than one
Jagged); gamma secretase inhibitors; and anti-DLL antibodies (including, but
not limited to,
anti-DLL1 antibodies and anti-DLL4 antibodies, and antibodies that bind to
more than one
DLL).
The term "package insert" is used to refer to instructions customarily
included in
commercial packages of therapeutic products, that contain information about
the indications,
usage, dosage, administration, combination therapy, contraindications and/or
warnings
concerning the use of such therapeutic products.
"Percent (%) amino acid sequence identity" with respect to a reference
polypeptide
sequence is defined as the percentage of amino acid residues in a candidate
sequence that are
identical with the amino acid residues in the reference polypeptide sequence,
after aligning the
sequences and introducing gaps, if necessary, to achieve the maximum percent
sequence
identity, and not considering any conservative substitutions as part of the
sequence identity.
Alignment for purposes of determining percent amino acid sequence identity can
be achieved
in various ways that are within the skill in the art, for instance, using
publicly available
computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR)
software.
Those skilled in the art can determine appropriate parameters for aligning
sequences, including
any algorithms needed to achieve maximal alignment over the full length of the
sequences
being compared. For purposes herein, however, % amino acid sequence identity
values are
32
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
generated using the sequence comparison computer program ALIGN-2. The ALIGN-2
sequence comparison computer program was authored by Genentech, Inc., and the
source code
has been filed with user documentation in the U.S. Copyright Office,
Washington D.C., 20559,
where it is registered under U.S. Copyright Registration No. TXU510087. The
ALIGN-2
program is publicly available from Genentech, Inc., South San Francisco,
California, or may be
compiled from the source code. The ALIGN-2 program should be compiled for use
on a UNIX
operating system, including digital UNIX V4.0D. All sequence comparison
parameters are set
by the ALIGN-2 program and do not vary.
In situations where ALIGN-2 is employed for amino acid sequence comparisons,
the %
amino acid sequence identity of a given amino acid sequence A to, with, or
against a given
amino acid sequence B (which can alternatively be phrased as a given amino
acid sequence A
that has or comprises a certain % amino acid sequence identity to, with, or
against a given
amino acid sequence B) is calculated as follows:
100 times the fraction X/Y
where X is the number of amino acid residues scored as identical matches by
the sequence
alignment program ALIGN-2 in that program's alignment of A and B, and where Y
is the total
number of amino acid residues in B. It will be appreciated that where the
length of amino
acid sequence A is not equal to the length of amino acid sequence B, the %
amino acid
sequence identity of A to B will not equal the % amino acid sequence identity
of B to A.
Unless specifically stated otherwise, all % amino acid sequence identity
values used herein are
obtained as described in the immediately preceding paragraph using the ALIGN-2
computer
program.
The term "pharmaceutical formulation" refers to a preparation which is in such
form as
to permit the biological activity of an active ingredient contained therein to
be effective, and
which contains no additional components which are unacceptably toxic to a
subject to which
the formulation would be administered.
A "pharmaceutically acceptable carrier" refers to an ingredient in a
pharmaceutical
formulation, other than an active ingredient, which is nontoxic to a subject.,
A
pharmaceutically acceptable carrier includes, but is not limited to, a buffer,
excipient,
stabilizer, or preservative.
The term "toxicity" associated with Notch pathway inhibition as used herein
refers to
adverse events occurring in individuals receiving Notch pathway inhibitors.
Nonlimiting
examples of such toxicity include secretory metaplasia, diarrhea,
gastrointestinal bleeding, liver
33
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
toxicity (including, but not limited to, sinusoidal dilation, centrilobular
hepatocyte atrophy, bile
ductular proliferation, and elevated alanine aminotransferase), lung toxicity
(including, but not
limited to, necrotic lesions), heart toxicity (including, but not limited to,
necrotic lesions),
subcutaneous tumors, and thymic atrophy. See, e.g., van Es et al., 2005,
Nature 435: 959-963;
Yan et al., 2010, Nature 463: E6-7.
As used herein, "treatment" (and grammatical variations thereof such as
"treat" or
"treating") refers to clinical intervention in an attempt to alter the natural
course of the
individual being treated, and can be performed either for prophylaxis or
during the course of
clinical pathology. Desirable effects of treatment include, but are not
limited to, preventing
occurrence or recurrence of disease, alleviation of symptoms, diminishment of
any direct or
indirect pathological consequences of the disease, preventing metastasis,
decreasing the rate of
disease progression, amelioration or palliation of the disease state, and
remission or improved
prognosis. In some embodiments, antibodies of the invention are used to delay
development of
a disease or to slow the progression of a disease.
The term "variable region" or "variable domain" refers to the domain of an
antibody
heavy or light chain that is involved in binding the antibody to antigen. The
variable domains
of the heavy chain and light chain (VH and VL, respectively) of a native
antibody generally
have similar structures, with each domain comprising four conserved framework
regions (FRs)
and three hypervariable regions (HVRs). (See, e.g., Kindt et al. Kuby
Immunology, 6th ed.,
W.H. Freeman and Co., page 91 (2007).) A single VH or VL domain may be
sufficient to
confer antigen-binding specificity. Furthermore, antibodies that bind a
particular antigen may
be isolated using a VH or VL domain from an antibody that binds the antigen to
screen a
library of complementary VL or VH domains, respectively. See, e.g., Portolano
et al., J.
Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991).
The term "vector," as used herein, refers to a nucleic acid molecule capable
of
propagating another nucleic acid to which it is linked. The term includes the
vector as a self-
replicating nucleic acid structure as well as the vector incorporated into the
genome of a host
cell into which it has been introduced. Certain vectors are capable of
directing the expression
of nucleic acids to which they are operatively linked. Such vectors are
referred to herein as
"expression vectors."
The term "Wnt" as used herein, refers to any native Wnt from any vertebrate
source,
including mammals such as primates (e.g. humans) and rodents (e.g., mice and
rats), unless
otherwise indicated. The term encompasses "full-length," unprocessed Wnt as
well as any
form of Wnt that results from processing in the cell. The term also
encompasses naturally
34
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
occurring variants of Wnt, e.g., splice variants or allelic variants. The
human Wnt gene family
of secreted ligands has includes at least 19 members (e.g., Wnt-1 (RefSeq.: NM-
005430),
Wnt-2 (RefSeq.: NM-003391), Wnt-2B (Wnt-13) (RefSeq.: NM-004185), Wnt-3
(ReSeq.:
NM-030753), Wnt3a (RefSeq.: NM-033131), Wnt-4 (RefSeq.: NM-030761), Wnt-5A
(RefSeq.: NM-003392), Wnt-5B (RefSeq.: NM-032642), Wnt-6 (RefSeq.: NM-006522),
Wnt-7A (RefSeq.: NM-004625), Wnt-7B (RefSeq.: NM-058238), Wnt-8A (RefSeq.: NM-
058244), Wnt-8B (RefSeq.: NM-003393), Wnt-9A (Wnt-14) (RefSeq.: NM-003395),
Wnt-
9B (Wnt-15) (RefSeq.: NM-003396), Wnt-10A (RefSeq.: NM-025216), Wnt-10B
(RefSeq.:
NM-003394), Wnt-11 (RefSeq.: NM-004626), Wnt-16 (RefSeq.: NM-016087)). Each
member has varying degrees of sequence identity but all contain 23-24
conserved cysteine
residues which show highly conserved spacing. See McMahon, A P et al., Trends
Genet. 1992;
8: 236-242; Miller, J R. Genome Biol. 2002; 3(1): 3001.1-3001.15.
The term "Wnt pathway inhibitor" or "inhibitor of Wnt pathway" as used herein
refers
to an agent that inhibits Wnt activity. A Wnt pathway inhibitor may be an
antibody, a soluble
receptor, a small molecule, or the like. Nonlimiting exemplary Wnt pathway
inhibitors include
small molecule inhibitors (including, but not limited to, Wnt-059 (2-(4-(2-
methylpyridin-4-
yl)pheny1)-N-(4-(pyridin-3-yl)phenyl)acetamide), LGK974 (see Liu et al., 2013,
PNAS,
110:20224-9)) anti-Wnt antibodies (including, but not limited to, antibodies
that bind to more
than one Wnt; see, e.g., U.S. Publication No. 2013/0045209); anti-LRP
antibodies (including,
but not limited to, anti-LRP5 antibodies, anti-LRP6 antibodies, anti-LRP5/6
antibodies, and
other antibodies that bind to more than one LRP); anti-Fzd antibodies
(including, but not
limited to, anti-Fzd7 antibodies and antibodies that bind to more than one
Fzd); soluble Fzd
receptors (including, but not limited to, soluble Fzd8); and small molecules
that inhibit p-
catenin (e.g., PRI-724, Prism Pharma Co.).
II. COMPOSITIONS AND METHODS
In one aspect, the invention is based, in part, on the finding that Wnt
pathway inhibition
alleviates the toxicity associated with Notch pathway inhibition. In certain
embodiments,
methods of treating cancer are provided, wherein the method comprises
administering at least
one Wnt pathway inhibitor to an individual who has received, is receiving, or
will receive
Notch pathway inhibitor therapy. Accordingly, the invention provides methods,
compositions,
kits, and articles of manufacture related to coordinated Notch pathway
inhibition and Wnt
pathway inhibition.
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
A. Notch Pathway Inhibitors
In some embodiments, the invention provides Notch pathway inhibitors. Notch
pathway inhibitors include, but are not limited to, small molecules such as
gamma secretase
inhibitors, and antibodies that bind to one or more proteins involved in Notch
signaling.
Nonlimiting exemplary antibodies that bind to one or more proteins involved in
Notch
signaling include anti-Notch antibodies, anti-Jagged antibodies, and anti-DLL
antibodies. Also
provided are bispecific antibodies comprising a first antigen binding region
that binds to one or
more proteins involved in Notch signaling and a second antigen binding region
that binds to
one or more proteins involved in Notch signaling or a second antigen binding
region that binds
to an antigen not directly involved in Notch signaling, such as VEGF.
1. Anti-Notch Antibodies
In some embodiments, anti-Notch antibodies are provided. Anti-Notch antibodies
include, but are not limited to, anti-Notch NRR antibodies and anti-Notch
antibodies that bind
to the EGF-like repeat region. In some such embodiments, an anti-Notch
antibody binds to
Notch 1. In some embodiments, an anti-Notch antibody binds to Notch2. In some
embodiments, an anti-Notch antibody binds to Notch3. In some embodiments, an
anti-Notch
antibody binds to Notch4. In some embodiments, an anti-Notch antibody binds to
more than
one Notch. In some embodiments, an anti-Notch antibody binds to Notchl and
Notch2. In
some embodiments, an anti-Notch antibody binds to Notch2 and Notch3.
Anti-Notch antibodies useful in the methods of the invention include, but are
not
limited to, the anti-Notch antibodies described in U.S. Patent Nos. 8,404,237;
8,404,239;
8,088,617; 8,435,513; 8,460,661; 8,425,903; 8,226,943; 8,206,713; 7,919,092;
7,994,285;
7,935,791; 8,513,388; 8,329,868; and 8,148,106; and U.S. Publication Nos.
2013/0266594;
2012/0213786; 2011/0311552; 2009/0258026; 2013/0323266; 2010/0080808;
2012/0328608;
2012/0093813; and 2013/0323257. In some embodiments, an anti-Notch antibody
comprises
the HVRs of any of the anti-Notch antibodies described in the patents and
applications listed
above.
In some embodiments, an anti-Notch antibody comprises the HVRs of, or the
variable
regions of, antibody 59R5, described in U.S. Patent No. 7,919,092. In some
embodiments, an
anti-Notch antibody is antibody 59R5, described in U.S. Patent No. 7,919,092.
In a Phase la
study in patients with solid tumors, 58% of patients experienced diarrhea,
with 14%
experiencing grade 3 or higher diarrhea. Further, a significant correlation
between diarrhea
grade and does of antibody 59R5 was found. See Dupont, "OMP-59R5: a Novel
Therapeutic
36
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
Antibody in Clinical Development for Patients with Cancer," available at
www.oncomed.com/presentations/OMP-59R5_Ph1a_Presenation_PEP.pdf.
In some embodiments, an anti-Notch antibody comprises the HVRs of, or the
variable
regions of, antibody 52M51 or a humanized version such as 52M51H4L3, described
in U.S.
Patent No. 8,435,513. In some embodiments, an anti-Notch antibody is antibody
52M51 or a
humanized version such as 52M51H4L3, described in U.S. Patent No. 8,435,513.
In a first-in-
human phase I study in patients with advanced solid tumors, 64% of patients
experienced
diarrhea. See Davis et al., "A first-in-human phase I study of the novel
cancer stem cell (CSC)
targeting antibody OMP-52M51 (anti-Notch 1)administered intravenously to
patients with
certain advanced solid tumors," available at www.oncomed.com/presentations/OMP-
52M51%20Ph1a_AACR-NCI-EORTC2013.pdf.
In some embodiments, an anti-Notch antibody comprises the HVRs of, or the
variable
regions of, antibody A, A-1, A-2, or A-3, described in U.S. Publication No.
2009/0258026. In
some embodiments, an anti-Notch antibody comprises the HVRs of, or the
variable regions of,
antibody A-2, described in U.S. Publication No. 2009/0258026. In some
embodiments, an
anti-Notch antibody is antibody A, A-1, A-2, or A-3, described in U.S.
Publication No.
2009/0258026. In some embodiments, an anti-Notch antibody is antibody A-2,
described in
U.S. Publication No. 2009/0258026.
In some embodiments, an anti-Notch antibody comprises the HVRs of, or the
variable
regions of, antibody D, D-1, D-2, or D-3, described in U.S. Patent No.
8,404,239. In some
embodiments, an anti-Notch antibody comprises the HVRs of, or the variable
regions of,
antibody D-3, described in U.S. Patent No. 8,404,239. In some embodiments, an
anti-Notch
antibody is antibody D, D-1, D-2, or D-3, described in U.S. Patent No.
8,404,239. In some
embodiments, an anti-Notch antibody is antibody D-3, described in U.S. Patent
No. 8,404,239.
In some embodiments, an anti-Notch antibody comprises the HVRs of, or the
variable
regions of, antibody 256A-4 or 256A-8, described in U.S. Patent No. 8,329,868.
In some
embodiments, an anti-Notch antibody is antibody 256A-4 or 256A-8, described in
U.S. Patent
No. 8,329,868. In some embodiments, an anti-Notch antibody comprises the HVRs
of, or the
variable regions of, antibody 256A-4, described in U.S. Patent No. 8,329,868.
In some
embodiments, an anti-Notch antibody is antibody 256A-4, described in U.S.
Patent No.
8,329,868.
In some embodiments, an anti-Notch antibody comprises the HVRs of, or the
variable
regions of, antibody 255A-71, 255A-77, or 256A-13, described in U.S. Patent
No. 8,513,388.
37
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
In some embodiments, an anti-Notch antibody is antibody 255A-71, 255A-77, or
256A-13,
described in U.S. Patent No. 8,513,388.
In some embodiments, an anti-Notch antibody comprises the HVRs of, or the
variable
regions of, antibody N248A, described in U.S. Publication No. 2012/0093813. In
some
embodiments, an anti-Notch antibody is antibody N248A, described in U.S.
Publication No.
2012/0093813.
2. Anti-Jagged Antibodies
In some embodiments, anti-Jagged antibodies are provided. In some such
embodiments, an anti-Jagged antibody binds to Jaggedl and Jagged2.
Anti-Jagged antibodies useful in the methods of the invention include, but are
not
limited to, the anti-Jagged antibodies described in U.S. Publication Nos.
2014/0010810;
2012/0301489; 2008/0317760; PCT Publication No. 2014/028446; and PCT
Publication No.
2014/111704. In some embodiments, an anti-Jagged antibody comprises the HVRs
of any of
the anti-Jagged antibodies described in the patents and applications listed
above.
In some embodiments, an anti-Jagged antibody comprises the HVRs of, or the
variable
regions of, antibody 4D11, described in U.S. Publication No. 2014/0010810. In
some
embodiments, an anti-Jagged antibody is antibody 4D11 or 5342-1204-4D11,
described in U.S.
Publication No. 2014/0010810.
In some embodiments, an anti-Jagged antibody comprises the HVRs of, or the
variable
regions of, antibody 64R7, described in U.S. Publication No. 2012/0301489. In
some
embodiments, an anti-Jagged antibody is antibody 64R7, described in U.S.
Publication No.
2012/0301489.
In some embodiments, an anti-Jagged antibody comprises the HVRs of, or the
variable
regions of, antibody 64M14, described in U.S. Publication No. 2008/0317760,
and deposited
with the ATCC under deposit number PTA-10416. In some embodiments, an anti-
Jagged
antibody is antibody 64M14, described in U.S. Publication No. 2008/0317760.
In some embodiments, an anti-Jagged antibody comprises the HVRs of, or the
variable
regions of, antibody 133R0201, described in U.S. Publication No. 2012/0301489.
In some
embodiments, an anti-Jagged antibody is antibody 133R0201, described in U.S.
Publication
No. 2012/0301489.
In some embodiments, an anti-Jagged antibody comprises the HVRs of, or the
variable
regions of, antibody 133R0203, described in U.S. Publication No. 2012/0301489.
In some
38
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
embodiments, an anti-Jagged antibody is antibody 133R0203, described in U.S.
Publication
No. 2012/0301489.
In some embodiments, an anti-Jagged antibody comprises the HVRs of, or the
variable
regions of, antibody 133R0205, described in U.S. Publication No. 2012/0301489.
In some
embodiments, an anti-Jagged antibody is antibody 133R0205, described in U.S.
Publication
No. 2012/0301489.
In some embodiments, an anti-Jagged antibody comprises the HVRs of, or the
variable
regions of, antibody 64M51, described in U.S. Publication No. 2012/0301489. In
some
embodiments, an anti-Jagged antibody is antibody 64M51, described in U.S.
Publication No.
2012/0301489.
In some embodiments, an anti-Jagged antibody comprises the HVRs of, or the
variable
regions of, antibody 64R1B, described in U.S. Publication No. 2012/0301489. In
some
embodiments, an anti-Jagged antibody is antibody 64R1B, described in U.S.
Publication No.
2012/0301489.
In some embodiments, an anti-Jagged antibody comprises the HVRs of, or the
variable
regions of, antibody J1-65D or antibody J1-183D or a variant of one of those
antibodies,
described in U.S. Publication No. 2014/111704 (see, e.g., Table 5 and Figures
23 and 24). In
some embodiments, an anti-Jagged antibody is antibody J1-65D or antibody J1-
183D or a
variant of one of those antibodies, described in U.S. Publication No.
2014/111704.
In some embodiments, an anti-Jagged antibody comprises the HVRs of, or the
variable
regions of, antibody A, A-1, or A-2, described in PCT Publication No. WO
2014/028446. In
some embodiments, an anti-Jagged antibody is antibody A, A-1, or A-2,
described in PCT
Publication No. WO 2014/028446. In some embodiments, an anti-Jagged antibody
comprises
the HVRs of, or the variable regions of, antibody A-2, described in PCT
Publication No. WO
2014/028446. In some embodiments, an anti-Jagged antibody is antibody A-2,
described in
PCT Publication No. WO 2014/028446.
In some embodiments, an anti-Jagged antibody comprises the HVRs of, or the
variable
regions of, antibody B, B-1, B-2, B-3, or B-4, described in PCT Publication
No. WO
2014/028446. In some embodiments, an anti-Jagged antibody is antibody B, B-1,
B-2, B-3, or
B-4, described in PCT Publication No. WO 2014/028446. In some embodiments, an
anti-
Jagged antibody comprises the HVRs of, or the variable regions of, antibody B-
3, described in
PCT Publication No. WO 2014/028446. In some embodiments, an anti-Jagged
antibody is
antibody B-3, described in PCT Publication No. WO 2014/028446.
39
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
In some embodiments, an anti-Jagged antibody comprises the HVRs of, or the
variable
regions of, antibody C-1, described in PCT Publication No. WO 2014/028446. In
some
embodiments, an anti-Jagged antibody is antibody C-1, described in PCT
Publication No. WO
2014/028446.
3. Anti-DLL Antibodies
In some embodiments, anti-DLL antibodies are provided. In some such
embodiments,
an anti-DLL antibody binds to DLL1 and/or DLL4. In some embodiments, an anti-
DLL
antibody is a bispecific antibody comprising a first antigen binding site that
binds to DLL and a
second antigen biding site that binds to a different antigen. In some
embodiments, an anti-DLL
antibody is a bispecific antibody comprising a first antigen binding site that
binds to DLL and a
second antigen biding site that binds to VEGF.
Anti-DLL antibodies useful in the methods of the invention include, but are
not limited
to, the anti-DLL antibodies described in U.S. Patent No. 7,803,377; U.S.
Publication No.
2010/0196385; 2014/0093521; 2013/0323248; and 2013/0164295. In some
embodiments, an
anti-DLL antibody comprises the HVRs of any of the anti-DLL antibodies
described in the
patents and applications listed above.
In some embodiments, an anti-DLL antibody comprises the HVRs of, or the
variable
regions of, antibody YW26.82, described in U.S. Patent No. 7,803,377. In some
embodiments,
an anti-DLL antibody is antibody YW26.82, described in U.S. Patent No.
7,803,377.
In some embodiments, an anti-DLL antibody comprises the HVRs of, or the
variable
regions of, antibody OMP-21M18, described in U.S. Publication No.
2013/0323265. In some
embodiments, an anti-DLL antibody is antibody OMP-21M18, described in U.S.
Publication
No. 2013/0323265. In some embodiments, an anti-DLL antibody comprises the HVRs
of, or
the variable regions of, an antibody encoded by the plasmid having ATCC
deposit no. PTA-
8425 or PTA-8427. See U.S. Publication No. 2013/0323265. In some embodiments,
an anti-
DLL antibody is demcizumab.
In some embodiments, an anti-DLL antibody is a bispecific antibody that binds
DLL4
and VEGF. In some embodiments, an anti-DLL antibody comprises the HVRs of, or
the
variable regions of, an anti-DLL4 antibody or bispecific antibody described in
U.S. Patent No.
2013/0164295. In some embodiments, an anti-DLL antibody is an anti-DLL4
antibody or
bispecific antibody that described in U.S. Patent No. 2013/0164295. In some
embodiments, an
anti-DLL antibody is a bispecific antibody comprising the HVRs of, or the
variable regions of,
anti-VEGF/anti-DLL4 bispecific antibody 219R45-MB-21M18 or 219R45-MB-21R83,
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
described in U.S. Publication No. 2013/0164295. In some embodiments, an anti-
DLL antibody
is anti-VEGF/anti-DLL4 bispecific antibody 219R45-MB-21M18 or 219R45-MB-21R83,
described in U.S. Publication No. 2013/0164295.
4. Gamma Secretase Inhibitors
In some embodiments, gamma secretase inhibitors are provided. Nonlimiting
exemplary gamma secretase inhibitors include tarenflurbil (Flurizan),
semagacestat
(LY450139), avagacestat, MK-0752 (3-((1r,4s)-4-(4-chlorophenylsulfony1)-4-(2,5-
difluorophenyBcyclohexyl)propanoic acid), N-N-(3,5-Difluorophenacety1)-L-
alanyll-S-
phenylglycine t-butyl ester (DAPT), (2S)-2-{ 11(3,5-
DifluorophenyBacetyllamino}-N-11(3S)-1-
methyl-2-oxo-5-pheny1-2,3-dihydro-1H-1,4-benzodiazepin-3-yllpropanamide
(compound E),
and N-R1S)-2-1R7S)-6,7-Dihydro-5-methy1-6-oxo-5H-dibenz[b,cflazepin-7-
yllaminol-l-
methy1-2-oxoethyll-3,5-difluorobenzeneacetamide (DBZ). U.S. Patent Nos.
6,756,511;
6,890,956; 6,984,626; 7,049,296; 7,101,895; 7,138,400; 7,144,910; 7,183,303;
8,377,886.
B. Wnt Pathway Inhibitors
In some embodiments, the invention provides Wnt pathway inhibitors. Wnt
pathway
inhibitors include, but are not limited to, small molecules, polypeptides, and
antibodies that
bind to one or more proteins involved in Wnt signaling. Nonlimiting exemplary
antibodies that
bind to one or more proteins involved in Wnt signaling include anti-LRP
antibodies, anti-
Frizzled antibodies, anti-RSPO antibodies, and anti-Wnt antibodies. Also
provided are
bispecific antibodies comprising a first antigen binding region that binds to
one or more
proteins involved in Wnt signaling and a second antigen binding region that
binds to one or
more proteins involved in Wnt signaling or a second antigen binding region
that binds to an
antigen not directly involved in Wnt. Also provided are soluble receptor
inhibitors of the Wnt
pathway, including but not limited to, soluble Fzd receptors. Also provided
are small molecule
inhibitors of the Wnt pathway, including but not limited to, small molecules
that inhibit p-
catenin.
I. Anti-LRP Antibodies
In some embodiments, anti-LRP antibodies are provided. In some such
embodiments,
an anti-LRP antibody binds to LRP5 and/or LRP6. In some embodiments, an anti-
LRP
antibody is a bispecific or biparatopic antibody comprising a first antigen
binding site that
binds to an LRP (such as LRP6) and a second antigen biding site that binds to
an LRP (such as
LRP6). In some embodiments, an anti-LRP antibody binds to both LRP5 and LRP6.
41
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
Anti-LRP antibodies useful in the methods of the invention include, but are
not limited
to, the anti-LRP antibodies described in U.S. Publication Nos. 2013/0183320;
2011/0256127;
2011/0243963; 2013/0064823; and 2012/0276089. In some embodiments, an anti-LRP
antibody comprises the HVRs of any of the anti-LRP antibodies described in the
patents and
applications listed above.
In some embodiments, an anti-LRP antibody comprises the HVRs of, or the
variable
regions of, antibody YW211.31.62 and/or YW210.09, described in U.S.
Publication No.
2011/0256127. In some embodiments, an anti-LRP antibody is antibody
YW211.31.62 or
YW210.09, described in U.S. Publication No. 2011/0256127. In some embodiments,
an anti-
LRP antibody is a bispecific antibody comprising a first antigen binding
region comprising the
HVRs of, or the variable regions of, antibody YW211.31.62, and a second
antigen binding
region comprising HVRs of, or the variable regions of, antibody YW210.09. In
some
embodiments, an anti-LRP antibody is bispecific antibody YW211.31.62/YW210.09.
In some embodiments, an anti-LRP antibody comprises the HVRs of, or the
variable
regions of, a biparatopic antibody described in U.S. Publication No.
2013/0064823. In some
embodiments, an anti-LRP antibody is a biparatopic antibody described in U.S.
Publication No.
2013/0064823.
In some embodiments, an anti-LRP antibody comprises the HVRs of, or the
variable
regions of, antibody P6C.51.61, described in U.S. Publication No.
2013/0183320. In some
embodiments, an anti-LRP antibody is antibody P6C.51.61, described in U.S.
Publication No.
2013/0183320.
In some embodiments, an anti-LRP antibody comprises the HVRs of, or the
variable
regions of, antibody 7E5C8, described in U.S. Publication No. 2012/0276089. In
some
embodiments, an anti-LRP antibody is antibody 7E5C8, described in U.S.
Publication No.
2012/0276089.
2. Anti-Frizzled Antibodies
In some embodiments, anti-Frizzled antibodies are provided. In some
embodiments, an
anti-Frizzled antibody binds Fzd7. In some embodiments, an anti-Frizzled
antibody binds
more than one Frizzled. In some embodiments, an anti-Frizzled antibody binds
one or more
Fzds selected from Fzdl, Fzd2, Fzd5, Fzd7, and Fzd8. In some embodiments, an
anti-Frizzled
antibody binds Fzd5 and/or Fzd8. In some embodiments, an anti-Frizzled
antibody binds
Fzd10.
42
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
Anti-Frizzled antibodies useful in the methods of the invention include, but
are not
limited to, the anti-Frizzled antibodies described in U.S. Patent Nos.
7,982,013; 8,507,442;
U.S. Publication Nos. 2013/0295106; 2012/0027778; and 2013/0095104. In some
embodiments, an anti-Frizzled antibody comprises the HVRs of any of the anti-
Frizzled
antibodies described in the patents and applications listed above.
In some embodiments, an anti-Fzd antibody comprises the HVRs of, or the
variable
regions of, antibody 18R5, described in U.S. Patent No. 8,507,442. In some
embodiments, an
anti-Fzd antibody is antibody 18R5, described in U.S. Patent No. 8,507,442.
In some embodiments, an anti-Fzd antibody comprises the HVRs of, or the
variable
regions of, antibody B9L9.3, described in U.S. Publication No. 2013/0095104.
In some
embodiments, an anti-Fzd antibody is a humanized antibody huB9L9.3, described
in U.S.
Publication No. 2013/0095104.
3. Anti-Wnt Antibodies
In some embodiments, anti-Wnt antibodies are provided. In some embodiments, an
anti-Wnt antibody binds to at least one Wnt selected from Wntl, Wnt2, Wnt2b,
Wnt3, Wnt3 a,
Wnt7a, Wnt7b, Wnt8a, Wnt8b, Wntl0a, and Wntl0b. In some embodiments, an anti-
Wnt
antibody binds to two or more Wnts selected from Wntl, Wnt2, Wnt2b, Wnt3,
Wnt3a, Wnt7a,
Wnt7b, Wnt8a, Wnt8b, Wntl0a, and Wntl0b.
Anti-Wnt antibodies useful in the methods of the invention include, but are
not limited
to, the anti-Wnt antibodies described in U.S. Publication No. 2013/0045209. In
some
embodiments, an anti-Wnt antibody comprises the HVRs of any of the anti-Wnt
antibodies
described in U.S. Publication No. 2013/0045209 (including, but not limited to,
an anti-Wnt
antibody comprising the HVRs of an antibody selected from 250M1, 250M2, 250M3,
250M6,
250M8, 250M11, 250M13, 250M17, 250M19, 25024, and 250M25).
4. Anti-RSPO Antibodies
In some embodiments, anti-RSPO antibodies are provided. In some embodiments,
an
anti-RSPO antibody binds at least one RSPO selected from RSP01, RSP02, and
RSP03. In
some embodiments, an anti-RSPO antibody binds RSP01. In some embodiments, an
anti-
RSPO antibody binds RSP02. In some embodiments, an anti-RSPO antibody binds
RSPO2
and RSP03.
Anti-RSPO antibodies useful in the methods of the invention include, but are
not
limited to, the anti-RSPO antibodies described in U.S. Publication No.
2013/0209473; PCT
Publication No. WO 2014/012007; U.S. Patent No. 8,802,097. In some
embodiments, an anti-
43
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
RSPO antibody comprises the HVRs of any of the anti-RSPO antibodies described
in the
patent and applications listed above.
In some embodiments, an anti-RSPO antibody comprises the HVRs of, or the
variable
regions of, antibody 131R010, described in PCT Publication No. WO 2014/012007.
In some
embodiments, an anti-RSPO antibody is antibody 131R010, described in PCT
Publication No.
WO 2014/012007.
In some embodiments, an anti-RSPO antibody comprises the HVRs of, or the
variable
regions of, antibody 89M5 or 130M23, described in U.S. Patent No. 8,802,097.
In some
embodiments, an anti-RSPO antibody is antibody 89M5 or 130M23, described in
U.S. Patent
No. 8,802,097.
5. Soluble Frizzled Receptors
In some embodiments, soluble Frizzled receptors are provided. In some
embodiments,
a soluble Frizzled receptor comprises the Fri domain of a Frizzled receptor
selected from Fzd4,
Fzd5, Fzd6, Fzd7, Fzd8, and Fzd10. See, e.g., U.S. Patent Nos. 7,723,477 and
7,947,277. In
some embodiments, a soluble Frizzled receptor comprises the Fri domain of
Fzd8. In some
embodiments, a soluble Frizzled receptor comprises the Fri domain of Fzd4. In
some
embodiments, a soluble Frizzled receptor comprises the Fri domain of Fzd5. In
some
embodiments, a soluble Frizzled receptor is fused to an Fc domain.
Soluble Frizzleds useful in the methods of the invention include, but are not
limited to,
the soluble Frizzled described in U.S. Patent No. 7,723,477. In some
embodiments, a soluble
Frizzled is 54F28, described in U.S. Patent No. 7,723,477.
Soluble Frizzleds useful in the methods of the invention include, but are not
limited to,
the soluble Frizzled described in U.S. Patent No. 7,947,277. In some
embodiments, a soluble
Frizzled is a soluble Fzd8, described in U.S. Patent No. 7,947,277.
6. Other Wnt Pathway Inhibitors
In some embodiments, small molecule and polypeptide inhibitors of the Wnt
pathway
are provided. In some embodiments, a Wnt pathway inhibitor is a polypeptide
described in
U.S. Patent No. 8,551,789. In some embodiments, a Wnt pathway inhibitor is a
peptide
described in U.S. Publication No. 2013/0273058.
Nonlimiting exemplary small molecule inhibitors of the Wnt pathway are
described,
e.g., in U.S. Patent No. 8,445,491; 8,450,340; U.S. Publication No.
2013/0296344;
2013/0190258; 2013/0267495; 2013/0225576; 2014/0031374; 2014/0005164; and
Landman et
al., 2013, Arthritis Research & Therapy 15:R93 (PKF115-584, PKF118-310, and
44
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
CGP049090); Chen et al., 2009, Nat. Chem. Biol. 5: 100-7 (IWP-2). Further
small molecule
inhibitors of the Wnt pathway include, but are not limited to, CCT036477
(Santa Cruz
Biotechnology), IWR-1 endo and exo (Santa Cruz Biotechnology), FH535 (Santa
Cruz
Biotechnology), LGK974 (2-(2',3-dimethyl-112,4'-bipyridin1-5-y1)-N-(5-(pyrazin-
2-yl)pyridin-2-
yl)acetamide), Wnt-059 (2-(4-(2-methylpyridin-4-yl)pheny1)-N-(4-(pyridin-3-
yl)phenyl)acetamide), AVN316 (Avalon Pharmaceuticals), and PRI-724 (Prism
Pharma Co.).
In a further aspect, any of the antibodies according to any of the above
embodiments
may incorporate any of the features, singly or in combination, as described in
Sections 1-7
below:
7. Antibody Affinity
In certain embodiments, an antibody provided herein has a dissociation
constant (Kd) of
< 1 M, < 100 nM, < 10 nM, < 1 nM, <0.1 nM, <0.01 nM, or < 0.001 nM (e.g. 10-8M
or less,
e.g. from 10-8M to 10-13M, e.g., from 10-9M to 10-13 M).
In one embodiment, Kd is measured by a radiolabeled antigen binding assay
(RIA). In
one embodiment, an RIA is performed with the Fab version of an antibody of
interest and its
antigen. For example, solution binding affinity of Fabs for antigen is
measured by
equilibrating Fab with a minimal concentration of (1251)-labeled antigen in
the presence of a
titration series of unlabeled antigen, then capturing bound antigen with an
anti-Fab antibody-
coated plate (see, e.g., Chen et al., J. Mol. Biol. 293:865-881(1999)). To
establish conditions
for the assay, MICROTITER multi-well plates (Thermo Scientific) are coated
overnight with
5 ug/m1 of a capturing anti-Fab antibody (Cappel Labs) in 50 mM sodium
carbonate (pH 9.6),
and subsequently blocked with 2% (w/v) bovine serum albumin in PBS for two to
five hours at
room temperature (approximately 23 C). In a non-adsorbent plate (Nunc
#269620), 100 pM or
26 pM antigen are mixed with serial dilutions of a Fab of interest (e.g.,
consistent with
assessment of the anti-VEGF antibody, Fab-12, in Presta et al., Cancer Res.
57:4593-4599
(1997)). The Fab of interest is then incubated overnight; however, the
incubation may continue
for a longer period (e.g., about 65 hours) to ensure that equilibrium is
reached. Thereafter, the
mixtures are transferred to the capture plate for incubation at room
temperature (e.g., for one
hour). The solution is then removed and the plate washed eight times with 0.1%
polysorbate
20 (TWEEN-20 ) in PBS. When the plates have dried, 150 1/well of scintillant
(MICROSCINT-20 TM; Packard) is added, and the plates are counted on a TOPCOUNT
TM
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
gamma counter (Packard) for ten minutes. Concentrations of each Fab that give
less than or
equal to 20% of maximal binding are chosen for use in competitive binding
assays.
According to another embodiment, Kd is measured using a BIACORE surface
plasmon resonance assay. For example, an assay using a BIACORE -2000 or a
BIACORE -
3000 (BIAcore, Inc., Piscataway, NJ) is performed at 25 C with immobilized
antigen CM5
chips at ¨10 response units (RU). In one embodiment, carboxymethylated dextran
biosensor
chips (CM5, BIACORE, Inc.) are activated with N-ethyl-N'- (3-
dimethylaminopropy1)-
carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to
the
supplier's instructions. Antigen is diluted with 10 mM sodium acetate, pH 4.8,
to 5 g/m1
(-0.2 M) before injection at a flow rate of 5 1/minute to achieve
approximately 10 response
units (RU) of coupled protein. Following the injection of antigen, 1 M
ethanolamine is
injected to block unreacted groups. For kinetics measurements, two-fold serial
dilutions of Fab
(0.78 nM to 500 nM) are injected in PBS with 0.05% polysorbate 20 (TWEEN-201m)
surfactant (PBST) at 25 C at a flow rate of approximately 25 1/min.
Association rates (kon)
and dissociation rates (kojf) are calculated using a simple one-to-one
Langmuir binding model
(BIACORE Evaluation Software version 3.2) by simultaneously fitting the
association and
dissociation sensorgrams. The equilibrium dissociation constant (Kd) is
calculated as the ratio
kojf/kon. See, e.g., Chen et al., J. Mol. Biol. 293:865-881 (1999). If the on-
rate exceeds 106
M-1 5-1 by the surface plasmon resonance assay above, then the on-rate can be
determined by
using a fluorescent quenching technique that measures the increase or decrease
in fluorescence
emission intensity (excitation = 295 nm; emission = 340 nm, 16 nm band-pass)
at 25 C of a 20
nM anti-antigen antibody (Fab form) in PBS, pH 7.2, in the presence of
increasing
concentrations of antigen as measured in a spectrometer, such as a stop-flow
equipped
spectrophometer (Aviv Instruments) or a 8000-series SLM-AMINCO 1'4
spectrophotometer
(ThermoSpectronic) with a stirred cuvette.
8. Antibody Fragments
In certain embodiments, an antibody provided herein is an antibody fragment.
Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH,
F(ab')2, Fv, and scFv
fragments, and other fragments described below. For a review of certain
antibody fragments,
see Hudson et al. Nat. Med. 9:129-134 (2003). For a review of scFv fragments,
see, e.g.,
Pluckthiin, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg
and Moore
eds., (Springer-Verlag, New York), pp. 269-315 (1994); see also WO 93/16185;
and U.S.
Patent Nos. 5,571,894 and 5,587,458. For discussion of Fab and F(ab')2
fragments comprising
46
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
salvage receptor binding epitope residues and having increased in vivo half-
life, see U.S.
Patent No. 5,869,046.
Diabodies are antibody fragments with two antigen-binding sites that may be
bivalent
or bispecific. See, for example, EP 404,097; WO 1993/01161; Hudson et al.,
Nat. Med. 9:129-
134 (2003); and Hollinger et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448
(1993). Triabodies
and tetrabodies are also described in Hudson et al., Nat. Med. 9:129-134
(2003).
Single-domain antibodies are antibody fragments comprising all or a portion of
the
heavy chain variable domain or all or a portion of the light chain variable
domain of an
antibody. In certain embodiments, a single-domain antibody is a human single-
domain
antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Patent No. 6,248,516
B1).
Antibody fragments can be made by various techniques, including but not
limited to
proteolytic digestion of an intact antibody as well as production by
recombinant host cells (e.g.
E. coli or phage), as described herein.
9. Chimeric and Humanized Antibodies
In certain embodiments, an antibody provided herein is a chimeric antibody.
Certain
chimeric antibodies are described, e.g., in U.S. Patent No. 4,816,567; and
Morrison et al., Proc.
Natl. Acad. Sci. USA, 81:6851-6855 (1984)). In one example, a chimeric
antibody comprises a
non-human variable region (e.g., a variable region derived from a mouse, rat,
hamster, rabbit,
or non-human primate, such as a monkey) and a human constant region. In a
further example,
a chimeric antibody is a "class switched" antibody in which the class or
subclass has been
changed from that of the parent antibody. Chimeric antibodies include antigen-
binding
fragments thereof.
In certain embodiments, a chimeric antibody is a humanized antibody.
Typically, a
non-human antibody is humanized to reduce immunogenicity to humans, while
retaining the
specificity and affinity of the parental non-human antibody. Generally, a
humanized antibody
comprises one or more variable domains in which HVRs, e.g., CDRs, (or portions
thereof) are
derived from a non-human antibody, and FRs (or portions thereof) are derived
from human
antibody sequences. A humanized antibody optionally will also comprise at
least a portion of a
human constant region. In some embodiments, some FR residues in a humanized
antibody are
substituted with corresponding residues from a non-human antibody (e.g., the
antibody from
which the HVR residues are derived), e.g., to restore or improve antibody
specificity or
affinity.
47
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
Humanized antibodies and methods of making them are reviewed, e.g., in Almagro
and
Fransson, Front. Biosci. 13:1619-1633 (2008), and are further described, e.g.,
in Riechmann et
al., Nature 332:323-329 (1988); Queen et al., Proc. Nat'l Acad. Sci. USA
86:10029-10033
(1989); US Patent Nos. 5, 821,337, 7,527,791, 6,982,321, and 7,087,409;
Kashmiri et al.,
Methods 36:25-34 (2005) (describing specificity determining region (SDR)
grafting); Padlan,
Mol. Immunol. 28:489-498 (1991) (describing "resurfacing"); Dall'Acqua et al.,
Methods
36:43-60 (2005) (describing "FR shuffling"); and Osbourn et al., Methods 36:61-
68 (2005) and
Klimka et al., Br. J. Cancer, 83:252-260 (2000) (describing the "guided
selection" approach to
FR shuffling).
Human framework regions that may be used for humanization include but are not
limited to: framework regions selected using the "best-fit" method (see, e.g.,
Sims et al. J.
Immunol. 151:2296 (1993)); framework regions derived from the consensus
sequence of
human antibodies of a particular subgroup of light or heavy chain variable
regions (see, e.g.,
Carter et al. Proc. Natl. Acad. Sci. USA, 89:4285 (1992); and Presta et al. J.
Immunol.,
151:2623 (1993)); human mature (somatically mutated) framework regions or
human germline
framework regions (see, e.g., Almagro and Fransson, Front. Biosci. 13:1619-
1633 (2008)); and
framework regions derived from screening FR libraries (see, e.g., Baca et al.,
J. Biol. Chem.
272:10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271:22611-22618
(1996)).
10. Haman Antibodies
In certain embodiments, an antibody provided herein is a human antibody. Human
antibodies can be produced using various techniques known in the art. Human
antibodies are
described generally in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5:
368-74 (2001)
and Lonberg, Curr. Opin. Immunol. 20:450-459 (2008).
Human antibodies may be prepared by administering an immunogen to a transgenic
animal that has been modified to produce intact human antibodies or intact
antibodies with
human variable regions in response to antigenic challenge. Such animals
typically contain all
or a portion of the human immunoglobulin loci, which replace the endogenous
immunoglobulin loci, or which are present extrachromosomally or integrated
randomly into the
animal's chromosomes. In such transgenic mice, the endogenous immunoglobulin
loci have
generally been inactivated. For review of methods for obtaining human
antibodies from
transgenic animals, see Lonberg, Nat. Biotech. 23:1117-1125 (2005). See also,
e.g., U.S.
Patent Nos. 6,075,181 and 6,150,584 describing XENOMOUSETm technology; U.S.
Patent No.
5,770,429 describing HuMAB technology; U.S. Patent No. 7,041,870 describing K-
M
48
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
MOUSE technology, and U.S. Patent Application Publication No. US
2007/0061900,
describing VELociMousE technology). Human variable regions from intact
antibodies
generated by such animals may be further modified, e.g., by combining with a
different human
constant region.
Human antibodies can also be made by hybridoma-based methods. Human myeloma
and mouse-human heteromyeloma cell lines for the production of human
monoclonal
antibodies have been described. (See, e.g., Kozbor J. Immunol., 133: 3001
(1984); Brodeur et
al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63
(Marcel Dekker,
Inc., New York, 1987); and Boemer et al., J. Immunol., 147: 86 (1991).) Human
antibodies
generated via human B-cell hybridoma technology are also described in Li et
al., Proc. Natl.
Acad. Sci. USA, 103:3557-3562 (2006). Additional methods include those
described, for
example, in U.S. Patent No. 7,189,826 (describing production of monoclonal
human IgM
antibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue, 26(4):265-268
(2006)
(describing human-human hybridomas). Human hybridoma technology (Trioma
technology) is
also described in Votimers and Brandlein, Histology and Histopathology,
20(3):927-937
(2005) and Votimers and Brandlein, Methods and Findings in Experimental and
Clinical
Pharmacology, 27(3):185-91 (2005).
Human antibodies may also be generated by isolating Fv clone variable domain
sequences selected from human-derived phage display libraries. Such variable
domain
sequences may then be combined with a desired human constant domain.
Techniques for
selecting human antibodies from antibody libraries are described below.
//. Library-Derived Antibodies
Antibodies of the invention may be isolated by screening combinatorial
libraries for
antibodies with the desired activity or activities. For example, a variety of
methods are known
in the art for generating phage display libraries and screening such libraries
for antibodies
possessing the desired binding characteristics. Such methods are reviewed,
e.g., in
Hoogenboom et al. in Methods in Molecular Biology 178:1-37 (O'Brien et al.,
ed., Human
Press, Totowa, NJ, 2001) and further described, e.g., in the McCafferty et
al., Nature 348:552-
554; Clackson et al., Nature 352: 624-628 (1991); Marks et al., J. Mol. Biol.
222: 581-597
(1992); Marks and Bradbury, in Methods in Molecular Biology 248:161-175 (Lo,
ed., Human
Press, Totowa, NJ, 2003); Sidhu et al., J. Mol. Biol. 338(2): 299-310 (2004);
Lee et al., J. Mol.
Biol. 340(5): 1073-1093 (2004); Fellouse, Proc. Natl. Acad. Sci. USA 101(34):
12467-12472
(2004); and Lee et al., J. Immunol. Methods 284(1-2): 119-132(2004).
49
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
In certain phage display methods, repertoires of VH and VL genes are
separately cloned
by polymerase chain reaction (PCR) and recombined randomly in phage libraries,
which can
then be screened for antigen-binding phage as described in Winter et al., Ann.
Rev. Immunol.,
12: 433-455 (1994). Phage typically display antibody fragments, either as
single-chain Fv
(scFv) fragments or as Fab fragments. Libraries from immunized sources provide
high-affinity
antibodies to the immunogen without the requirement of constructing
hybridomas.
Alternatively, the naive repertoire can be cloned (e.g., from human) to
provide a single source
of antibodies to a wide range of non-self and also self antigens without any
immunization as
described by Griffiths et al., EMBO J, 12: 725-734 (1993). Finally, naive
libraries can also be
made synthetically by cloning unrearranged V-gene segments from stem cells,
and using PCR
primers containing random sequence to encode the highly variable CDR3 regions
and to
accomplish rearrangement in vitro, as described by Hoogenboom and Winter, J.
Mol. Biol.,
227: 381-388 (1992). Patent publications describing human antibody phage
libraries include,
for example: US Patent No. 5,750,373, and US Patent Publication Nos.
2005/0079574,
2005/0119455, 2005/0266000, 2007/0117126, 2007/0160598, 2007/0237764,
2007/0292936,
and 2009/0002360.
Antibodies or antibody fragments isolated from human antibody libraries are
considered human antibodies or human antibody fragments herein.
6. Multispecific Antibodies
In certain embodiments, an antibody provided herein is a multispecific
antibody, e.g. a
bispecific antibody. Multispecific antibodies are monoclonal antibodies that
have binding
specificities for at least two different sites. In certain embodiments, one of
the binding
specificities is for a first antigen selected from Notch 1, Notch2, Notch3,
Notch4, Jagged 1, and
Jagged2; and the other is for a second antigen selected from the same list. In
certain
embodiments, one of the binding specificities is for a first antigen selected
from Notchl,
Notch2, Notch3, Notch4, Jagged 1, and Jagged2; and the other is for a second
antigen not
selected from the same list. In certain embodiments, bispecific antibodies may
bind to two
different epitopes of the same antigen. Bispecific antibodies can be prepared
as full length
antibodies or antibody fragments.
Techniques for making multispecific antibodies include, but are not limited
to,
recombinant co-expression of two immunoglobulin heavy chain-light chain pairs
having
different specificities (see Milstein and Cuello, Nature 305: 537 (1983)), WO
93/08829, and
Traunecker et al., EMBO J. 10: 3655 (1991)), and "knob-in-hole" engineering
(see, e.g., U.S.
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
Patent No. 5,731,168). Multi-specific antibodies may also be made by
engineering electrostatic
steering effects for making antibody Fc-heterodimeric molecules (WO
2009/089004A1); cross-
linking two or more antibodies or fragments (see, e.g., US Patent No.
4,676,980, and Brennan
et al., Science, 229: 81(1985)); using leucine zippers to produce bi-specific
antibodies (see,
e.g., Kostelny et al., J. Immunol., 148(5):1547-1553 (1992)); using "diabody"
technology for
making bispecific antibody fragments (see, e.g., Hollinger et al., Proc. Natl.
Acad. Sci. USA,
90:6444-6448 (1993)); and using single-chain Fv (sFv) dimers (see,e.g. Gruber
et al., J.
Immunol., 152:5368 (1994)); and preparing trispecific antibodies as described,
e.g., in Tutt et
al. J. Immunol. 147: 60 (1991).
Engineered antibodies with three or more functional antigen binding sites,
including
"Octopus antibodies," are also included herein (see, e.g. US 2006/0025576A1).
The antibody or fragment herein also includes a "Dual Acting FAb" or "DAF"
comprising an antigen binding site that binds to a first antigen as well as
another, different
antigen (see, US 2008/0069820, for example).
7. Antibody Variants
In certain embodiments, amino acid sequence variants of the antibodies
provided herein
are contemplated. For example, it may be desirable to improve the binding
affinity and/or
other biological properties of the antibody. Amino acid sequence variants of
an antibody may
be prepared by introducing appropriate modifications into the nucleotide
sequence encoding
the antibody, or by peptide synthesis. Such modifications include, for
example, deletions from,
and/or insertions into and/or substitutions of residues within the amino acid
sequences of the
antibody. Any combination of deletion, insertion, and substitution can be made
to arrive at the
final construct, provided that the final construct possesses the desired
characteristics, e.g.,
antigen-binding.
a) Substitution, Insertion, and Deletion Variants
In certain embodiments, antibody variants having one or more amino acid
substitutions
are provided. Sites of interest for substitutional mutagenesis include the
HVRs and FRs.
Conservative substitutions are shown in Table 1 under the heading of
"preferred substitutions."
More substantial changes are provided in Table 1 under the heading of
"exemplary
substitutions," and as further described below in reference to amino acid side
chain classes.
Amino acid substitutions may be introduced into an antibody of interest and
the products
screened for a desired activity, e.g., retained/improved antigen binding,
decreased
immunogenicity, or improved ADCC or CDC.
51
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
TABLE 1
Original Exemplary
Preferred
Residue Substitutions
Substitutions
Ala (A) Val; Leu; He Val
Arg (R) Lys; Gln; Asn Lys
Asn (N) Gln; His; Asp, Lys; Arg Gln
Asp (D) Glu; Asn Glu
Cys (C) Ser; Ala Ser
Gln (Q) Asn; Glu Asn
Glu (E) Asp; Gln Asp
Gly (G) Ala Ala
His (H) Asn; Gln; Lys; Arg Arg
Ile (I) Leu; Val; Met; Ala; Phe; Norleucine Leu
Leu (L) Norleucine; Ile; Val; Met; Ala; Phe Ile
Lys (K) Arg; Gln; Asn Arg
Met (M) Leu; Phe; Ile Leu
Phe (F) Trp; Leu; Val; He; Ala; Tyr Tyr
Pro (P) Ala Ala
Ser (S) Thr Thr
Thr (T) Val; Ser Ser
Trp (W) Tyr; Phe Tyr
Tyr (Y) Trp; Phe; Thr; Ser Phe
Val (V) Ile; Leu; Met; Phe; Ala; Norleucine Leu
Amino acids may be grouped according to common side-chain properties:
(1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile;
(2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;
(3) acidic: Asp, Glu;
(4) basic: His, Lys, Arg;
(5) residues that influence chain orientation: Gly, Pro;
(6) aromatic: Trp, Tyr, Phe.
Non-conservative substitutions will entail exchanging a member of one of these
classes
for another class.
One type of substitutional variant involves substituting one or more
hypervariable
region residues of a parent antibody (e.g. a humanized or human antibody).
Generally, the
52
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
resulting variant(s) selected for further study will have modifications (e.g.,
improvements) in
certain biological properties (e.g., increased affinity, reduced
immunogenicity) relative to the
parent antibody and/or will have substantially retained certain biological
properties of the
parent antibody. An exemplary substitutional variant is an affinity matured
antibody, which
may be conveniently generated, e.g., using phage display-based affinity
maturation techniques
such as those described herein. Briefly, one or more HVR residues are mutated
and the variant
antibodies displayed on phage and screened for a particular biological
activity (e.g. binding
affinity).
Alterations (e.g., substitutions) may be made in HVRs, e.g., to improve
antibody
affinity. Such alterations may be made in HVR "hotspots," i.e., residues
encoded by codons
that undergo mutation at high frequency during the somatic maturation process
(see, e.g.,
Chowdhury, Methods Mol. Biol. 207:179-196 (2008)), and/or residues that
contact antigen,
with the resulting variant VH or VL being tested for binding affinity.
Affinity maturation by
constructing and reselecting from secondary libraries has been described,
e.g., in Hoogenboom
et al. in Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., Human
Press, Totowa,
NJ, (2001).) In some embodiments of affinity maturation, diversity is
introduced into the
variable genes chosen for maturation by any of a variety of methods (e.g.,
error-prone PCR,
chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library
is then created.
The library is then screened to identify any antibody variants with the
desired affinity. Another
method to introduce diversity involves HVR-directed approaches, in which
several HVR
residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved
in antigen
binding may be specifically identified, e.g., using alanine scanning
mutagenesis or modeling.
CDR-H3 and CDR-L3 in particular are often targeted.
In certain embodiments, substitutions, insertions, or deletions may occur
within one or
more HVRs so long as such alterations do not substantially reduce the ability
of the antibody to
bind antigen. For example, conservative alterations (e.g., conservative
substitutions as
provided herein) that do not substantially reduce binding affinity may be made
in HVRs. Such
alterations may, for example, be outside of antigen contacting residues in the
HVRs. In certain
embodiments of the variant VH and VL sequences provided above, each HVR either
is
unaltered, or contains no more than one, two or three amino acid
substitutions.
A useful method for identification of residues or regions of an antibody that
may be
targeted for mutagenesis is called "alanine scanning mutagenesis" as described
by Cunningham
and Wells (1989) Science, 244:1081-1085. In this method, a residue or group of
target residues
(e.g., charged residues such as arg, asp, his, lys, and glu) are identified
and replaced by a
53
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
neutral or negatively charged amino acid (e.g., alanine or polyalanine) to
determine whether the
interaction of the antibody with antigen is affected. Further substitutions
may be introduced at
the amino acid locations demonstrating functional sensitivity to the initial
substitutions.
Alternatively, or additionally, a crystal structure of an antigen-antibody
complex to identify
contact points between the antibody and antigen. Such contact residues and
neighboring
residues may be targeted or eliminated as candidates for substitution.
Variants may be
screened to determine whether they contain the desired properties.
Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions
ranging in length from one residue to polypeptides containing a hundred or
more residues, as
well as intrasequence insertions of single or multiple amino acid residues.
Examples of
terminal insertions include an antibody with an N-terminal methionyl residue.
Other
insertional variants of the antibody molecule include the fusion to the N- or
C-terminus of the
antibody to an enzyme (e.g. for ADEPT) or a polypeptide which increases the
serum half-life
of the antibody.
b) Glycosylation variants
In certain embodiments, an antibody provided herein is altered to increase or
decrease
the extent to which the antibody is glycosylated. Addition or deletion of
glycosylation sites to
an antibody may be conveniently accomplished by altering the amino acid
sequence such that
one or more glycosylation sites is created or removed.
Where the antibody comprises an Fc region, the carbohydrate attached thereto
may be
altered. Native antibodies produced by mammalian cells typically comprise a
branched,
biantennary oligosaccharide that is generally attached by an N-linkage to
Asn297 of the CH2
domain of the Fc region. See, e.g., Wright et al. TIB TECH 15:26-32 (1997).
The
oligosaccharide may include various carbohydrates, e.g., mannose, N-acetyl
glucosamine
(G1cNAc), galactose, and sialic acid, as well as a fucose attached to a GlcNAc
in the "stem" of
the biantennary oligosaccharide structure. In some embodiments, modifications
of the
oligosaccharide in an antibody of the invention may be made in order to create
antibody
variants with certain improved properties.
In one embodiment, antibody variants are provided having a carbohydrate
structure that
lacks fucose attached (directly or indirectly) to an Fc region. For example,
the amount of
fucose in such antibody may be from 1% to 80%, from 1% to 65%, from 5% to 65%
or from
20% to 40%. The amount of fucose is determined by calculating the average
amount of fucose
within the sugar chain at Asn297, relative to the sum of all glycostructures
attached to Asn 297
54
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
(e. g. complex, hybrid and high mannose structures) as measured by MALDI-TOF
mass
spectrometry, as described in WO 2008/077546, for example. Asn297 refers to
the asparagine
residue located at about position 297 in the Fc region (Eu numbering of Fe
region residues);
however, Asn297 may also be located about 3 amino acids upstream or
downstream of
position 297, i.e., between positions 294 and 300, due to minor sequence
variations in
antibodies. Such fucosylation variants may have improved ADCC function. See,
e.g., US
Patent Publication Nos. US 2003/0157108 (Presta, L.); US 2004/0093621 (Kyowa
Hakko
Kogyo Co., Ltd). In some embodiments, an IgG1 constant region comprising an
N297G or
N297A mutation substantially lacks effector function. Examples of publications
related to
"defucosylated" or "fucose-deficient" antibody variants include: US
2003/0157108; WO
2000/61739; WO 2001/29246; US 2003/0115614; US 2002/0164328; US 2004/0093621;
US
2004/0132140; US 2004/0110704; US 2004/0110282; US 2004/0109865; WO
2003/085119;
WO 2003/084570; WO 2005/035586; WO 2005/035778; W02005/053742; W02002/031140;
Okazaki et al. J. Mol. Biol. 336:1239-1249 (2004); Yamane-Ohnuki et al.
Biotech. Bioeng. 87:
614 (2004). Examples of cell lines capable of producing defucosylated
antibodies include
Lec13 CHO cells deficient in protein fucosylation (Ripka et al. Arch. Biochem.
Biophys.
249:533-545 (1986); US Pat Appl No US 2003/0157108 Al, Presta, L; and WO
2004/056312
Al, Adams et al., especially at Example 11), and knockout cell lines, such as
alpha-1,6-
fucosyltransferase gene, FUT8, knockout CHO cells (see, e.g., Yamane-Ohnuki et
al. Biotech.
Bioeng. 87: 614 (2004); Kanda, Y. et al., Biotechnol. Bioeng., 94(4):680-688
(2006); and
W02003/085107).
Antibodies variants are further provided with bisected oligosaccharides, e.g.,
in which a
biantennary oligosaccharide attached to the Fc region of the antibody is
bisected by GleNAc.
Such antibody variants may have reduced fucosylation and/or improved ADCC
function.
Examples of such antibody variants are described, e.g., in WO 2003/011878
(Jean-Mairet et
al.); US Patent No. 6,602,684 (Umana et al.); and US 2005/0123546 (Umana et
al.). Antibody
variants with at least one galactose residue in the oligosaccharide attached
to the Fc region are
also provided. Such antibody variants may have improved CDC function. Such
antibody
variants are described, e.g., in WO 1997/30087 (Patel et al.); WO 1998/58964
(Raju, S.); and
WO 1999/22764 (Raju, S.).
c) Fc region variants
In certain embodiments, one or more amino acid modifications may be introduced
into
the Fc region of an antibody provided herein, thereby generating an Fe region
variant. The Fc
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
region variant may comprise a human Fc region sequence (e.g., a human IgGl,
IgG2, IgG3 or
IgG4 Fe region) comprising an amino acid modification (e.g. a substitution) at
one or more
amino acid positions.
In certain embodiments, the invention contemplates an antibody variant that
possesses
some but not all effector functions, which make it a desirable candidate for
applications in
which the half life of the antibody in vivo is important yet certain effector
functions (such as
complement and ADCC) are unnecessary or deleterious. In vitro and/or in vivo
cytotoxicity
assays can be conducted to confirm the reduction/depletion of CDC and/or ADCC
activities.
For example, Fc receptor (FcR) binding assays can be conducted to ensure that
the antibody
lacks FeyR binding (hence likely lacking ADCC activity), but retains FcRn
binding ability.
The primary cells for mediating ADCC, NK cells, express Fe(RIII only, whereas
monocytes
express Fe(RI, Fe(RII and Fe(RIII. FcR expression on hematopoietic cells is
summarized in
Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492
(1991). Non-
limiting examples of in vitro assays to assess ADCC activity of a molecule of
interest is
described in U.S. Patent No. 5,500,362 (see, e.g. Hellstrom, I. et al. Proc.
Nat'l Acad. Sci. USA
83:7059-7063 (1986)) and Hellstrom, let al., Proc. Nat'l Acad. Sci. USA
82:1499-1502 (1985);
5,821,337 (see Bruggemann, M. et al., J. Exp. Med. 166:1351-1361 (1987)).
Alternatively,
non-radioactive assays methods may be employed (see, for example, ACTITm non-
radioactive
cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, CA;
and CytoTox
96 non-radioactive cytotoxicity assay (Promega, Madison, WI). Useful effector
cells for such
assays include peripheral blood mononuclear cells (PBMC) and Natural Killer
(NK) cells.
Alternatively, or additionally, ADCC activity of the molecule of interest may
be assessed in
vivo, e.g., in a animal model such as that disclosed in Clynes et al. Proc.
Nat'l Acad. Sci. USA
95:652-656 (1998). Clq binding assays may also be carried out to confirm that
the antibody is
unable to bind Clq and hence lacks CDC activity. See, e.g., Clq and C3c
binding ELISA in
WO 2006/029879 and WO 2005/100402. To assess complement activation, a CDC
assay may
be performed (see, for example, Gazzano-Santoro et al., J. Immunol. Methods
202:163 (1996);
Cragg, M.S. et al., Blood 101:1045-1052 (2003); and Cragg, M.S. and M.J.
Glennie, Blood
103:2738-2743 (2004)). FcRn binding and in vivo clearance/half life
determinations can also
be performed using methods known in the art (see, e.g., Petkova, S.B. et al.,
Int'l. Immunol.
18(12):1759-1769 (2006)).
Antibodies with reduced effector function include those with substitution of
one or
more of Fc region residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Patent
No. 6,737,056).
Such Fc mutants include Fc mutants with substitutions at two or more of amino
acid positions
56
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
265, 269, 270, 297 and 327, including the so-called "DANA" Fc mutant with
substitution of
residues 265 and 297 to alanine (US Patent No. 7,332,581).
Certain antibody variants with improved or diminished binding to FcRs are
described.
(See, e.g., U.S. Patent No. 6,737,056; WO 2004/056312, and Shields et al., J.
Biol. Chem. 9(2):
6591-6604 (2001).)
In certain embodiments, an antibody variant comprises an Fc region with one or
more
amino acid substitutions which improve ADCC, e.g., substitutions at positions
298, 333, and/or
334 of the Fc region (EU numbering of residues).
In some embodiments, alterations are made in the Fc region that result in
altered (i.e.,
either improved or diminished) Clq binding and/or Complement Dependent
Cytotoxicity
(CDC), e.g., as described in US Patent No. 6,194,551, WO 99/51642, and
Idusogie et al. J.
Immunol. 164: 4178-4184 (2000).
Antibodies with increased half lives and improved binding to the neonatal Fc
receptor
(FcRn), which is responsible for the transfer of maternal IgGs to the fetus
(Guyer et al., J.
Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)), are
described in
U52005/0014934A1 (Hinton et al.). Those antibodies comprise an Fc region with
one or more
substitutions therein which improve binding of the Fe region to FcRn. Such Fc
variants
include those with substitutions at one or more of Fc region residues: 238,
256, 265, 272, 286,
303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424
or 434, e.g.,
substitution of Fc region residue 434 (US Patent No. 7,371,826).
See also Duncan & Winter, Nature 322:738-40 (1988); U.S. Patent No. 5,648,260;
U.S. Patent No. 5,624,821; and WO 94/29351 concerning other examples of Fc
region variants.
d) Cvsteine engineered antibody variants
In certain embodiments, it may be desirable to create cysteine engineered
antibodies,
e.g., THIOMAB antibodies, in which one or more residues of an antibody are
substituted with
cysteine residues. In particular embodiments, the substituted residues occur
at accessible sites
of the antibody. By substituting those residues with cysteine, reactive thiol
groups are thereby
positioned at accessible sites of the antibody and may be used to conjugate
the antibody to
other moieties, such as drug moieties or linker-drug moieties, to create an
immunoconjugate, as
described further herein. In certain embodiments, any one or more of the
following residues
may be substituted with cysteine: V205 (Kabat numbering) of the light chain;
A118 (EU
numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc
region.
57
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
Cysteine engineered antibodies may be generated as described, e.g., in U.S.
Patent No.
7,521,541.
e) Antibody Derivatives
In certain embodiments, an antibody provided herein may be further modified to
contain additional nonproteinaceous moieties that are known in the art and
readily available.
The moieties suitable for derivatization of the antibody include but are not
limited to water
soluble polymers. Non-limiting examples of water soluble polymers include, but
are not
limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene
glycol,
carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone,
poly-1, 3-
dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer,
polyaminoacids (either
homopolymers or random copolymers), and dextran or poly(n-vinyl
pyrrolidone)polyethylene
glycol, propropylene glycol homopolymers, prolypropylene oxide/ethylene oxide
co-polymers,
polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures
thereof.
Polyethylene glycol propionaldehyde may have advantages in manufacturing due
to its stability
in water. The polymer may be of any molecular weight, and may be branched or
unbranched.
The number of polymers attached to the antibody may vary, and if more than one
polymer are
attached, they can be the same or different molecules. In general, the number
and/or type of
polymers used for derivatization can be determined based on considerations
including, but not
limited to, the particular properties or functions of the antibody to be
improved, whether the
antibody derivative will be used in a therapy under defined conditions, etc.
In another embodiment, conjugates of an antibody and nonproteinaceous moiety
that
may be selectively heated by exposure to radiation are provided. In one
embodiment, the
nonproteinaceous moiety is a carbon nanotube (Kam et al., Proc. Natl. Acad.
Sci. USA 102:
11600-11605 (2005)). The radiation may be of any wavelength, and includes, but
is not
limited to, wavelengths that do not harm ordinary cells, but which heat the
nonproteinaceous
moiety to a temperature at which cells proximal to the antibody-
nonproteinaceous moiety are
killed.
C. Recombinant Methods and Compositions
Antibodies may be produced using recombinant methods and compositions, e.g.,
as
described in U.S. Patent No. 4,816,567. In one embodiment, isolated nucleic
acid encoding an
antibody described herein is provided. Such nucleic acid may encode an amino
acid sequence
comprising the VL and/or an amino acid sequence comprising the VH of the
antibody (e.g., the
58
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
light and/or heavy chains of the antibody). In a further embodiment, one or
more vectors (e.g.,
expression vectors) comprising such nucleic acid are provided. In a further
embodiment, a host
cell comprising such nucleic acid is provided. In one such embodiment, a host
cell comprises
(e.g., has been transformed with): (1) a vector comprising a nucleic acid that
encodes an amino
acid sequence comprising the VL of the antibody and an amino acid sequence
comprising the
VH of the antibody, or (2) a first vector comprising a nucleic acid that
encodes an amino acid
sequence comprising the VL of the antibody and a second vector comprising a
nucleic acid that
encodes an amino acid sequence comprising the VH of the antibody. In one
embodiment, the
host cell is eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell or lymphoid
cell (e.g., YO,
NSO, Sp20 cell). In one embodiment, a method of making an antibody is
provided, wherein the
method comprises culturing a host cell comprising a nucleic acid encoding the
antibody, as
provided above, under conditions suitable for expression of the antibody, and
optionally
recovering the antibody from the host cell (or host cell culture medium).
For recombinant production of an antibody, nucleic acid encoding an antibody,
e.g., as
described above, is isolated and inserted into one or more vectors for further
cloning and/or
expression in a host cell. Such nucleic acid may be readily isolated and
sequenced using
conventional procedures (e.g., by using oligonucleotide probes that are
capable of binding
specifically to genes encoding the heavy and light chains of the antibody).
Suitable host cells for cloning or expression of antibody-encoding vectors
include
prokaryotic or eukaryotic cells described herein. For example, antibodies may
be produced in
bacteria, in particular when glycosylation and Fc effector function are not
needed. For
expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S.
Patent Nos.
5,648,237, 5,789,199, and 5,840,523. (See also Charlton, Methods in Molecular
Biology, Vol.
248 (B.K.C. Lo, ed., Humana Press, Totowa, NJ, 2003), pp. 245-254, describing
expression of
antibody fragments in E. coli.) After expression, the antibody may be isolated
from the
bacterial cell paste in a soluble fraction and can be further purified.
In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or
yeast are
suitable cloning or expression hosts for antibody-encoding vectors, including
fungi and yeast
strains whose glycosylation pathways have been "humanized," resulting in the
production of an
antibody with a partially or fully human glycosylation pattern. See Gerngross,
Nat. Biotech.
22:1409-1414 (2004), and Li et al., Nat. Biotech. 24:210-215 (2006).
Suitable host cells for the expression of glycosylated antibody are also
derived from
multicellular organisms (invertebrates and vertebrates). Examples of
invertebrate cells include
59
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
plant and insect cells. Numerous baculoviral strains have been identified
which may be used in
conjunction with insect cells, particularly for transfection of Spodoptera
frugiperda cells.
Plant cell cultures can also be utilized as hosts. See, e.g., US Patent Nos.
5,959,177,
6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIESTm
technology
for producing antibodies in transgenic plants).
Vertebrate cells may also be used as hosts. For example, mammalian cell lines
that are
adapted to grow in suspension may be useful. Other examples of useful
mammalian host cell
lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic
kidney
line (293 or 293 cells as described, e.g., in Graham et al., J. Gen Virol.
36:59 (1977)); baby
hamster kidney cells (BHK); mouse sertoli cells (TM4 cells as described, e.g.,
in Mather, Biol.
Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey
kidney cells
(VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK;
buffalo rat
liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2);
mouse mammary
tumor (MMT 060562); TRI cells, as described, e.g., in Mather et al., Annals
N.Y. Acad. Sci.
383:44-68 (1982); MRC 5 cells; and F54 cells. Other useful mammalian host cell
lines include
Chinese hamster ovary (CHO) cells, including DHFR- CHO cells (Urlaub et al.,
Proc. Natl.
Acad. Sci. USA 77:4216 (1980)); and myeloma cell lines such as YO, NSO and
5p2/0. For a
review of certain mammalian host cell lines suitable for antibody production,
see, e.g., Yazaki
and Wu, Methods in Molecular Biology, Vol. 248 (B.K.C. Lo, ed., Humana Press,
Totowa, NJ),
pp. 255-268 (2003).
D. Assays
Antibodies provided herein may be identified, screened for, or characterized
for their
physical/chemical properties and/or biological activities by various assays
known in the art.
1. Binding assays and other assays
In one aspect, an antibody of the invention is tested for its antigen binding
activity, e.g.,
by known methods such as ELISA, Western blot, etc.
In another aspect, competition assays may be used to identify an antibody that
competes
with any of the antibodies described herein for binding to human antigen. In
certain
embodiments, such a competing antibody binds to the same epitope that is bound
by an antibody
described herein.
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
Detailed exemplary methods for mapping an epitope to which an antibody binds
are
provided in Morris (1996) "Epitope Mapping Protocols," in Methods in Molecular
Biology vol.
66 (Humana Press, Totowa, NJ).
In an exemplary competition assay, immobilized antigen is incubated in a
solution
comprising a first labeled antibody that binds to the antigen and a second
unlabeled antibody
that is being tested for its ability to compete with the first antibody for
binding to the antigen.
The second antibody may be present in a hybridoma supernatant. As a control,
immobilized
antigen is incubated in a solution comprising the first labeled antibody but
not the second
unlabeled antibody. After incubation under conditions permissive for binding
of the first
antibody to antigen, excess unbound antibody is removed, and the amount of
label associated
with immobilized antigen is measured. If the amount of label associated with
immobilized
antigen is substantially reduced in the test sample relative to the control
sample, then that
indicates that the second antibody is competing with the first antibody for
binding to antigen.
See Harlow and Lane (1988) Antibodies: A Laboratory Manual ch.14 (Cold Spring
Harbor
Laboratory, Cold Spring Harbor, NY).
2. Activity assays
In one aspect, assays are provided for identifying antibodies having
biological activity.
Biological activity may include, e.g., inhibition of the Notch pathway or
inhibition of the Wnt
pathway. In certain other embodiments, an antibody of the invention is tested
for its ability to
inhibit expression of a reporter gene that is responsive to the Notch pathway
and/or the Wnt
pathway. Nonlimiting exemplary assays are provided in the Examples. In certain
embodiments, an antibody of the invention is tested for such biological
activity. Antibodies
having such biological activity in vivo and/or in vitro are also provided.
E. Immunoconjugates
The invention also provides immunoconjugates comprising an antibody herein
conjugated to one or more cytotoxic agents, such as chemotherapeutic agents or
drugs, growth
inhibitory agents, toxins (e.g., protein toxins, enzymatically active toxins
of bacterial, fungal,
plant, or animal origin, or fragments thereof), or radioactive isotopes.
In one embodiment, an immunoconjugate is an antibody-drug conjugate (ADC) in
which an antibody is conjugated to one or more drugs, including but not
limited to a
maytansinoid (see U.S. Patent Nos. 5,208,020, 5,416,064 and European Patent EP
0 425 235
B1); an auristatin such as monomethylauristatin drug moieties DE and DF (MMAE
and
61
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
MMAF) (see U.S. Patent Nos. 5,635,483 and 5,780,588, and 7,498,298); a
dolastatin; a
calicheamicin or derivative thereof (see U.S. Patent Nos. 5,712,374,
5,714,586, 5,739,116,
5,767,285, 5,770,701, 5,770,710, 5,773,001, and 5,877,296; Hinman et al.,
Cancer Res.
53:3336-3342 (1993); and Lode et al., Cancer Res. 58:2925-2928 (1998)); an
anthracycline
such as daunomycin or doxorubicin (see Kratz et al., Current Med. Chem. 13:477-
523 (2006);
Jeffrey et al., Bioorganic & Med. Chem. Letters 16:358-362 (2006); Torgov et
al., Bioconj.
Chem. 16:717-721 (2005); Nagy et al., Proc. Natl. Acad. Sci. USA 97:829-834
(2000);
Dubowchik et al., Bioorg. & Med. Chem. Letters 12:1529-1532 (2002); King et
al., J. Med.
Chem. 45:4336-4343 (2002); and U.S. Patent No. 6,630,579); methotrexate;
vindesine; a
taxane such as docetaxel, paclitaxel, larotaxel, tesetaxel, and ortataxel; a
trichothecene; and
CC1065.
In another embodiment, an immunoconjugate comprises an antibody as described
herein conjugated to an enzymatically active toxin or fragment thereof,
including but not
limited to diphtheria A chain, nonbinding active fragments of diphtheria
toxin, exotoxin A
chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A
chain, alpha-
sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana
proteins (PAPI, PAM,
and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria
officinalis inhibitor,
gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the
tricothecenes.
In another embodiment, an immunoconjugate comprises an antibody as described
herein conjugated to a radioactive atom to form a radioconjugate. A variety of
radioactive
isotopes are available for the production of radioconjugates. Examples include
At211, 1131, 1125,
Y90, Re186, Re188, sm153, Bi212, P32, Pb 212
and radioactive isotopes of Lu. When the
radioconjugate is used for detection, it may comprise a radioactive atom for
scintigraphic
studies, for example tc99m or 1123, or a spin label for nuclear magnetic
resonance (NMR)
imaging (also known as magnetic resonance imaging, mri), such as iodine-123
again, iodine-
131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium,
manganese or
iron.
Conjugates of an antibody and cytotoxic agent may be made using a variety of
bifunctional protein coupling agents such as N-succinimidy1-3-(2-
pyridyldithio) propionate
(SPDP), succinimidy1-4-(N-maleimidomethyl) cyclohexane-l-carboxylate (SMCC),
iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl
adipimidate HC1),
active esters (such as disuccinimidyl suberate), aldehydes (such as
glutaraldehyde), bis-azido
compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium
derivatives (such as
bis-(p-diazoniumbenzoy1)-ethylenediamine), diisocyanates (such as toluene 2,6-
diisocyanate),
62
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
and his-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene).
For example, a
ricin immunotoxin can be prepared as described in Vitetta et al., Science
238:1098 (1987).
Carbon-14-labeled 1-isothiocyanatobenzy1-3-methyldiethylene
triaminepentaacetic acid (MX-
DTPA) is an exemplary chelating agent for conjugation of radionucleotide to
the antibody. See
W094/11026. The linker may be a "cleavable linker" facilitating release of a
cytotoxic drug in
the cell. For example, an acid-labile linker, peptidase-sensitive linker,
photolabile linker,
dimethyl linker or disulfide-containing linker (Chari et al., Cancer Res.
52:127-131(1992);
U.S. Patent No. 5,208,020) may be used.
The immunuoconjugates or ADCs herein expressly contemplate, but are not
limited to
such conjugates prepared with cross-linker reagents including, but not limited
to, BMPS,
EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH,
sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and
sulfo-
SMPB, and SVSB (succinimidy1-(4-vinylsulfone)benzoate) which are commercially
available
(e.g., from Pierce Biotechnology, Inc., Rockford, IL., U.S.A).
F. Methods and Compositions for Diagnostics and Detection
In certain embodiments, any of the antibodies provided herein is useful for
detecting the
presence of its respective antigen in a biological sample. The term
"detecting" as used herein
encompasses quantitative or qualitative detection. In certain embodiments, a
biological sample
comprises a cell or tissue, such as cancerous tissues.
In one embodiment, an antibody for use in a method of diagnosis or detection
is
provided. In a further aspect, a method of detecting the presence of an
antigen in a biological
sample is provided. In certain embodiments, the method comprises contacting
the biological
sample with an antibody as described herein under conditions permissive for
binding of the
antibody to its antigen, and detecting whether a complex is formed between the
antibody and
antigen. Such method may be an in vitro or in vivo method. In one embodiment,
an anti-
antibody is used to select subjects eligible for therapy with the antibody,
e.g. where the antigen
is a biomarker for selection of patients.
Exemplary disorders that may be diagnosed using an antibody of the invention
include
cancer, e.g., breast cancer, lung cancer, brain cancer, cervical cancer, colon
cancer, liver cancer,
bile duct cancer, pancreatic cancer, skin cancer, B-cell malignancies, and T-
cell malignancies.
In certain embodiments, labeled antibodies are provided. Labels include, but
are not
limited to, labels or moieties that are detected directly (such as
fluorescent, chromophoric,
electron-dense, chemiluminescent, and radioactive labels), as well as
moieties, such as
63
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
enzymes or ligands, that are detected indirectly, e.g., through an enzymatic
reaction or
molecular interaction. Exemplary labels include, but are not limited to, the
radioisotopes 32P,
14C, 125.,
1 3H, and 1311, fluorophores such as rare earth chelates or fluorescein and
its derivatives,
rhodamine and its derivatives, dansyl, umbelliferone, luceriferases, e.g.,
firefly luciferase and
bacterial luciferase (U.S. Patent No. 4,737,456), luciferin, 2,3-
dihydrophthalazinediones,
horseradish peroxidase (HRP), alkaline phosphatase, P-galactosidase,
glucoamylase, lysozyme,
saccharide oxidases, e.g., glucose oxidase, galactose oxidase, and glucose-6-
phosphate
dehydrogenase, heterocyclic oxidases such as uricase and xanthine oxidase,
coupled with an
enzyme that employs hydrogen peroxide to oxidize a dye precursor such as HRP,
lactoperoxidase, or microperoxidase, biotin/avidin, spin labels, bacteriophage
labels, stable free
radicals, and the like.
G. Pharmaceutical Formulations
Pharmaceutical formulations of an antibody as described herein are prepared by
mixing
such antibody having the desired degree of purity with one or more optional
pharmaceutically
acceptable carriers (Remington's Pharmaceutical Sciences 16th edition, Osol,
A. Ed. (1980)),
in the form of lyophilized formulations or aqueous solutions. Pharmaceutically
acceptable
carriers are generally nontoxic to recipients at the dosages and
concentrations employed, and
include, but are not limited to: buffers such as phosphate, citrate, and other
organic acids;
antioxidants including ascorbic acid and methionine; preservatives (such as
octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride;
benzalkonium
chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl
parabens such as
methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and
m-cresol); low
molecular weight (less than about 10 residues) polypeptides; proteins, such as
serum albumin,
gelatin, or immunoglobulins; hydrophilic polymers such as
polyvinylpyrrolidone; amino acids
such as glycine, glutamine, asparagine, histidine, arginine, or lysine;
monosaccharides,
disaccharides, and other carbohydrates including glucose, mannose, or
dextrins; chelating
agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol;
salt-forming
counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes);
and/or non-ionic
surfactants such as polyethylene glycol (PEG). Exemplary pharmaceutically
acceptable
carriers herein further include insterstitial drug dispersion agents such as
soluble neutral-active
hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20
hyaluronidase
glycoproteins, such as rHuPH20 (HYLENEX , Baxter International, Inc.). Certain
exemplary
sHASEGPs and methods of use, including rHuPH20, are described in US Patent
Publication
64
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
Nos. 2005/0260186 and 2006/0104968. In one aspect, a sHASEGP is combined with
one or
more additional glycosaminoglycanases such as chondroitinases.
Exemplary lyophilized antibody formulations are described in US Patent No.
6,267,958.
Aqueous antibody formulations include those described in US Patent No.
6,171,586 and
W02006/044908, the latter formulations including a histidine-acetate buffer.
The formulation herein may also contain more than one active ingredients as
necessary
for the particular indication being treated, preferably those with
complementary activities that
do not adversely affect each other. For example, it may be desirable to
further provide a
cytotoxic agent, e.g., a chemotherapeutic agent. Such active ingredients are
suitably present in
combination in amounts that are effective for the purpose intended.
Active ingredients may be entrapped in microcapsules prepared, for example, by
coacervation techniques or by interfacial polymerization, for example,
hydroxymethylcellulose
or gelatin-microcapsules and poly-(methylmethacylate) microcapsules,
respectively, in
colloidal drug delivery systems (for example, liposomes, albumin microspheres,
microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such
techniques are
disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed.
(1980).
Sustained-release preparations may be prepared. Suitable examples of sustained-
release preparations include semipermeable matrices of solid hydrophobic
polymers containing
the antibody, which matrices are in the form of shaped articles, e.g. films,
or microcapsules.
The formulations to be used for in vivo administration are generally sterile.
Sterility
may be readily accomplished, e.g., by filtration through sterile filtration
membranes.
H. Therapeutic Methods and Compositions
Methods of alleviating the toxicity associated with Notch pathway inhibition
are
provided. In some embodiments, the method comprises administering at least one
Wnt
pathway inhibitor before, during, or after treatment with at least one Notch
pathway inhibitor.
In one aspect, Notch pathway inhibitors and Wnt pathway inhibitors for use as
medicaments are provided. In further aspects, Notch pathway inhibitors and Wnt
pathway
inhibitors for use in treating a disease or disorder associated with aberrant
Notch signaling,
e.g., cancer, are provided. In certain embodiments, Notch pathway inhibitors
and Wnt pathway
inhibitors for use in methods of treatment are provided. In certain
embodiments, Notch
pathway inhibitors and Wnt pathway inhibitors for use in methods of treating
Notch-mediated
disorders are provided. In certain embodiments, the invention provides Notch
pathway
inhibitors and Wnt pathway inhibitors for use in a method of treating an
individual having a
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
cancer comprising administering to the individual an effective amount of a
Notch pathway
inhibitor and an effective amount of a Wnt pathway inhibitor. In further
embodiments, the
invention provides Notch pathway inhibitors and Wnt pathway inhibitors for use
in inhibiting
lung cancer growth. In certain embodiments, the invention provides an Notch
pathway
inhibitors and Wnt pathway inhibitors for use in a method of reducing lung
cancer growth in an
individual comprising administering to the individual an effective of at least
one Notch
pathway inhibitor and an effective amount of at least one Wnt pathway
inhibitor to reduce lung
cancer growth with less toxicity than with the at least one Notch pathway
inhibitor alone. In
certain embodiments, the invention provides Notch pathway inhibitors and Wnt
pathway
inhibitors for use in methods of reducing breast cancer growth in an
individual comprising
administering to the individual an effective of at least one Notch pathway
inhibitor and an
effective amount of at least one Wnt pathway inhibitor to reduce breast cancer
growth with less
toxicity than with the at least one Notch pathway inhibitor alone. An
"individual" according to
any of the above embodiments is preferably a human.
In some embodiments, the method comprises administering an anti-Notch
antibody,
including but not limited to, an anti-Notch antibody described herein, and an
anti-LRP
antibody, including but not limited to, an anti-LRP antibody described herein.
In some
embodiments, the method comprises administering an anti-Notch antibody,
including but not
limited to, an anti-Notch antibody described herein, and an anti-Fzd antibody,
including but not
limited to, an anti-Fzd antibody described herein. In some embodiments, the
method
comprises administering an anti-Notch antibody, including but not limited to,
an anti-Notch
antibody described herein, and an anti-Wnt antibody, including but not limited
to, an anti-Wnt
antibody described herein. In some embodiments, the method comprises
administering an anti-
Notch antibody, including but not limited to, an anti-Notch antibody described
herein, and an
anti-RSPO antibody, including but not limited to, an anti-RSPO antibody
described herein. In
some embodiments, the method comprises administering an anti-Notch antibody,
including but
not limited to, an anti-Notch antibody described herein, and a soluble
Frizzled receptor,
including but not limited to, a soluble Frizzled receptor described herein. In
some
embodiments, the method comprises administering an anti-Notch antibody,
including but not
limited to, an anti-Notch antibody described herein, and a small molecule Wnt
pathway
inhibitor, including but not limited to, a small molecule Wnt pathway
inhibitor described
herein.
In some embodiments, the method comprises administering an anti-Jagged
antibody,
including but not limited to, an anti-Jagged antibody described herein, and an
anti-LRP
66
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
antibody, including but not limited to, an anti-LRP antibody described herein.
In some
embodiments, the method comprises administering an anti-Jagged antibody,
including but not
limited to, an anti-Jagged antibody described herein, and an anti-Fzd
antibody, including but
not limited to, an anti-Fzd antibody described herein. In some embodiments,
the method
comprises administering an anti-Jagged antibody, including but not limited to,
an anti-Jagged
antibody described herein, and an anti-Wnt antibody, including but not limited
to, an anti-Wnt
antibody described herein. In some embodiments, the method comprises
administering an anti-
Jagged antibody, including but not limited to, an anti-Jagged antibody
described herein, and a
soluble Frizzled receptor, including but not limited to, a soluble Frizzled
receptor described
herein. In some embodiments, the method comprises administering an anti-Jagged
antibody,
including but not limited to, an anti-Jagged antibody described herein, and a
small molecule
Wnt pathway inhibitor, including but not limited to, a small molecule Wnt
pathway inhibitor
described herein.
In some embodiments, the method comprises administering an anti-DLL antibody,
including but not limited to, an anti-DLL antibody described herein, and an
anti-LRP antibody,
including but not limited to, an anti-LRP antibody described herein. In some
embodiments, the
method comprises administering an anti-DLL antibody, including but not limited
to, an anti-
DLL antibody described herein, and an anti-Fzd antibody, including but not
limited to, an anti-
Fzd antibody described herein. In some embodiments, the method comprises
administering an
anti-DLL antibody, including but not limited to, an anti-DLL antibody
described herein, and an
anti-Wnt antibody, including but not limited to, an anti-Wnt antibody
described herein. In
some embodiments, the method comprises administering an anti-DLL antibody,
including but
not limited to, an anti-DLL antibody described herein, and a soluble Frizzled
receptor,
including but not limited to, a soluble Frizzled receptor described herein. In
some
embodiments, the method comprises administering an anti-DLL antibody,
including but not
limited to, an anti-DLL antibody described herein, and a small molecule Wnt
pathway
inhibitor, including but not limited to, a small molecule Wnt pathway
inhibitor described
herein.
In some embodiments, the method comprises administering a gamma secretase
inhibitor, including but not limited to, a gamma secretase inhibitor described
herein, and an
anti-LRP antibody, including but not limited to, an anti-LRP antibody
described herein. In
some embodiments, the method comprises administering a gamma secretase
inhibitor,
including but not limited to, a gamma secretase inhibitor described herein,
and an anti-Fzd
antibody, including but not limited to, an anti-Fzd antibody described herein.
In some
67
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
embodiments, the method comprises administering a gamma secretase inhibitor,
including but
not limited to, a gamma secretase inhibitor described herein, and an anti-Wnt
antibody,
including but not limited to, an anti-Wnt antibody described herein. In some
embodiments, the
method comprises administering a gamma secretase inhibitor, including but not
limited to, a
gamma secretase inhibitor described herein, and a soluble Frizzled receptor,
including but not
limited to, a soluble Frizzled receptor described herein. In some embodiments,
the method
comprises administering a gamma secretase inhibitor, including but not limited
to, a gamma
secretase inhibitor described herein, and a small molecule Wnt pathway
inhibitor, including but
not limited to, a small molecule Wnt pathway inhibitor described herein.
In some embodiments, the method comprises administering to an individual an
effective amount of an anti-Notch antibody comprising the HVRs or variable
regions of an
antibody selected from A-2, D-3, and 256A-4 and an effective amount of a Wnt
pathway
inhibitor, including but not limited to, a Wnt pathway inhibitor described
herein. In some
embodiments, the method comprises administering to an individual an effective
amount of an
anti-Notch antibody comprising the HVRs or variable regions of an antibody
selected from A-
2, D-3, and 256A-4 and an effective amount of an anti-LRP antibody or
bispecific antibody
comprising the HVRs or variable regions of an antibody selected from
YW211.31.62 and/or
YW210.09. In some embodiments, the method comprises administering to an
individual an
effective amount of an anti-Notch antibody comprising the HVRs or variable
regions of an
antibody selected from A-2, D-3, and 256A-4 and an effective amount of an anti-
LRP antibody
comprising the HVRs or variable regions of P6C.51.61. In some embodiments, the
method
comprises administering to an individual an effective amount of an anti-Notch
antibody
comprising the HVRs or variable regions of an antibody selected from A-2, D-3,
and 256A-4
and an effective amount of a soluble Fzd8 receptor, such as FZD8CRD.
In some embodiments, the method comprises administering to an individual an
effective amount of an anti-Notch antibody comprising the HVRs or variable
regions of 59R5
and an effective amount of a Wnt pathway inhibitor, including but not limited
to, a Wnt
pathway inhibitor described herein. In some embodiments, the method comprises
administering to an individual an effective amount of an anti-Notch antibody
comprising the
HVRs or variable regions of 59R5 and an effective amount of an anti-Frizzled
antibody
comprising the HVRs or variable regions of 18R5. In some embodiments, the
method
comprises administering to an individual an effective amount of an anti-Notch
antibody
comprising the HVRs or variable regions of 59R5 and an effective amount of an
anti-RSPO
antibody comprising the HVRs or variable regions of an antibody selected from
13R10,
68
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
13R102, 13R103, 89M5, and 130M23. In any of the embodiments described herein,
the
method may comprise administering to an individual an effective amount of an
anti-Notch
antibody comprising the HVRs or variable regions of 59R5 and an effective
amount of soluble
Frizzled receptor 54F28. In any of the embodiments described herein, the
method may
comprise administering to an individual an effective amount of an anti-Notch
antibody
comprising the HVRs or variable regions of 59R5 and an effective amount of an
anti-LRP
antibody comprising the HVRs or variable regions of 7E5C8.
In some embodiments, the method comprises administering to an individual an
effective amount of an anti-Notch antibody comprising the HVRs or variable
regions of 52M51
and an effective amount of a Wnt pathway inhibitor, including but not limited
to, a Wnt
pathway inhibitor described herein. In some embodiments, the method comprises
administering to an individual an effective amount of an anti-Notch antibody
comprising the
HVRs or variable regions of 52M51 and an effective amount of an anti-Frizzled
antibody
comprising the HVRs or variable regions of 18R5. In some embodiments, the
method
comprises administering to an individual an effective amount of an anti-Notch
antibody
comprising the HVRs or variable regions of 52M51 and an effective amount of an
anti-RSPO
antibody comprising the HVRs or variable regions of an antibody selected from
13R10,
13R102, 13R103, 89M5, and 130M23. In any of the embodiments described herein,
the
method may comprise administering to an individual an effective amount of an
anti-Notch
antibody comprising the HVRs or variable regions of 52M51 and an effective
amount of
soluble Frizzled receptor 54F28. In any of the embodiments described herein,
the method may
comprise administering to an individual an effective amount of an anti-Notch
antibody
comprising the HVRs or variable regions of 52M51 and an effective amount of an
anti-LRP
antibody comprising the HVRs or variable regions of 7E5C8.
In some embodiments, the method comprises administering to an individual an
effective amount of an anti-Notch antibody comprising the HVRs or variable
regions of N248A
and an effective amount of a Wnt pathway inhibitor, including but not limited
to, a Wnt
pathway inhibitor described herein.
In some embodiments, the method comprises administering to an individual an
effective amount of an anti-Jagged antibody comprising the HVRs or variable
regions of an
antibody selected from A-2, B-3, and C-1 and an effective amount of a Wnt
pathway inhibitor,
including but not limited to, a Wnt pathway inhibitor described herein. In
some embodiments,
the method comprises administering to an individual an effective amount of an
anti-Jagged
antibody comprising the HVRs or variable regions of an antibody selected from
A-2, B-3, and
69
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
C-1 and an effective amount of an anti-LRP antibody or bispecific antibody
comprising the
HVRs or variable regions of an antibody selected from YW211.31.62 and/or
YW210.09. In
some embodiments, the method comprises administering to an individual an
effective amount
of an anti-Jagged antibody comprising the HVRs or variable regions of an
antibody selected
from A-2, B-3, and C-1 and an effective amount of an anti-LRP antibody
comprising the HVRs
or variable regions of P6C.51.61. In some embodiments, the method comprises
administering
to an individual an effective amount of an anti-Jagged antibody comprising the
HVRs or
variable regions of an antibody selected from A-2, B-3, and C-1 and an
effective amount of a
soluble Fzd8 receptor, such as FZD8CRD.
In some embodiments, the method comprises administering to an individual an
effective amount of an anti-Jagged antibody comprising the HVRs or variable
regions of an
antibody selected from anti-Jagged antibody 64R7, anti-Jagged antibody 64M14,
anti-Jagged
antibody 133R0201, anti-Jagged antibody 133R0203, anti-Jagged antibody
133R0205, anti-
Jagged antibody 64M51, and anti-Jagged antibody 64R1B and an effective amount
of a Wnt
pathway inhibitor, including but not limited to, a Wnt pathway inhibitor
described herein. In
some embodiments, the method comprises administering to an individual an
effective amount
of anti-Jagged antibody comprising the HVRs or variable regions of an antibody
selected from
anti-Jagged antibody 64R7, anti-Jagged antibody 64M14, anti-Jagged antibody
133R0201,
anti-Jagged antibody 133R0203, anti-Jagged antibody 133R0205, anti-Jagged
antibody 64M51,
and anti-Jagged antibody 64R1B, and an effective amount of an anti-Frizzled
antibody
comprising the HVRs or variable regions of 18R5. In some embodiments, the
method
comprises administering to an individual an effective amount of anti-Jagged
antibody
comprising the HVRs or variable regions of an antibody selected from anti-
Jagged antibody
64R7, anti-Jagged antibody 64M14, anti-Jagged antibody 133R0201, anti-Jagged
antibody
133R0203, anti-Jagged antibody 133R0205, anti-Jagged antibody 64M51, and anti-
Jagged
antibody 64R1B, and an effective amount of an anti-RSPO antibody comprising
the HVRs or
variable regions of an antibody selected from 13R10, 13R102, 13R103, 89M5, and
130M23.
In any of the embodiments described herein, the method may comprise
administering to an
individual an effective amount of anti-Jagged antibody comprising the HVRs or
variable
regions of an antibody selected from anti-Jagged antibody 64R7, anti-Jagged
antibody 64M14,
anti-Jagged antibody 133R0201, anti-Jagged antibody 133R0203, anti-Jagged
antibody
133R0205, anti-Jagged antibody 64M51, and anti-Jagged antibody 64R1B, and an
effective
amount of soluble Frizzled receptor 54F28. In any of the embodiments described
herein, the
method may comprise administering to an individual an effective amount of an
anti-Jagged
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
antibody comprising the HVRs or variable regions of an antibody selected from
anti-Jagged
antibody 64R7, anti-Jagged antibody 64M14, anti-Jagged antibody 133R0201, anti-
Jagged
antibody 133R0203, anti-Jagged antibody 133R0205, anti-Jagged antibody 64M51,
and anti-
Jagged antibody 64R1B, and an effective amount of an anti-LRP antibody
comprising the
HVRs or variable regions of 7E5C8.
In some embodiments, the method comprises administering to an individual an
effective amount of an anti-Jagged antibody comprising the HVRs or variable
regions of 4D11
or 5342-1204-4D11 and an effective amount of a Wnt pathway inhibitor,
including but not
limited to, a Wnt pathway inhibitor described herein.
In some embodiments, the method comprises administering to an individual an
effective amount of an anti-DLL antibody comprising the HVRs or variable
regions of
YW26.82 and an effective amount of a Wnt pathway inhibitor, including but not
limited to, a
Wnt pathway inhibitor described herein. In some embodiments, the method
comprises
administering to an individual an effective amount of an anti-DLL antibody
comprising the
HVRs or variable regions of YW26.82 and an effective amount of an anti-LRP
antibody or
bispecific antibody comprising the HVRs or variable regions of an antibody
selected from
YW211.31.62 and/or YW210.09. In some embodiments, the method comprises
administering
to an individual an effective amount of an anti-DLL antibody comprising the
HVRs or variable
regions of YW26.82 and an effective amount of an anti-LRP antibody comprising
the HVRs or
variable regions of P6C.51.61. In some embodiments, the method comprises
administering to
an individual an effective amount of an anti-DLL antibody comprising the HVRs
or variable
regions of YW26.82 and an effective amount of a soluble Fzd8 receptor, such as
FZD8CRD.
In some embodiments, the method comprises administering to an individual an
effective amount of an anti-DLL antibody comprising the HVRs or variable
regions of an
antibody selected from 21M18, 305B83, 219R45-MB-21M18, or 219R45-MB-21R83 and
an
effective amount of a Wnt pathway inhibitor, including but not limited to, a
Wnt pathway
inhibitor described herein. In some embodiments, the method comprises
administering to an
individual an effective amount of an anti-DLL antibody comprising the HVRs or
variable
regions of an antibody selected from 21M18, 305B83, 219R45-MB-21M18, or 219R45-
MB-
21R83 and an effective amount of an anti-Frizzled antibody comprising the HVRs
or variable
regions of 18R5. In some embodiments, the method comprises administering to an
individual
an effective amount of an anti-DLL antibody comprising the HVRs or variable
regions of an
antibody selected from 21M18, 305B83, 219R45-MB-21M18, or 219R45-MB-21R83 and
an
effective amount of an anti-RSPO antibody comprising the HVRs or variable
regions of an
71
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
antibody selected from 13R10, 13R102, 13R103, 89M5, and 130M23. In any of the
embodiments described herein, the method may comprise administering to an
individual an
effective amount of an anti-DLL antibody comprising the HVRs or variable
regions of an
antibody selected from 21M18, 305B83, 219R45-MB-21M18, or 219R45-MB-21R83 and
an
effective amount of soluble Frizzled receptor 54F28. In any of the embodiments
described
herein, the method may comprise administering to an individual an effective
amount of an anti-
DLL antibody comprising the HVRs or variable regions of an antibody selected
from 21M18,
305B83, 219R45-MB-21M18, or 219R45-MB-21R83 and an effective amount of an anti-
LRP
antibody comprising the HVRs or variable regions of 7E5C8.
In some embodiments, the method comprises administering to an individual an
effective amount of a Notch pathway inhibitor, including but not limited to, a
Notch pathway
inhibitor described herein and an effective amount of an anti-LRP antibody or
bispecific
antibody comprising the HVRs or variable regions of an antibody selected from
YW211.31.62
and/or YW210.09. In some embodiments, the method comprises administering to an
individual an effective amount of a Notch pathway inhibitor, including but not
limited to, a
Notch pathway inhibitor described herein and an effective amount of a
biparatropic antibody
described in U.S. Publication No. 2013/0064823. In some embodiments, the
method
comprises administering to an individual an effective amount of a Notch
pathway inhibitor,
including but not limited to, a Notch pathway inhibitor described herein and
an effective
amount of an anti-LRP antibody comprising the HVRs or variable regions of
P6C.51.61.
In some embodiments, the method comprises administering to an individual an
effective amount of a Notch pathway inhibitor, including but not limited to, a
Notch pathway
inhibitor described herein and an effective amount of an anti-Frizzled
antibody comprising the
HVRs or variable regions of 18R5. In some embodiments, the method comprises
administering to an individual an effective amount of a Notch pathway
inhibitor, including but
not limited to, a Notch pathway inhibitor described herein and an effective
amount of an anti-
Frizzled antibody comprising the HVRs or variable regions of B9L9.3.
In some embodiments, the method comprises administering to an individual an
effective amount of a Notch pathway inhibitor, including but not limited to, a
Notch pathway
inhibitor described herein and an effective amount of an anti-Wnt antibody
comprising the
HVRs or variable regions of an anti-Wnt antibody described in U.S. Publication
No.
2013/0045209.
In some embodiments, the method comprises administering to an individual an
effective amount of a Notch pathway inhibitor, including but not limited to, a
Notch pathway
72
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
inhibitor described herein and an effective amount of soluble Frizzled 54F28.
In some
embodiments, the method comprises administering to an individual an effective
amount of a
Notch pathway inhibitor, including but not limited to, a Notch pathway
inhibitor described
herein and an effective amount of a soluble Fzd8 receptor, such as FZD8CRD.
In some embodiments, the method comprises administering to an individual an
effective amount of a Notch pathway inhibitor, including but not limited to, a
Notch pathway
inhibitor described herein and an effective amount of a Wnt pathway inhibitor
selected from
LGK974, AVN316, and PRI-724.
In some embodiments, methods of alleviating the toxicity associated with Notch
pathway inhibition are provided. Nonlimiting examples of such toxicity include
secretory
metaplasia, diarrhea, gastrointestinal bleeding, liver toxicity (including,
but not limited to,
sinusoidal dilation, centrilobular hepatocyte atrophy, bile ductula
proliferation, and elevated
alanine aminotransferase), lung toxicity (including, but not limited to,
necrotic lesions), heart
toxicity (including, but not limited to, necrotic lesions), subcutaneous
tumors, and thymic
atrophy. See, e.g., van Es et al., 2005, Nature 435: 959-963; Yan et al.,
2010, Nature 463: E6-
7. In some embodiments, the toxicity is diarrhea.
In some embodiments, the method comprises administering to an individual who
has
received, is receiving, or is going to receive at least one a Notch pathway
inhibitor, at least one
Wnt pathway inhibitor. The at least one Wnt pathway inhibitor may be
administered prior to
administration of the at least one Notch pathway inhibitor, at the same time
as administration
of the at least one Notch pathway inhibitor, or after administration of the at
least one Notch
pathway inhibitor.
In some embodiments, the method comprises administering to an individual who
has
received, is receiving, or is going to receive an anti-Notch antibody
comprising the HVRs or
variable regions of an antibody selected from A-2, D-3, and 256A-4, an
effective amount of a
Wnt pathway inhibitor, including but not limited to a Wnt pathway inhibitor
described herein.
In some embodiments, the method comprises administering to an individual who
has received,
is receiving, or is going to receive an anti-Notch antibody comprising the
HVRs or variable
regions of an antibody selected from A-2, D-3, and 256A-4, an effective amount
of an anti-
LRP antibody or bispecific antibody comprising the HVRs or variable regions of
an antibody
selected from YW211.31.62 and/or YW210.09. In some embodiments, the method
comprises
administering to an individual who has received, is receiving, or is going to
receive an anti-
Notch antibody comprising the HVRs or variable regions of an antibody selected
from A-2, D-
3, and 256A-4, an effective amount of an anti-LRP antibody comprising the HVRs
or variable
73
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
regions of P6C.51.61. In some embodiments, the method comprises administering
to an
individual who has received, is receiving, or is going to receive an anti-
Notch antibody
comprising the HVRs or variable regions of an antibody selected from A-2, D-3,
and 256A-4,
an effective amount of a soluble Fzd8 receptor, such as FZD8CRD.
In some embodiments, the method comprises administering to an individual who
has
received, is receiving, or is going to receive anti-Notch antibody 59R5, an
effective amount of
a Wnt pathway inhibitor, including but not limited to a Wnt pathway inhibitor
described herein.
In some embodiments, the method comprises administering to an individual who
has received,
is receiving, or is going to receive anti-Notch antibody 59R5, an effective
amount of anti-
Frizzled antibody 18R5. In some embodiments, the method comprises
administering to an
individual who has received, is receiving, or is going to receive anti-Notch
antibody 59R5, an
effective amount of an anti-RSPO antibody comprising the HVRs or variable
regions of an
antibody selected from 13R10, 13R102, 13R103, 89M5, and 130M23. In some
embodiments,
the method comprises administering to an individual who has received, is
receiving, or is going
to receive anti-Notch antibody 59R5, an effective amount of soluble Frizzled
receptor 54F28.
In some embodiments, the method comprises administering to an individual who
has received,
is receiving, or is going to receive anti-Notch antibody 59R5, an effective
amount of anti-LRP
antibody 7E5C8.
In some embodiments, the method comprises administering to an individual who
has
received, is receiving, or is going to receive anti-Notch antibody 52M51, an
effective amount
of a Wnt pathway inhibitor, including but not limited to a Wnt pathway
inhibitor described
herein. In some embodiments, the method comprises administering to an
individual who has
received, is receiving, or is going to receive anti-Notch antibody 52M51, an
effective amount
of anti-Frizzled antibody 18R5. In some embodiments, the method comprises
administering to
an individual who has received, is receiving, or is going to receive anti-
Notch antibody 52M51,
an effective amount of an anti-RSPO antibody comprising the HVRs or variable
regions of an
antibody selected from 13R10, 13R102, 13R103, 89M5, and 130M23. In some
embodiments,
the method comprises administering to an individual who has received, is
receiving, or is going
to receive anti-Notch antibody 52M51, an effective amount of soluble Frizzled
receptor 54F28.
In In some embodiments, the method comprises administering to an individual
who has
received, is receiving, or is going to receive anti-Notch antibody 52M51, an
effective amount
of anti-LRP antibody 7E5C8.
In some embodiments, the method comprises administering to an individual who
has
received, is receiving, or is going to receive an anti-Notch antibody
comprising the HVRs or
74
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
variable regions of N248A, an effective amount of a Wnt pathway inhibitor,
including but not
limited to, a Wnt pathway inhibitor described herein.
In some embodiments, the method comprises administering to an individual who
has
received, is receiving, or is going to receive an anti-Jagged antibody
comprising the HVRs or
variable regions of an antibody selected from A-2, B-3, and C-1, an effective
amount of a Wnt
pathway inhibitor, including but not limited to, a Wnt pathway inhibitor
described herein. In
some embodiments, the method comprises administering to an individual who has
received, is
receiving, or is going to receive an anti-Jagged antibody comprising the HVRs
or variable
regions of an antibody selected from A-2, B-3, and C-1, an effective amount of
an anti-LRP
antibody or bispecific antibody comprising the HVRs or variable regions of an
antibody
selected from YW211.31.62 and/or YW210.09. In some embodiments, the method
comprises
administering to an individual who has received, is receiving, or is going to
receive an anti-
Jagged antibody comprising the HVRs or variable regions of an antibody
selected from A-2, B-
3, and C-1, an effective amount of an anti-LRP antibody comprising the HVRs or
variable
regions of P6C.51.61. In some embodiments, the method comprises administering
to an
individual who has received, is receiving, or is going to receive an anti-
Jagged antibody
comprising the HVRs or variable regions of an antibody selected from A-2, B-3,
and C-1, an
effective amount of a soluble Fzd8 receptor, such as FZD8CRD.
In some embodiments, the method comprises administering to an individual who
has
received, is receiving, or is going to receive an anti-Jagged antibody
selected from anti-Jagged
antibody 64R7, anti-Jagged antibody 64M14, anti-Jagged antibody 133R0201, anti-
Jagged
antibody 133R0203, anti-Jagged antibody 133R0205, anti-Jagged antibody 64M51,
and anti-
Jagged antibody 64R1B, an effective amount of a Wnt pathway inhibitor,
including but not
limited to a Wnt pathway inhibitor described herein. In some embodiments, the
method
comprises administering to an individual who has received, is receiving, or is
going to receive
an anti-Jagged antibody selected from anti-Jagged antibody 64R7, anti-Jagged
antibody
64M14, anti-Jagged antibody 133R0201, anti-Jagged antibody 133R0203, anti-
Jagged antibody
133R0205, anti-Jagged antibody 64M51, and anti-Jagged antibody 64R1B; an
effective amount
of anti-Frizzled antibody 18R5. In some embodiments, the method comprises
administering to
an individual who has received, is receiving, or is going to receive an anti-
Jagged antibody
selected from anti-Jagged antibody 64R7, anti-Jagged antibody 64M14, anti-
Jagged antibody
133R0201, anti-Jagged antibody 133R0203, anti-Jagged antibody 133R0205, anti-
Jagged
antibody 64M51, and anti-Jagged antibody 64R1B; an effective amount of an anti-
RSPO
antibody comprising the HVRs or variable regions of an antibody selected from
13R10,
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
13R102, 13R103, 89M5, and 130M23. In some embodiments, the method comprises
administering to an individual who has received, is receiving, or is going to
receive anti-Jagged
antibody selected from anti-Jagged antibody 64R7, anti-Jagged antibody 64M14,
anti-Jagged
antibody 133R0201, anti-Jagged antibody 133R0203, anti-Jagged antibody
133R0205, anti-
Jagged antibody 64M51, and anti-Jagged antibody 64R1B; an effective amount of
soluble
Frizzled receptor 54F28. In some embodiments, the method comprises
administering to an
individual who has received, is receiving, or is going to receive anti-Jagged
antibody selected
from anti-Jagged antibody 64R7, anti-Jagged antibody 64M14, anti-Jagged
antibody
133R0201, anti-Jagged antibody 133R0203, anti-Jagged antibody 133R0205, anti-
Jagged
antibody 64M51, and anti-Jagged antibody 64R1B; an effective amount of anti-
LRP antibody
7E5C8.
In some embodiments, the method comprises administering to an individual who
has
received, is receiving, or is going to receive an anti-Jagged antibody
comprising the HVRs or
variable regions of 4D11 or 5342-1204-4D11, an effective amount of a Wnt
pathway inhibitor,
including but not limited to, a Wnt pathway inhibitor described herein.
In some embodiments, the method comprises administering to an individual who
has
received, is receiving, or is going to receive an anti-DLL antibody comprising
the HVRs or
variable regions of YW26.82, an effective amount of a Wnt pathway inhibitor,
including but
not limited to, a Wnt pathway inhibitor described herein. In some embodiments,
the method
comprises administering to an individual who has received, is receiving, or is
going to receive
an anti-DLL antibody comprising the HVRs or variable regions of YW26.82, an
effective
amount of an anti-LRP antibody or bispecific antibody comprising the HVRs or
variable
regions of an antibody selected from YW211.31.62 and/or YW210.09. In some
embodiments,
the method comprises administering to an individual who has received, is
receiving, or is going
to receive an anti-DLL antibody comprising the HVRs or variable regions of
YW26.82, an
effective amount of an anti-LRP antibody comprising the HVRs or variable
regions of
P6C.51.61. In some embodiments, the method comprises administering to an
individual who
has received, is receiving, or is going to receive an anti-DLL antibody
comprising the HVRs or
variable regions of YW26.82, an effective amount of a soluble Fzd8 receptor,
such as
FZD8CRD.
In some embodiments, the method comprises administering to an individual who
has
received, is receiving, or is going to receive an anti-DLL antibody selected
from 21M18,
305B83, 219R45-MB-21M18, and 219R45-MB-21R83, an effective amount of a Wnt
pathway
inhibitor, including but not limited to a Wnt pathway inhibitor described
herein. In some
76
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
embodiments, the method comprises administering to an individual who has
received, is
receiving, or is going to receive an anti-DLL antibody selected from 21M18,
305B83, 219R45-
MB-21M18, and 219R45-MB-21R83, an effective amount of anti-Frizzled antibody
18R5. In
some embodiments, the method comprises administering to an individual who has
received, is
receiving, or is going to receive an anti-DLL antibody selected from 21M18,
305B83, 219R45-
MB-21M18, and 219R45-MB-21R83, an effective amount of soluble Frizzled
receptor 54F28.
In some embodiments, the method comprises administering to an individual who
has received,
is receiving, or is going to receive an anti-DLL antibody selected from 21M18,
305B83,
219R45-MB-21M18, and 219R45-MB-21R83, an effective amount of anti-LRP antibody
7E5C8.
In some embodiments, the method comprises administering to an individual who
has
received, is receiving, or is going to receive a Notch pathway inhibitor,
including but not
limited to, a Notch pathway inhibitor described herein, an effective amount of
an anti-LRP
antibody or bispecific antibody comprising the HVRs or variable regions of an
antibody
selected from YW211.31.62 and/or YW210.09. In some embodiments, the method
comprises
administering to an individual who has received, is receiving, or is going to
receive a Notch
pathway inhibitor, including but not limited to, a Notch pathway inhibitor
described herein, an
effective amount of a biparatropic antibody described in U.S. Publication No.
2013/0064823.
In some embodiments, the method comprises administering to an individual who
has received,
is receiving, or is going to receive a Notch pathway inhibitor, including but
not limited to, a
Notch pathway inhibitor described herein, an effective amount of an anti-LRP
antibody
comprising the HVRs or variable regions of P6C.51.61.
In some embodiments, the method comprises administering to an individual who
has
received, is receiving, or is going to receive a Notch pathway inhibitor,
including but not
limited to, a Notch pathway inhibitor described herein, an effective amount of
an anti-Frizzled
antibody comprising the HVRs or variable regions of 18R5. In some embodiments,
the method
comprises administering to an individual who has received, is receiving, or is
going to receive a
Notch pathway inhibitor, including but not limited to, a Notch pathway
inhibitor described
herein, an effective amount of an anti-Frizzled antibody comprising the HVRs
or variable
regions of B9L9.3.
In some embodiments, the method comprises administering to an individual who
has
received, is receiving, or is going to receive a Notch pathway inhibitor,
including but not
limited to, a Notch pathway inhibitor described herein, an effective amount of
an anti-Wnt
77
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
antibody comprising the HVRs or variable regions of an anti-Wnt antibody
described in U.S.
Publication No. 2013/0045209.
In some embodiments, the method comprises administering to an individual who
has
received, is receiving, or is going to receive a Notch pathway inhibitor,
including but not
limited to, a Notch pathway inhibitor described herein, an effective amount of
soluble Frizzled
54F28. In some embodiments, the method comprises administering to an
individual who has
received, is receiving, or is going to receive a Notch pathway inhibitor,
including but not
limited to, a Notch pathway inhibitor described herein, an effective amount of
a soluble Fzd8
receptor, such as FZD8CRD.
In some embodiments, the method comprises administering to an individual who
has
received, is receiving, or is going to receive a Notch pathway inhibitor,
including but not
limited to, a Notch pathway inhibitor described herein, an effective amount of
a Wnt pathway
inhibitor selected from LGK974, AVN316, and PRI-724.
In some embodiments, at least one dose of the at least one Wnt pathway
inhibitor is
administered less than 1 hour, less than 2 hours, less than 4 hours, less than
6 hours, less than 8
hours, less than 12 hours, less than 24 hours, less than 36 hours, or less
than 48 hours before
administration of at least one dose of at least one Notch pathway inhibitor.
In some
embodiments, at least one dose of the at least one Wnt pathway inhibitor is
administered within
4 hours (i.e., anytime from 4 hours before to 4 hours after), or within 3
hours, or within 2
hours, or within 1 hour, of administration of at least one dose of at least
one Notch pathway
inhibitor. In some embodiments, at least one dose of the at least one Wnt
pathway inhibitor is
administered less than 1 hour, less than 2 hours, less than 4 hours, less than
6 hours, less than 8
hours, less than 12 hours, less than 24 hours, less than 36 hours, or less
than 48 hours after
administration of at least one dose of at least one Notch pathway inhibitor.
In a further aspect, the invention provides for the use of Notch pathway
inhibitors and
Wnt pathway inhibitors in the manufacture or preparation of a medicament. In
one
embodiment, the medicament is for treatment of a disease or disorder
associated with aberrant
Notch signaling. In one embodiment, the medicament is for treatment of a
cancer. In a further
embodiment, the medicament is for use in a method of treating a cancer
comprising
administering to an individual having a cancer an effective amount of the
medicament. In one
such embodiment, the method further comprises administering to the individual
an effective
amount of at least one additional therapeutic agent, e.g., as described below.
An "individual"
according to any of the above embodiments may be a human.
78
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
In a further aspect, the invention provides a method for treating a disease or
disorder
associated with aberrant Notch signaling. In one embodiment, the method
comprises
administering to an individual having such disease or disorder an effective
amount of at least
one Notch pathway inhibitor and an effective amount of at least one Wnt
pathway inhibitor. In
one embodiment, the method comprises administering to an individual having a
cancer an
effective amount of at least one Notch pathway inhibitor and an effective
amount of at least
one Wnt pathway inhibitor. In one such embodiment, the method further
comprises
administering to the individual an effective amount of at least one additional
therapeutic agent,
as described below. An "individual" according to any of the above embodiments
may be a
human.
In a further aspect, the invention provides a method for inhibiting cancer
cell growth in
an individual. In one embodiment, the method comprises administering to the
individual an
effective amount of at least one Notch pathway inhibitor and an effective
amount of at least
one Wnt pathway inhibitor to inhibit cancer cell growth. In one embodiment, an
"individual"
is a human.
In a further aspect, the invention provides pharmaceutical formulations
comprising any
of the Notch pathway inhibitors and/or any of the Wnt pathway inhibitors
provided herein, e.g.,
for use in any of the above therapeutic methods. In one embodiment, a
pharmaceutical
formulation comprises any of the Notch pathway inhibitors and/or any of the
Wnt pathway
inhibitors provided herein and a pharmaceutically acceptable carrier. In
another embodiment, a
pharmaceutical formulation comprises any of the Notch pathway inhibitors
and/or any of the
Wnt pathway inhibitors provided herein and at least one additional therapeutic
agent, e.g., as
described below.
Notch pathway inhibitors and Wnt pathway inhibitors of the invention can be
used
either alone or in combination with other agents in a therapy. For instance,
the inhibitors of the
invention may be co-administered with at least one additional therapeutic
agent. In certain
embodiments, an additional therapeutic agent is a cytotoxic agent. In certain
embodiments, an
additional therapeutic agent is an antibody.
Such combination therapies noted above encompass combined administration
(where
two or more therapeutic agents are included in the same or separate
formulations), and separate
administration, in which case, administration of the inhibitor of the
invention can occur prior
to, simultaneously, and/or following, administration of the additional
therapeutic agent or
agents. In one embodiment, administration of at least one Notch pathway
inhibitor and
administration of at least one Wnt pathway inhibitor occur within about one
month, or within
79
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
about one, two or three weeks, or within about one, two, three, four, five, or
six days, of each
other. Inhibitors of the invention can also be used in combination with
radiation therapy.
An inhibitor of the invention (and any additional therapeutic agent) can be
administered
by any suitable means, including parenteral, intrapulmonary, and intranasal,
and, if desired for
local treatment, intralesional administration. Parenteral infusions include
intramuscular,
intravenous, intraarterial, intraperitoneal, or subcutaneous administration.
Dosing can be by
any suitable route, e.g. by injections, such as intravenous or subcutaneous
injections, depending
in part on whether the administration is brief or chronic. Various dosing
schedules including
but not limited to single or multiple administrations over various time-
points, bolus
administration, and pulse infusion are contemplated herein.
Inhibitors of the invention would be formulated, dosed, and administered in a
fashion
consistent with good medical practice. Factors for consideration in this
context include the
particular disorder being treated, the particular mammal being treated, the
clinical condition of
the individual patient, the cause of the disorder, the site of delivery of the
agent, the method of
administration, the scheduling of administration, and other factors known to
medical
practitioners. The inhibitor need not be, but is optionally formulated with
one or more agents
currently used to prevent or treat the disorder in question. The effective
amount of such other
agents depends on the amount of inhibitor present in the formulation, the type
of disorder or
treatment, and other factors discussed above. These are generally used in the
same dosages and
with administration routes as described herein, or about from 1 to 99% of the
dosages
described herein, or in any dosage and by any route that is
empirically/clinically determined to
be appropriate.
For the prevention or treatment of disease, the appropriate dosage of an
inhibitor of the
invention (when used alone or in combination with one or more other additional
therapeutic
agents) will depend on the type of disease to be treated, the type of
inhibitor, the severity and
course of the disease, whether the inhibitor is administered for preventive or
therapeutic
purposes, previous therapy, the patient's clinical history and response to the
inhibitor, and the
discretion of the attending physician. The inhibitor is suitably administered
to the patient at
one time or over a series of treatments. Depending on the type and severity of
the disease,
about 1 p g/kg to 15 mg/kg (e.g. 0.1mg/kg-10mg/kg) of inhibitor can be an
initial candidate
dosage for administration to the patient, whether, for example, by one or more
separate
administrations, or by continuous infusion. One typical daily dosage might
range from about 1
p g/kg to 100 mg/kg or more, depending on the factors mentioned above. For
repeated
administrations over several days or longer, depending on the condition, the
treatment would
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
generally be sustained until a desired suppression of disease symptoms occurs.
One exemplary
dosage of the inhibitor would be in the range from about 0.05 mg/kg to about
10 mg/kg. Thus,
one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 4.0 mg/kg or 10 mg/kg (or any
combination
thereof) may be administered to the patient. Such doses may be administered
intermittently,
e.g. every week or every three weeks (e.g. such that the patient receives from
about two to
about twenty, or e.g. about six doses of the inhibitor). An initial higher
loading dose, followed
by one or more lower doses may be administered. An exemplary dosing regimen
comprises
administering an initial loading dose of about 4 mg/kg, followed by a weekly
maintenance dose
of about 2 mg/kg of the inhibitor. However, other dosage regimens may be
useful. The
progress of this therapy is easily monitored by conventional techniques and
assays.
It is understood that any of the above formulations or therapeutic methods may
be
carried out using an immunoconjugate in place of or in addition to the
antibodies discussed
above.
I. Articles of Manufacture
In another aspect of the invention, an article of manufacture containing
materials useful
for the treatment, prevention and/or diagnosis of the disorders described
above is provided.
The article of manufacture comprises a container and a label or package insert
on or associated
with the container. Suitable containers include, for example, bottles, vials,
syringes, W
solution bags, etc. The containers may be formed from a variety of materials
such as glass or
plastic. The container holds a composition which is by itself or combined with
another
composition effective for treating, preventing and/or diagnosing the condition
and may have a
sterile access port (for example the container may be an intravenous solution
bag or a vial
having a stopper pierceable by a hypodermic injection needle). At least one
active agent in the
composition is an inhibitor of the invention. The label or package insert
indicates that the
composition is used for treating the condition of choice. Moreover, the
article of manufacture
may comprise (a) a first container with a composition contained therein,
wherein the
composition comprises a Notch pathway inhibitor; and (b) a second container
with a
composition contained therein, wherein the composition comprises a Wnt pathway
inhibitor.
The article of manufacture in this embodiment of the invention may further
comprise a package
insert indicating that the compositions can be used to treat a particular
condition.
Alternatively, or additionally, the article of manufacture may further
comprise a second (or
third) container comprising a pharmaceutically-acceptable buffer, such as
bacteriostatic water
for injection (BWFI), phosphate-buffered saline, Ringer's solution and
dextrose solution. It
81
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
may further include other materials desirable from a commercial and user
standpoint, including
other buffers, diluents, filters, needles, and syringes.
III. EXAMPLES
The following are examples of methods and compositions of the invention. It is
understood that various other embodiments may be practiced, given the general
description
provided above.
Example 1. Materials and Methods
Mice
All procedures were performed while observing UCSF regulations and guidelines.
Mouse strains used: C57B1/6, Lgr5GFPiresCreER (Jax strain stock number
008875),
BmilCreER (Jax strain stock number 010531), Axin2lacZ (Jax strain stock number
009120),
Mathl GFP (Jax strain stock number 013593), and R26RFP (Jax strain stock
number 007908).
The intestine was flushed and stretched out with 4% PFA after cardiac
perfusion on a cold
glass plate. Alternating 2 cm pieces were collected in two cassettes. One
cassette was fixed for
4 hr with 4% PFA, followed by a 30% sucrose incubation overnight at 4 C.
Tissues were
embedded in frozen OCT and sectioned at 7 nm. The other cassette was fixed
overnight with
4% PFA and processed for paraffin embedding and sectioned at 2 nm. For lineage
tracing,
Lgr5;RosaRFP/ mice were treated with Tamoxifen dissolved in corn oil at
0.08mg/g, IP,
at the time point indicated in the figure panels. For blocking antibody
treatments, dosing of a-
Notchl and a-Notch2 blocking antibodies was given at 1 mg/kg each, by
intraperitoneal
injection as indicated in the figure panels. a-LRP6 blocking antibody was
given at 30 mg/kg,
IP. FZD8CRD was given at 10 mg/k every 24 hours.
Immunohistochemistry and immunofluorescence
Immunohistochemistry was performed using Dako Envision+ system-HRP polymer
detection kit. For immunofluorescence staining, samples were blocked with Dako
protein-free
blocking solution. Primary and secondary antibodies were diluted in Dako
antibody diluent and
staining conditions are summarized in Table Si. Secondary antibodies were from
Jackson
Immunology.
82
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
Table Si. Antibodies used in this study.
Antigen Catalog# dilution Processing Species Company
B-gal 559761 5000 frozen rabbit MP
bioscience
GFP TP401 5000 paraffin/Frozen rabbit Torrey Pines
GFP NB100- 3000 paraffin/Frozen chicken Novus
1614
D114 AF1389 100 frozen goat R&D
systems
NICD 4147 100 paraffin rabbit Cell
signaling
Full-length 3608 100 Paraffin rabbit Cell
Notch signaling
D111 ab10554 200 frozen rabbit abcam
Mathl SC-98520 300 Paraffin/frozen rabbit Santa Cruz
ckit af1356 300 Paraffin/frozen goat R&Dsystems
ki67 TEC3 300 paraffin rat Dako
ki67 rm-9106-s 300 Paraffin/frozen rabbit Thermo
EdU c10337 500 Paraffin/frozen Invitrogen
Sox9 ab5535 300 Paraffin/frozen rabbit Millipore
EphB3 AF432 100 Paraffin/frozen goat R&D
systems
RFP 600-401- 1000 Paraffin/frozen rabbit Rockland
379
b-catenin c2206 6000 paraffin rabbit Sigma
Lysozyme A0099 10000 Paraffin/frozen rabbit Dako
Construction of the LRP6 bispecific antibody
Two LRP6 specific antibodies were identified and optimized from human
synthetic
antibody libraries (Gong et al., 2010). YW210.09 binds to the El domain of
LRP6 and
YW211.31.57 binds to the E3E4 domain of LRP6. We used knobs-into-holes
engineering
(Ridgeway et al., 1996) to construct a bispecific IgG hybrid with YW211.31.62
and YW210.09
heavy chain heterodimers (Gong, Bourhis et al. 2010; U.S. Publication No.
2011/0256127).
Antibodies were cloned into E.coli expression vectors that expressed full
length IgG (Simmons
et al., 2002). YW210.09 was cloned into the IgG vector with a Knob mutation,
while
YW211.31.57 was cloned into the IgG vector with a Hole mutation. The
bispecific antibody
was developed using a method to express heavy-light half antibodies that are
subsequently
combined to form an intact bispecific immunoglobulin. Detailed protocols of
half antibody
expression, purification and assembly are described (Spiess et al., 2013). The
final bispecific
antibody was characterized by Intact and Reduced Mass Spectrometric Analysis
and size
exclusion chromatography.
83
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
Isolation of crypts for qRTPCR and microarray analysis
Four groups of C57B1/6 mice were injected IF with 1 mg/kg Notchl and Notch2
blocking antibodies, 30 mg/kg Lrp6 blocking antibody, 1 mg/kg Notchl, Notch2
and 30 mg/kg
Lrp6 blocking antibodies, or 30 mg/kg anti-ragweed antibody. 24 hr later,
isolated small
intestines were opened longitudinally, and washed with cold PBS. The tissue
was then chopped
into 5 mm pieces and incubated in cold chelation buffer (2 mM EDTA, 0.5 mM DL-
Dithiothreitol in PBS) for 30 mM on ice. Chelation buffer was then removed and
tissue
fragments were vigorously resuspended in cold PBS using a 10 mL pipette. The
process was
repeated until individual crypts were released from the tissue chunks. The
crypt suspension
fractions were pooled and strained through a 70 micron filter. Crypts were
pelleted and RNA
was extracted using the Qiagen RNeasy mini kit.
Microarray analysis
RNA samples were hybridized against Agilent Mouse GE 4x44K v2 Microarrays
using
Universal Mouse RNA in the control channel. Data were processed with
ExpressionPlot version 3.5 standard Agilent pipeline, which uses R 3Ø0,
and limma 3.6.7. Briefly, (1) background outliers (>50 intensity) were reset
to median
background intensity in both channels, (2) background correction was performed
using the
background Correct function with the "normexp" method with an offset of 50,
(3) within-array
normalization was performed using the normalize WithinAnraysfunction with the
"loess"
method, (4) replicate probes were averaged using theaveReps function, (5)
between-array
normalization was performed using the nonnalizeI3etweenArrays function with
the "Aquantile"
method, (6) control probes (those not beginning with "A_" followed by a digit)
were discarded,
(7) probe expression levels were summarized as log2 of expression ratio, (8)
to obtain gene
levels, one probe was seleted per gene using by maximizing the inter-quartile
range, (9) limma
was used for differential expression analysis. Complete data are provided in
Table 2. Further
analysis to obtain final gene lists was performed using ExpressionPlot:
genomebiology.com/2011/12/7/R69.
Example 2. Localization of Wnt and Notch signaling in the intestinal crypt.
To investigate the role of the Notch and Wnt pathways in maintaining crypt
homeostasis, it was determined which cells within the crypts receive Notch and
Wnt signaling.
Wnt signaling is required for ISC maintenance (Fevr, Robine et al. 2007; van
Es, Haegebarth et
al. 2012), and expression of Lgr5GFP and the Wnt reporter Axin2Lacz was
detected in CBCs
(Figure 1A,B). Axin2Lacz expression was also detected in proliferating TA
cells (Figure 1B),
84
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
reflecting Wnt signaling in these cycling cells. Approximately 76% of crypts
analyzed showed
that Math1GFP expression also overlapped with the Wnt reporter in cells near
the border of the
stem cell compartment and TA zone (Figure 1C, arrowheads; n=3, >100 crypts per
mouse
analyzed). These findings are consistent with the notion that Wnt signaling
plays an active role
in specifying progenitors for the secretory cell fate (Pinto, Gregorieff et
al. 2003).
Lgr5 is a Wnt target gene and an established marker of CBCs. It was found that
CBCs
marked by Lgr5GFP were also positive for the transcriptionally active form of
Notch (NICD)
(Figure 1D), confirming that the Notch pathway is active in ISCs. Nuclear NICD
staining was
also detected in the most proximal proliferating TA cells relative to the
crypt bottom (Figure
1E). NICD staining and the secretory progenitor marker Math1GFP never
overlapped in these
cells (Figure 1F; n=3,? 100 crypts per sample analyzed), consistent with the
role of Notch
signaling in contributing primarily to absorptive lineages (Fre, Huyghe et al.
2005; van Es, van
Gijn et al. 2005). These results reinforce the notion that both pathways are
active in CBCs.
However, the complete lack of NICD in Math1GFP and Axin2Lacz double positive
progenitors
indicates that Notch and Wnt signaling pathways also have divergent functions
during cell fate
specification.
Example 3: Notch signaling blockade impairs ISC function.
Based on the observations that both the Notch and Wnt signaling pathways are
active in
ISCs, their respective roles were tested by reducing the levels of signaling
through the use of
pharmacological agents. Established antibodies that specifically block the
activity of Notch
receptors 1 and 2 (Wu, Cain-Hom et al. 2010) were used, as well as a
bispecific antibody that
inhibits the activity of the Wnt co-receptor LRP6 (Example 1: Materials and
methods).
Inhibiting Notchl and Notch2 together effectively blocked Notch signaling,
based on a
complete loss of NICD accumulation in ISCs and TA cells, and induced a loss of
CBC
morphology (Figure 2A,B). Notch inhibition also decreased proliferation
associated with the
TA zone (Figure 2C,D) and a substantially increased expression of the Paneth
cell marker
lysozyme (Figure 2E,F). These results indicated that this dosing scheme
effectively blocked
Notch signaling in the small intestine.
The ISC markers Lgr5 and Olfm4 were down-regulated 7 hours after Notch
antibody
treatment (Figure 3A-D and Figure 4A,B), suggesting that stem cell maintenance
was affected
by Notch pathway inhibition. In addition, the number of proliferating CBCs
marked by Lgr5GFP
and Ki67 staining expression was greatly reduced 24 hours after Notch blockade
(Figure 5D,L
and Figure 3F). Surprisingly, Lgr5 expression recovered 72 hours following
initiation of Notch
blockade, and Lgr5 was ectopically expressed throughout the crypt base and
extended upward
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
to the region normally occupied by TA cells (Figure 3G,H). On the other hand,
expression of
the Notch target gene Olfm4 (VanDussen, Carulli et al. 2012) remained down
regulated during
the entire Notch blockade (Figure 4A-D). The differential effect of Notch
inhibition on the
expression of these two stem cell markers may reflect distinct pathway
requirements.
Nevertheless, the extended loss of Olfm4 expression, coupled with the results
on stem cell
activity described below, suggest that Olfm4 down regulation correlates with
loss of stem cell
activity. Increased levels of Lgr5 at later timepoints are likely due to the
Lgr5 responsiveness to
Wnt signaling, as described below.
Treatment of mice with the anti-Lrp6 blocking antibody led to a marked
reduction in
secretory cell progenitors (Figure 2G,H), consistent with previous reports
linking Wnt to
secretory differentiation (Farmn et al., 2012; Pinto, Gregorieff et al. 2003)
and with the
observation that Axin2Lacz overlaps with Math1GFP expression. Paneth cells,
marked by the
presence of lysozyme staining, were maintained in the presence of anti-LRP6
treatment (data
not shown). Attenuation of the Wnt pathway also led to the loss of Lgr5GFP
expression in
CBCs while maintaining normal crypt proliferation in the intestine (Figure
2I,J). This result
raises the possibility that different Wnt signaling thresholds are required to
maintain Lgr5
levels vs. maintaining proliferation. Although a near complete down-regulation
of Axin2Lacz
levels in mice treated with anti-Lrp6 blocking antibody was observed (Figure
2H), it is possible
that the Axin2Lacz reporter is insensitive to very low levels of Wnt signaling
or that input(s)
from other signaling pathway(s) play a role in maintaining TA cell
proliferation during anti-
Lrp6 blockade.
To more definitively determine if normal CBC stem cell multipotency requires
Notch
and Wnt signaling, genetic lineage tracing experiments were performed using
Lgr5;RosaRFP/ mice. First, mice were given Notch blocking antibodies before
induction
of recombination with Tamoxifen (Tam). Compared with control mice where Notch
signaling
is left intact (Figure 2K), treatment with Notch blocking antibodies before
Tam induction
completely prevented lineage tracing from Lgr5-expressing cells (Figure 2L).
In samples from
these mice, RFP-marked cells were present at the crypt base (Figure 2L, inset)
and expressed
the secretory marker lysozyme (Figure 6B), indicating that CBCs had converted
directly into
Paneth cells during Notch blockade. In addition, Notch blocking antibodies
were injected
following tamoxifen-induced recombination. Under these conditions, lineage
tracing from the
base of the crypts was almost completely absent with patchy lineage tracing
remaining in cells
near the top of villi (Figure 2M). RFP marked cells were also detected at the
crypt base (Figure
2M) and expressed lysozyme (Figure 6D), indicating that a small population of
CBCs had
86
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
given rise to Paneth cells during Notch blockade. Together, these results show
that Notch
signaling is required for CBC stem cell activity.
Treating mice with the Lrp6 blocking antibody before induction with Tam caused
a
complete loss of Lgr5 lineage tracing events (Figure 2N). To differentiate
between lost stem
cell activity and suppression of Lgr5 expression through Wnt signaling
attenuation,
recombination was induced in CBCs followed by Lrp6 blocking antibody
treatments. This led
to un-interrupted lineage tracing similar to that observed in control mice
(Figure 20),
indicating that CBC stem cells function normally under LRP6 signaling
attenuation, and that
the loss of lineage tracing seen in the pre-Tam treatments was likely due to
loss of Lgr5
expression. This observation was corroborated by the presence of proliferating
CBCs and
Olfm4 expression in the anti-Lrp6 treated animals (Figure 2J, Figure 4E).
Example 4: Notch blockade leads to Wnt signaling up-regulation, which promotes
secretory cell hyperplasia.
The down-regulation of Math1GFP expression by administration of the Lrp6
blocking
antibody is consistent with a role for Wnt signaling in promotion of secretory
cell fate
decisions. Indeed, down-regulation of Math1GFP expression was detected as
early as 24 hours
after anti-Lrp6 injection (Figure 50). As a result, Wnt signaling readouts
during Notch
blockade were examined. By 7 hours after injection with the Notch blocking
antibodies,
intestinal crypts showed a pronounced increase in Axin2Lacz expression (Figure
5B,F) without
an apparent increase in Math1GFP expression (Figure 5C ,G).. Notch signaling
has been shown
to repress expression of Math] in the intestine (Fre, Huyghe et al. 2005; van
Es, van Gijn et al.
2005), and a substantial increase in Math1GFP expression was similarly
detected by 24 hours
post treatment (Figure 5A,K). Interestingly, at this time point, Math1GFP -
positive cells
overlapped with Axin2Lacz expression, which was increased (Figure 5A,J),
indicating that the
Notch secretory hyperplasia phenotype correlated with cells that were actively
undergoing high
levels of Wnt signaling.
As a result of these observations, gene expression analysis using expression
microarrays
followed by qPCR validation on isolated intestinal crypts from mice treated
with Notch
blocking antibodies for 24 hours was performed (Figure 5A and Tables 2-4). The
top
differentially expressed genes were bona fide Notch targets (01fm4 (log2(fold
change)=-4.07))
and Neurog3 (log2(fold change)=3.83)(Fre, Huyghe et al. 2005; VanDussen,
Carulli et al.
2012). In addition, up-regulation of several known Wnt target genes was also
detected. The
ligand Wnt3 was strongly up regulated, as were the Wnt target genes Kit, Cc19,
Sox4, Rnf43,
Tnfsrf25. In addition to the Wnt targets, several known regulators of
secretory cell
87
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
differentiation such as AtohllMathl , D114, D111, Pax4, Foxa2, and Nkx2-2,
Rfx6, and Neurog3
were also up regulated. Within the set of anti-Notch up-regulated genes, two
groups were
distinguished based on responsiveness to co-treatment with anti-LRP6. One
group showed a
greater than 2 fold decrease in expression relative to anti-Notch treatment
alone and included
Wnt3 and Atohl/Mathl (Table 4), whereas the other showed minimal
responsiveness to anti-
LRP6 treatment and included Pax4 (<2 fold, Table 5). Several of the minimally
responsive
genes have been identified previously in screens for Wnt target genes (de Lau
et al., 2011),
suggesting that treatment with the anti-LRP6 antibody represents an incomplete
Wnt signaling
blockade. Expression of other Wnt targets based on the microarray results such
as Sox9 and
EphB3 was monitored and it was found that they were also increased during the
early Notch
blockade (Figure 5E,I,M). Thus, the immunofluorescence and microarray results
indicated that
Notch signaling attenuates Wnt signaling, preventing secretory differentiation
in the intestinal
epithelium.
Table 2: Genes downregulated after anti-Notch treatment.
gene symbol gene name log2(fold
change)
Olfm4 olfactomedin 4 -4.07
Rbp7 retinol binding protein 7, cellular -3.18
C3 complement component 3 -1.75
Cyplal cytochrome P450, family 1, subfamily a, polypeptide 1 -
1.74
Ugt2b5 UDP glucuronosyltransferase 2 family, polypeptide B5 -1.73
Ctse cathepsin E -1.68
Ugt2b38 UDP glucuronosyltransferase 2 family, polypeptide B38 -
1.57
Cnn3 calponin 3, acidic -1.52
Ugt2b36 UDP glucuronosyltransferase 2 family, polypeptide B36 -
1.46
Akp3 alkaline phosphatase 3, intestine, not Mn requiring -1.45
Asc12 achaete-scute complex homolog 2 (Drosophila) -1.45
Tmprss15 transmembrane protease, serine 15 -1.44
Adck3 aarF domain containing kinase 3 -1.43
Cbr3 carbonyl reductase 3 -1.43
Aqp8 aquaporin 8 -1.43
Dcn decorin -1.39
Sema5a sema domain, seven thrombospondin repeats (type 1 and type 1-
-1.39
like), transmembrane domain (TM) and short cytoplasmic
domain, (semaphorin) 5A
Pdk4 pyruvate dehydrogenase kinase, isoenzyme 4 -1.33
Cybrdl cytochrome b reductase 1 -1.29
Acsm3 acyl-CoA synthetase medium-chain family member 3 -1.29
Rspol R-spondin homolog (Xenopus laevis) -1.28
Lum lumican -1.27
Slc40a1 solute carrier family 40 (iron-regulated transporter), member
1 -1.27
88
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
Cyp39a1 cytochrome P450, family 39, subfamily a, polypeptide 1 -1.23
Ugt2b37 UDP glucuronosyltransferase 2 family, polypeptide B37 -1.22
S1c16a9 solute carrier family 16 (monocarboxylic acid transporters), -
1.22
member 9
Shmtl serine hydroxymethyltransferase 1 (soluble) -1.2
Msln me sothelin -1.18
Nkx6-3 NK6 homeobox 3 -1.16
Add3 adducin 3 (gamma) -1.15
Impa2 inositol (myo)-1 (or 4)-monophosphatase 2 -1.15
Rarres2 retinoic acid receptor responder (tazarotene induced) 2 -1.14
Ugt2b35 UDP glucuronosyltransferase 2 family, polypeptide B35 -1.14
Wtl Wilms tumor 1 homolog -1.14
Slc14a1 solute carrier family 14 (urea transporter), member 1 -1.13
Upk3b uroplakin 3B -1.13
Pbk PDZ binding kinase -1.11
Alalc12 aldo-keto reductase family 1, member C12 -1.11
1110020GO9Rik RIKEN cDNA 1110020G09 gene -1.1
Clu clusterin -1.1
Cth cystathionase (cystathionine gamma-lyase) -1.09
Alalc14 aldo-keto reductase family 1, member C14 -1.09
Clra complement component 1, r subcomponent A -1.07
Cenpp centromere protein P -1.07
Angpt2 angiopoietin 2 -1.06
Rgn regucalcin -1.06
Ptgis prostaglandin 12 (prostacyclin) synthase -1.05
Adamts2 a disintegrin-like and metallopeptidase (reprolysin type) with
-1.05
thrombospondin type 1 motif, 2
Fabp4 fatty acid binding protein 4, adipocyte -1.03
Scn2b sodium channel, voltage-gated, type II, beta -1.03
Snx7 sorting nexin 7 -1.03
Kcnql potassium voltage-gated channel, subfamily Q, member 1 -1.03
Lmcdl LIM and cysteine-rich domains 1 -1.03
Aldhla3 aldehyde dehydrogenase family 1, subfamily A3 -1.02
Slpi secretory leukocyte peptidase inhibitor -1.02
Stmnl stathmin 1 -1.02
Hpdl 4-hydroxyphenylpyruvate dioxygenase-like -1.01
Aqp4 aquaporin 4 -1
Table 3: Genes upregulated after anti-Notch treatment.
gene symbol gene name log2(fold
change)
Neurog3 neurogenin 3 3.83
Cbfa2t3 core-binding factor, runt domain, alpha subunit 2, translocated
2.52
to, 3 (human)
Gfra3 glial cell line derived neurotrophic factor family receptor
alpha 2.44
3
Kit kit oncogene 2.42
89
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
Rcor2 REST corepressor 2 2.4
Cacnala calcium channel, voltage-dependent, P/Q type, alpha lA 2.24
subunit
Cc19 chemokine (C-C motif) ligand 9 2.21
Rfx6 regulatory factor X, 6 2.21
Kcnh3 potassium voltage-gated channel, subfamily H (eag-related),
2.15
member 3
C2cd4b C2 calcium-dependent domain containing 4B 2.15
Celf3 CUGBP, Elav-like family member 3 2.14
Fcgbp Fc fragment of IgG binding protein 2.09
Selm selenoprotein M 2.04
Rasa4 RAS p21 protein activator 4 2.01
Vldlr very low density lipoprotein receptor 1.98
Pax4 paired box gene 4 1.97
Atohl atonal homolog 1 (Drosophila) 1.96
Gm5595 predicted gene 5595 1.96
Aim n antisense Igf2r RNA 1.93
Qsoxl quiescin Q6 sulfhydryl oxidase 1 1.91
Wnt3 wingless-related MMTV integration site 3 1.91
Rapgef3 Rap guanine nucleotide exchange factor (GEF) 3 1.91
Spdef SAM pointed domain containing ets transcription factor 1.9
Fut2 fucosyltransferase 2 1.88
Phf2lb PHD finger protein 21B 1.85
Itga6 integrin alpha 6 1.82
Retnlb resistin like beta 1.82
Dll t delta-like 1 (Drosophila) 1.82
Ern2 endoplasmic reticulum (ER) to nucleus signalling 2 1.81
Futl fucosyltransferase 1 1.8
Serpina9 serine (or cysteine) peptidase inhibitor, clade A (alpha-1
1.79
antiproteinase, antitrypsin), member 9
Hrh3 histamine receptor H3 1.78
51c17a9 solute carrier family 17, member 9 1.75
Insml insulinoma-associated 1 1.75
Raplgap Rapl GTPase-activating protein 1.7
Ffar2 free fatty acid receptor 2 1.69
Pla2g2a phospholipase A2, group IIA (platelets, synovial fluid) 1.66
Rep15 RAB15 effector protein 1.65
Creb314 cAMP responsive element binding protein 3-like 4 1.65
Chrml cholinergic receptor, muscarinic 1, CNS 1.65
Gpr20 G protein-coupled receptor 20 1.64
51c15a2 solute carrier family 15 (H+/peptide transporter), member 2
1.64
Gadd45g growth arrest and DNA-damage-inducible 45 gamma 1.62
Syt12 synaptotagmin-like 2 1.61
Creb311 cAMP responsive element binding protein 3-like 1 1.61
Gsdma2 gasdermin A2 1.6
Tmem44 transmembrane protein 44 1.6
Phldal pleckstrin homology-like domain, family A, member 1 1.58
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
Ras sf6 Ras association (Ra1GDS/AF-6) domain family member 6 1.58
Atp2a3 ATPase, Ca++ transporting, ubiquitous 1.57
Syt13 synaptotagmin XIII 1.55
Wtip WT1 -interacting protein 1.55
Sox4 SRY-box containing gene 4 1.53
Dmpk dystrophia myotonica-protein kinase 1.51
Tecprl tectonin beta-propeller repeat containing 1 1.5
Pdia5 protein disulfide isomerase associated 5 1.5
Bhlhal5 basic helix-loop-helix family, member a15 1.49
Myo5c myosin VC 1.49
Utrn utrophin 1.48
Tnfrsf25 tumor necrosis factor receptor superfamily, member 25 1.47
Hepacam2 HEPACAM family member 2 1.46
Celsr3 cadherin, EGF LAG seven-pass G-type receptor 3 (flamingo
1.45
homolog, Drosophila)
Hpd 4-hydroxyphenylpyruvic acid dioxygenase 1.44
Lama5 laminin, alpha 5 1.43
Galnt12 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N- 1.43
acetylgalactosaminyltransferase 12
Gm14207 predicted gene 14207 1.42
Gcnt3 glucosaminyl (N-acetyl) transferase 3, mucin type 1.42
Eya2 eyes absent 2 homolog (Drosophila) 1.41
Efcab4a EF-hand calcium binding domain 4A 1.41
Pde2a phosphodiesterase 2A, cGMP-stimulated 1.41
Unc5a unc-5 homolog A (C. elegans) 1.41
D114 delta-like 4 (Drosophila) 1.39
Tubb2b tubulin, beta 2B class BB 1.38
Foxa2 forkhead box A2 1.35
Cd97 CD97 antigen 1.34
Thbsl thrombospondin 1 1.33
Pnma2 paraneoplastic antigen MA2 1.33
Kcnk6 potassium inwardly-rectifying channel, subfamily K, member
1.33
6
Dok7 docking protein 7 1.31
Txndc5 thioredoxin domain containing 5 1.29
Hgfac hepatocyte growth factor activator 1.29
Olfml olfactomedin 1 1.27
Sennla sodium channel, nonvoltage-gated 1 alpha 1.26
Gm11937 predicted gene 11937 1.26
Fxyd3 FXYD domain-containing ion transport regulator 3 1.26
Fam174b family with sequence similarity 174, member B 1.25
S1c34a1 solute carrier family 34 (sodium phosphate), member 1 1.24
Slc2a10 solute carrier family 2 (facilitated glucose transporter),
1.23
member 10
Nkx2-2 NK2 transcription factor related, locus 2 (Drosophila) 1.23
Cfi complement component factor i 1.23
L 1 tdl LINE-1 type transposase domain containing 1 1.23
91
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
Agr2 anterior gradient 2 (Xenopus laevis) 1.23
Ical islet cell autoantigen 1 1.23
Ttc39a tetratricopeptide repeat domain 39A 1.22
Hpca hippocalcin 1.21
Dnaj c10 DnaJ (Hsp40) homolog, subfamily C, member 10 1.21
Fsdll fibronectin type III and SPRY domain containing 1-like 1.21
Rundc3a RUN domain containing 3A 1.2
B3galt5 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, 1.2
polypeptide 5
51c27a3 solute carrier family 27 (fatty acid transporter), member 3
1.2
X1r3b X-linked lymphocyte-regulated 3B 1.2
Foxa3 forkhead box A3 1.2
51c43a1 solute carrier family 43, member 1 1.18
Sidtl S1D1 transmembrane family, member 1 1.18
Cd200 CD200 antigen 1.16
Pla2g10 phospholipase A2, group X 1.16
Chst4 carbohydrate (chondroitin 6/keratan) sulfotransferase 4 1.13
4930404N11Rik RIKEN cDNA 4930404N11 gene 1.13
Galnt7 UDP-N-acetyl-alpha-D-galactosamine: polypeptide N- 1.13
acetylgalactosaminyltransferase 7
Gm5796 predicted gene 5796 1.13
C630004H02Rik RIKEN cDNA C630004H02 gene 1.12
St6galnac6 5T6 (alpha-N-acetyl-neuraminy1-2,3-beta-galactosy1-1,3)-N-
1.12
acetylgalactosaminide alpha-2,6-sialyltransferase 6
Capn8 calpain 8 1.11
Manscl MANSC domain containing 1 1.11
Rnf150 ring finger protein 150 1.11
BC057022 cDNA sequence BC057022 1.1
Wars tryptophanyl-tRNA synthetase 1.1
Caszl castor homolog 1, zinc finger (Drosophila) 1.09
Hk2 hexokinase 2 1.09
Tbc 1 d2 TBC1 domain family, member 2 1.09
DlOBwg1379e DNA segment, Chr 10, Brigham & Women's Genetics 1379 1.09
expressed
Lrrc27 leucine rich repeat containing 27 1.08
Neurod2 neurogenic differentiation 2 1.08
Gm20558 predicted gene, 20558 1.08
Pecr peroxisomal trans-2-enoyl-CoA reductase 1.08
C2cd4a C2 calcium-dependent domain containing 4A 1.08
Mcf21 mcf.2 transforming sequence-like 1.08
Gm13023 predicted gene 13023 1.07
Sgsml small G protein signaling modulator 1 1.07
Igdcc4 immunoglobulin superfamily, DCC subclass, member 4 1.07
Rn4.5s 4.5S RNA 1.07
51c23a3 solute carrier family 23 (nucleobase transporters), member 3
1.06
Fryl furry homolog-like (Drosophila) 1.06
Vwa5b2 von Willebrand factor A domain containing 5B2 1.06
92
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
Fkbpll FK506 binding protein 11 1.05
Nsf N-ethylmaleimide sensitive fusion protein 1.04
Krt7 keratin 7 1.04
Ptpro protein tyrosine phosphatase, receptor type, 0 1.03
Cmtm7 CKLF-like MARVEL transmembrane domain containing 7 1.03
Inf2 inverted formin, FH2 and WH2 domain containing 1.03
Tat tyrosine aminotransferase 1.03
Serpinal0 serine (or cysteine) peptidase inhibitor, clade A (alpha-1
1.03
antiproteinase, antitrypsin), member 10
Krtap10-10 keratin associated protein 10-10 1.03
S1c7a4 solute carrier family 7 (cationic amino acid transporter, y+
1.03
system), member 4
Tmem132a transmembrane protein 132A 1.03
Naipl NLR family, apoptosis inhibitory protein 1 1.02
Hsp90b1 heat shock protein 90, beta (Grp94), member 1 1.02
Pq1c1 PQ loop repeat containing 1 1.02
Pdia4 protein disulfide isomerase associated 4 1.02
Zc3h7a zinc finger CCCH type containing 7 A 1.02
Map3k15 mitogen-activated protein kinase kinase kinase 15 1.01
Mex3a mex3 homolog A (C. elegans) 1.01
Sgsm3 small G protein signaling modulator 3 1.01
Rmrp RNA component of mitochondrial RNAase P 1.01
Table 4: Genes downregulated after anti-Notch and anti-Lrp6 treatment.
gene symbol gene name log2(fold log2(fold
change) due to change)
Notch Blockade Notch_Lrp
6 relative
to Notch
Cbfa2t3 core-binding factor, runt domain, alpha 2.52 -1.43
subunit 2, translocated to, 3 (human)
Kit kit oncogene 2.42 -1.28
Rcor2 REST corepressor 2 2.4 -0.958
Cacnala calcium channel, voltage-dependent, P/Q 2.24 -1.13
type, alpha 1 A subunit
Rfx6 regulatory factor X, 6 2.21 -1.34
Kcnh3 potassium voltage-gated channel, subfamily 2.15 -
1.23
H (eag-related), member 3
C2cd4b C2 calcium-dependent domain containing 2.15 -1.47
4B
Celf3 CUGBP, Elav-like family member 3 2.14 -1.35
Fcgbp Fc fragment of IgG binding protein 2.09 -1.22
Rasa4 RAS p21 protein activator 4 2.01 -1.07
Vldlr very low density lipoprotein receptor 1.98 -1.38
Gm5595 predicted gene 5595 1.96 -1.18
Atohl atonal homolog 1 (Drosophila) 1.96 -0.928
Aim n antisense Igf2r RNA 1.93 -1.74
Wnt3 wingless-related MMTV integration site 3 1.91 -1.22
93
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
Rapgef3 Rap guanine nucleotide exchange factor 1.91 -1.38
(GEF) 3
Qsoxl quiescin Q6 sulfhydryl oxidase 1 1.91 -1.27
Spdef SAM pointed domain containing ets 1.9 -0.955
transcription factor
Fut2 fucosyltransferase 2 1.88 -1.73
Phf2lb PHD finger protein 21B 1.85 -1.42
D111 delta-like 1 (Drosophila) 1.82 -1.05
Itga6 integrin alpha 6 1.82 -1.13
Retnlb resistin like beta 1.82 -1.29
Ern2 endoplasmic reticulum (ER) to nucleus 1.81 -1.27
signalling 2
Futl fucosyltransferase 1 1.8 -1.18
14581 growth factor independent 1 1.77 -1.26
51c17a9 solute carrier family 17, member 9 1.75 -1.55
Raplgap Rapl GTPase-activating protein 1.7 -0.982
Ffar2 free fatty acid receptor 2 1.69 -1.27
Pla2g2a phospholipase A2, group IIA (platelets, 1.66 -1.21
synovial fluid)
Chrml cholinergic receptor, muscarinic 1, CNS 1.65 -1.38
51c15a2 solute carrier family 15 (H+/peptide 1.64 -1.61
transporter), member 2
Gpr20 G protein-coupled receptor 20 1.64 -1.21
Gadd45g growth arrest and DNA-damage-inducible 1.62 -1.06
45 gamma
Syt12 synaptotagmin-like 2 1.61 -1.25
Gsdma2 gasdermin A2 1.6 -1.41
Rassf6 Ras association (Ra1GDS/AF-6) domain 1.58 -1.14
family member 6
Atp2a3 ATPase, Ca++ transporting, ubiquitous 1.57 -1.04
Wtip WT1-interacting protein 1.55 -1.48
Dmpk dystrophia myotonica-protein kinase 1.51 -1.05
Pdia5 protein disulfide isomerase associated 5 1.5 -0.946
Tecprl tectonin beta-propeller repeat containing 1 1.5 -1.06
Myo5c myosin VC 1.49 -1.11
Utrn utrophin 1.48 -1.39
Tnfrsf25 tumor necrosis factor receptor superfamily, 1.47 -1.47
member 25
Celsr3 cadherin, EGF LAG seven-pass G-type 1.45 -1.2
receptor 3 (flamingo homolog, Drosophila)
Galnt12 UDP-N-acetyl-alpha-D- 1.43 -0.924
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 12
Lama5 laminin, alpha 5 1.43 -1.39
Gcnt3 glucosaminyl (N-acetyl) transferase 3, 1.42 -0.903
mucin type
Pde2a phosphodiesterase 2A, cGMP-stimulated 1.41 -0.951
Eya2 eyes absent 2 homolog (Drosophila) 1.41 -0.91
D114 delta-like 4 (Drosophila) 1.39 -0.956
94
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
1300002K09Rik RIKEN cDNA 1300002K09 gene 1.36 -0.96
1810019D21Rik RIKEN cDNA 1810019D21 gene 1.35 -1.2
Cd97 CD97 antigen 1.34 -1.06
Thbsl thrombospondin 1 1.33 -1.09
Kcnk6 potassium inwardly-rectifying channel, 1.33 -1.08
subfamily K, member 6
Lltdl LINE-1 type transposase domain containing 1.23 -1.02
1
Slc2a10 solute carrier family 2 (facilitated glucose 1.23 -0.95
transporter), member 10
Cfi complement component factor i 1.23 -1.12
S1c27a3 solute carrier family 27 (fatty acid 1.2 -1.13
transporter), member 3
B3galt5 UDP-Gal:betaGlcNAc beta 1,3- 1.2 -1.44
galactosyltransferase, polypeptide 5
Cd200 CD200 antigen 1.16 -1.41
Chst4 carbohydrate (chondroitin 6/keratan) 1.13 -0.949
sulfotransferase 4
St6galnac6 ST6 (alpha-N-acetyl-neuraminy1-2,3-beta- 1.12 -1.01
galactosy1-1,3)-N-acetylgalactosaminide
alpha-2,6-sialyltransferase 6
Capn8 calpain 8 1.11 -0.966
Hk2 hexokinase 2 1.09 -0.903
Rn4.5s 4.5S RNA 1.07 -1.23
Nsf N-ethylmaleimide sensitive fusion protein 1.04 -1.27
Serpinal0 serine (or cysteine) peptidase inhibitor, 1.03 -0.933
clade A (alpha-1 antiproteinase, antitrypsin),
member 10
Hsp90b1 heat shock protein 90, beta (Grp94), 1.02 -1.26
member 1
Zc3h7a zinc finger CCCH type containing 7 A 1.02 -1.11
Pdia4 protein disulfide isomerase associated 4 1.02 -1.11
Chpf2 chondroitin polymerizing factor 2 1 -1.35
Table 5: Gene expression changes after anti-Notch and combination anti-
Notch/anti-Lrp6
treatment.
gene symbol gene name log2(fold
log2(fold
change) change)
Notch Notch_LRP6
treatment relative to
Notch
Neurog3 neurogenin 3 3.83 -0.548
glial cell line derived neurotrophic factor
Gfra3 family receptor alpha 3 2.44 -0.463
Rcor2 REST corepressor 2 2.41 -0.965
Cc19 chemokine (C-C motif) ligand 9 2.21 -0.713
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
Seim selenoprotein M 2.05 -0.632
Pax4 paired box gene 4 1.97 -0.824
Atohl atonal homolog 1 (Drosophila) 1.96 -0.927
SAM pointed domain containing ets
Spdef transcription factor 1.91 -0.96
serine (or cysteine) peptidase inhibitor,
clade A (alpha-1 antiproteinase, antitrypsin),
Serpina9 member 9 1.79 -0.565
Hrh3 histamine receptor H3 1.78 -0.694
Insml insulinoma-associated 1 1.75 -0.0589
Raplgap Rapl GTPase-activating protein 1.71 -0.989
Rep15 RAB15 effector protein 1.65 -0.864
cAMP responsive element binding protein
Creb314 3-like 4 1.65 -0.697
cAMP responsive element binding protein
Creb311 3-like 1 1.62 -0.887
pleckstrin homology-like domain, family A,
Phldal member 1 1.6 -0.679
Tmem44 transmembrane protein 44 1.6 -0.715
Syt13 synaptotagmin XIII 1.56 -0.702
Sox4 SRY-box containing gene 4 1.53 -0.333
Pdia5 protein disulfide isomerase associated 5 1.5 -0.949
Bhlhal5 basic helix-loop-helix family, member a15 1.49 -0.8
Hepacam2 HEPACAM family member 2 1.46 -0.824
UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
Galnt12 acetylgalactosaminyltransferase 12 1.45 -0.938
Hpd 4-hydroxyphenylpyruvic acid dioxygenase 1.44 -0.685
5330417C22Rik RIKEN cDNA 5330417C22 gene 1.44 -0.805
Pde2a phosphodiesterase 2A, cGMP-stimulated 1.42 -0.958
Gm14207 predicted gene 14207 1.42 -0.369
Efcab4a EF-hand calcium binding domain 4A 1.41 -0.823
glucosaminyl (N-acetyl) transferase 3,
Gcnt3 mucin type 1.41 -0.903
Unc5a unc-5 homolog A (C. elegans) 1.41 -0.829
Eya2 eyes absent 2 homolog (Drosophila) 1.4 -0.909
96
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
D114 delta-like 4 (Drosophila) 1.39 -0.956
Tubb2b tubulin, beta 2B class IIB 1.38 -0.23
Foxa2 forkhead box A2 1.35 -0.355
1300002K09Rik RIKEN cDNA 1300002K09 gene 1.35 -0.959
Pnma2 paraneoplastic antigen MA2 1.33 -0.419
Dok7 docking protein 7 1.31 -0.801
Txndc5 thioredoxin domain containing 5 1.31 -0.865
Hgfac hepatocyte growth factor activator 1.29 -0.863
Gm11937 predicted gene 11937 1.27 0.0122
Olfml olfactomedin 1 1.27 -0.369
Agr2 anterior gradient 2 (Xenopus laevis) 1.27 -0.761
FXYD domain-containing ion transport
Fxyd3 regulator 3 1.26 -0.248
Scnnla sodium channel, nonvoltage-gated 1 alpha 1.26 -0.718
family with sequence similarity 174,
Fam174b member B 1.25 -0.626
solute carrier family 34 (sodium phosphate),
S1c34a1 member 1 1.24 -0.775
DnaJ (Hsp40) homolog, subfamily C,
Dnajc10 member 10 1.24 -0.645
Ical islet cell autoantigen 1 1.23 -0.735
solute carrier family 2 (facilitated glucose
Slc2a10 transporter), member 10 1.23 -0.95
NK2 transcription factor related, locus 2
Nkx2-2 (Drosophila) 1.23 -0.66
Ttc39a tetratricopeptide repeat domain 39A 1.22 -0.768
Hpca hippocalcin 1.21 -0.787
fibronectin type III and SPRY domain
Fsdll containing 1-like 1.21 -0.822
Rundc3a RUN domain containing 3A 1.2 -0.619
2210020M01Rik RIKEN cDNA 2210020M01 gene 1.2 -0.817
Foxa3 forkhead box A3 1.2 -0.488
X1r3b X-linked lymphocyte-regulated 3B 1.2 -0.6
Sidtl SID1 transmembrane family, member 1 1.19 -0.894
51c43a1 solute carrier family 43, member 1 1.18 -0.758
Pla2g10 phospholipase A2, group X 1.16 -0.679
97
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
Wars tryptophanyl-tRNA synthetase 1.14 -0.433
C630004H02Rik RIKEN cDNA C630004H02 gene 1.13
UDP-N-acetyl-alpha-D-galactosamine:
polypeptide N-
Galnt7 acetylgalactosaminyltransferase 7 1.13
carbohydrate (chondroitin 6/keratan)
Chst4 sulfotransferase 4 1.13
4930404N11Rik RIKEN cDNA 4930404N11 gene 1.13
Gm5796 predicted gene 5796 1.12
Hk2 hexokinase 2 1.11
Rnf150 ring finger protein 150 1.11
Capn8 calpain 8 1.11
Manscl MANSC domain containing 1 1.11
Tbc1d2 TBC1 domain family, member 2 1.1
BC057022 cDNA sequence BC057022 1.1
DNA segment, Chr 10, Brigham &
DlOBwg1379e Women's Genetics 1379 expressed 1.09
Mcf21 mcf.2 transforming sequence-like 1.09
Caszl castor homolog 1, zinc finger (Drosophila) 1.09
Pecr peroxisomal trans-2-enoyl-CoA reductase 1.08
C2 calcium-dependent domain containing
C2cd4a 4A 1.08
Lrrc27 leucine rich repeat containing 27 1.08
Neurod2 neurogenic differentiation 2 1.08
Gm20558 predicted gene, 20558 1.08
Gm13023 predicted gene 13023 1.07
immunoglobulin superfamily, DCC
Igdcc4 subclass, member 4 1.07
Sgsml small G protein signaling modulator 1 1.06
solute carrier family 23 (nucleobase
51c23a3 transporters), member 3 1.06
inverted formin, FH2 and WH2 domain
Inf2 containing 1.06
Fryl furry homolog-like (Drosophila) 1.06
von Willebrand factor A domain containing
Vwa5b2 5B2 1.06
98
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
Fkbpll FK506 binding protein 11 1.05
Krt7 keratin 7 1.04
Tmem132a transmembrane protein 132A 1.04
Krtap10-10 keratin associated protein 10-10 1.04
CKLF-like MARVEL transmembrane
Cmtm7 domain containing 7 1.03
solute carrier family 7 (cationic amino acid
S1c7a4 transporter, y+ system), member 4 1.03
protein tyrosine phosphatase, receptor type,
Ptpro 0 1.02
Naipl NLR family, apoptosis inhibitory protein 1 1.02
Pq1c1 PQ loop repeat containing 1 1.02
Tat tyrosine aminotransferase 1.02
serine (or cysteine) peptidase inhibitor,
clade A (alpha-1 antiproteinase, antitrypsin),
Serpinal0 member 10 1.02
RNA component of mitochondrial RNAase
Rmrp P 1.01
mitogen-activated protein kinase kinase
Map3k15 kinase 15 1.01
Sgsm3 small G protein signaling modulator 3 1.01
Mex3a mex3 homolog A (C. elegans) 1.01
Example 5: Wnt signaling up-regulation occurs independently of Paneth cell
hyperplasia
Paneth cells are a major source of Wnt3 in the small intestine, which led us
to ask if
Paneth cell hyperplasia represents the sole mechanism by which Wnt signaling
up-regulation is
achieved during Notch blockade. Levels of the Paneth cell marker Defal
(microarray data not
shown) and lysozyme staining in the small intestine (Figure 9A,B) were not
significantly
increased at the 24 hour time point. To test if Paneth cells are required for
a Wnt response, we
blocked Notch signaling in Villin Cre;Mathlflifi mice that lack both secretory
progenitors as
well as differentiated secretory cells, including Paneth cells. Villin
Cre;Mathlfvfl mice had
significantly reduced levels of Defal that did not change with Notch blockade
(Figure 9C).
These mice, like their control littermates, appeared to have increased Ki67
and SOX9 staining
after Notch blockade (Figure 9D-J), which suggested to us that Wnt signaling
was up-regulated
even in the complete absence of Paneth cells. To test this idea, we examined
the levels of Wnt
99
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
target genes, Wnt isoforms, and Rspondin1-4 in the intestines of Villin
Cre;Mathl" treated
mice. Although Wnt3 was not up-regulated in mice lacking Paneth cells (Figure
9K),
consistent with the notion that Wnt3 is produced by Paneth cells, we observed
a consistent up-
regulation of several Wnt target genes (Figure 5Z), as well as mesenchyme
derived Wnt5a and
epithelium derived Wnt9b (Figure 5Z-1). Of note, Wnt9b was previously shown to
compensate
for loss of Wnt3 in an organoid growth assay (FarM et al., 2012) and Wnt5a has
also been
shown to enhance proliferation in the small intestine (Cervantes et al.,
2009). In addition, the
Wnt signaling agonist Rspondin-4 (Rspo4) was significantly increased in both
WT and Villin
Cre;Mathl" treated mice (Figure 9M and Figure 5Z-1).
From these results, we conclude that, although the Paneth cells are likely an
important
source of Wnt proteins when Notch signaling is blocked in control mice, the
small intestine can
still mount a Wnt response in the absence of Paneth cells. Moreover, the
activation of the Wnt
pathway due to loss of Notch signaling in control mice most likely results at
least in part from
an initial amplification of Wnt signaling through up-regulation of the
canonical ligand Wnt9b
and Wnt signaling agonist Rspo4. Subsequent Wnt3 production stemming from
ongoing Paneth
cell hyperplasia may then lock in place the secretory cell fate decision.
Example 6: Co-treatment with Notch and Wnt blocking antibodies rescues
secretory
cell metaplasia.
To functionally determine whether elevated Wnt signaling was responsible for
the
Notch phenotype, co-treatment with Notch and Lrp6 blocking antibodies was
tested. Further
microarray analysis was performed, and demonstrated that genes up regulated
under Notch
blockade could be partially or completely repressed by co-treatment with Lrp6
blocking
antibodies; interestingly, such genes included Wnt3 and the pro-secretory fate
genes Math],
D111, D114, Pax4 and Ngn3 (Figure 5A). Without intending to be bound by any
particular
theory, this suggested that up-regulated Wnt signaling caused the mis-
regulation of pro-
secretory genes during Notch blockade.
To functionally test whether Wnt attenuation could prevent the secretory cell
metaplasia
induced by Notch inhibition, secretory cell differentiation and stem cell
activity while
simultaneously blocking Notch signaling and attenuating Wnt signaling was
analyzed.
Treatment with Lrp6 blocking antibody alone caused a decrease in the average
number of
goblet cells per villus compared to controls (6.5 compared to 10.5 goblet
cells/villus; n=3, >49
villi per sample analyzed). It was observed that the increased goblet cell
content and reduced
crypt proliferation seen in Notch antibody treated animals was restored to a
normal distribution
in mice co-treated with Lrp6 blocking antibody (Figure 7A-D). Thus, co-
blockade of Wnt and
100
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
Notch signaling prevents secretory metaplasia and restores intestine
homeostasis. As a
definitive test of CBC stem cell activity, Lgr5c.
reER;RosaRFP mice were treated with both Notch
and Lrp6 blocking antibodies after induction of recombination with Tam. Notch
and Lrp6
antibody co-treatment dramatically rescued CBC proliferation (Figure 6T) and
stem cell
activity (Figure 7F). CBCs, in this context, no longer express the stem cell
markers Lgr5 (inset,
Figure 7F) and Olfm4 (Figure 4F), indicating that these markers are
dispensable for stem cell
activity. Together, these data implicate up-regulated Wnt signaling as the
mechanism that
underlies secretory metaplasia when levels of Notch signaling are reduced.
To complement the above experiments using the anti-LRP6 antibody, we also
tested
whether a decoy Wnt receptor, Frizzled 8 CRD (F8CRD) (DeAlmeida et al., 2007),
could
similarly rescue the effect of Notch antibody blockade. As with single agent
anti-LRP6
treatment, F8CRD treatment led to down-regulation of Wnt signaling, as
assessed by Axin2Lacz,
and secretory differentiation, as assessed by Math1GFP (Figure 8). Combined
treatment with
Notch antibodies and F8CRD led to complete rescue of the secretory metaplasia
phenotype
(Figure 7G,H), reinforcing the notion that Notch blockade leads to secretory
conversion in
large part through driving an increase in Wnt signaling via upregulation of
Wnt ligand
expression.
Example 7: Discussion.
Notch signaling antagonizes Wnt signaling to maintain stem cell activity
Previous studies have found that Notch activity plays an essential role in
maintaining
CBCs and TA cell proliferation while preventing secretory differentiation (van
Es, van Gijn et
al. 2005; VanDussen, Carulli et al. 2012). The data indicate that Notch
signaling is active in
CBCs and TA cells and is absent from all secretory progenitors and their
differentiated
progeny. Using function blocking antibodies against Notch receptors, up-
regulation of Wnt
signaling shortly after Notch blockade was observed, indicating that Notch
signaling
antagonizes Wnt signaling in the intestinal epithelium. This finding has
surprising implications
for how Wnt signaling normally regulates the maintenance and activity of CBC
stem cells.
First, when Wnt signaling is elevated due to Notch blockade, CBC activity and
proliferation in
the crypt are severely compromised. These phenotypes are likely meditated
through increased
Wnt ligand expression, particularly Wnt3, and not other downstream components
of the Wnt
signaling pathway, as CBC activity and TA cell proliferation could be rescued
by attenuating
Wnt signaling at the ligand and receptor level with either anti-LRP6 or F8CRD.
Second,
attenuation of normal Wnt signaling levels with anti-LRP6 or F8CRD had no
effect on stem
cell activity, such that diminished levels of Wnt signaling were sufficient
for normal stem cell
101
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
function. Together, these results indicate that Notch activity is required for
maintaining the
proper level of Wnt signaling in the crypt that allows for the simultaneous
maintenance and
activity of ISCs as well as crypt proliferation.
The finding that anti-LRP6 or F8CRD treatment alone failed to reduce CBC
activity
and TA proliferation is surprising given the ability of these reagents to
suppress Wnt target
genes. Potential explanations for why these reagents do not completely
eliminate Wnt signaling
include technical reasons, such as an inability of F8CRD to completely titrate
all WNT3 ligand,
or partial blockade of Wnt signaling by the anti-LRP6 antibody; alternatively,
signaling events
initiated by compensating Wnt pathway components may play a role. These ideas
are supported
by in vitro studies showing that LRP6 ECD selectively binds a subset of WNTs
with high
affinity (Bourhis et al., 2010). For instance, LRP6 blocking antibodies have
been shown to
specifically inhibit WNT3 and WNT3a while potentiating other WNT isoforms in
signaling
assays (Gong et al., 2010). F8CRD is capable of binding four different WNT
isoforms, albeit
with highly differing affinities (Bourhis et al., 2010). Aside from Wnt3,
additional Wnts and
the Lrp5 co-receptor are also expressed in the crypt epithelium (Gregorieff et
al., 2005), and
these may provide alternative signaling mechanisms that are not fully blocked
by F8CRD or
anti-LRP6.
Our experiments with the anti-LRP6 antibody point to a differential
requirement for
Wnt signaling in ISC self-renewal and secretory differentiation. This may
reflect functional
differences between the LRP6 and LRP5 receptors, although a recent report
indicates that these
molecules are functionally overlapping (Zhong et al., 2012). Wnt signaling
attenuation in our
studies caused down-regulation of secretory differentiation, while leaving CBC
stem cell
activity intact. This points to a model in which lower levels of Wnt signaling
are needed for
stem cell maintenance and higher levels for secretory cell differentiation,
which is similar to
the gradient of Wnt activity seen in hair follicle stem cell maintenance and
differentiation
(Blanpain and Fuchs, 2006). However, ISCs are embedded in a WNT-rich
environment
(Gregorieff et al., 2005), with the expectation that CBCs transduce the
highest levels of Wnt
signaling. Our analysis of Wnt activity, as assessed by the Axin21"z reporter,
shows that cells
near the border of the stem cell compartment express Axin2z as strongly or
even higher than
CBCs (Figure I AC). Based on these observations, and together with our
findings that the
highest intensity of nuclear NICD occurs in CBCs and that high expression of
the Notch target
gene Olfm4 also occurs in CBCs, we propose that the lower level of Wnt
signaling needed for
ISC activity is achieved through the antagonistic activity of Notch signaling.
In line with this
hypothesis, Notch blockade caused an increase in Axin21"z expression
throughout the crypt,
102
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
with a particular increase in intensity detected at the crypt base (Figure
5F,J), along with
aberrant secretory cell differentiation and a complete loss of ISC activity.
The exact mechanism
underlying the collaboration between Notch and Wnt signaling in maintenance of
ISCs is still
unknown, but our rescue experiments suggest that Notch signaling is
dispensable for ISC
activity as long as the Wnt signaling output approximates normal levels
(Figure 7F). This
notion is supported by published work showing that intestinal homeostasis, and
presumably
ISC activity, remains intact in Mathl mutants when Notch activity is removed.
Conversely,
NICD-induced progenitor proliferation is dependent on intact Wnt signaling
(Munoz-Descalzo
et al., 2011).
Notch and Wnt signaling interplay controls cell differentiation
Mathl/Atohl, which is negatively regulated by Notch signaling, is the key
mediator of
secretory metaplasia after Notch loss of function (Kazanjian, Noah et al.
2010). Math] deletion
has been shown to completely prevent secretory cell metaplasia in animals
treated with Notch
inhibitors (Kazanjian, Noah et al. 2010). In addition to rescuing secretory
cell metaplasia,
Math] deletion also restored proliferation after Notch blockade, suggesting
that Math] -
mediated cell cycle exit is a factor in maintaining crypt homeostasis. It was
found that
attenuation of the Wnt pathway by treatment with anti-LRP6 restored the normal
distribution of
Math/-expressing cells, and this treatment rescued the Notch phenotype,
including restoration
of proliferation. Importantly, the notion that increased Wnt signaling
mediates the Notch
phenotype through up-regulation of Math] is substantiated by the observation
that Lrp6
blockade represses Math] expression on its own and that Wnt/[3-catenin
signaling directly
regulates Math] expression in other contexts (Shi, Cheng et al. 2010). We also
found that the
up-regulation of Axin2/acz and other Wnt target genes preceded the activation
of Math] and
secretory cell metaplasia. During Notch blockade, the small intestine
increases the production
of Wnts as well as the agonist Rspo4 in the absence of Math] and the secretory
cell lineage.
This strongly suggests that the trigger for secretory cell metaplasia in Notch
deficient mice is
an immediate hyper-activation of the Wnt pathway. Our data, together with
previous studies,
indicate that Notch activity is required for maintaining the correct balance
of Wnt signaling in
the crypt, which allows for simultaneous maintenance of IS Cs, proliferation,
and
differentiation. Interestingly, unlike in perinatal mice (Fre, Huyghe et al.
2005), over-
expression of NICD in the adult intestine epithelium does not provide a
proliferative
advantage, lending support to the hypothesis that a primary role of Notch in
adult intestine
epithelium is to antagonize Wnt signaling, thereby preventing secretory
differentiation through
subsequent repression of Math].
103
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
Notch and Wnt signaling may also converge on D114 expression to fine-tune the
Notch
signaling output. Here, it was found that Math] expression correlates with
D114 expression
(Figure 81), and DLL4 protein rapidly accumulates on Math/ -expressing
secretory cells during
Notch blockade, (Figure 80). Although it remains unclear if D114 is a bona
fide Wnt target,
overlapping domains of D114 expression and Axin21"z were detected (Figure 8J).
Elevated
levels of D114 could down-regulate Notch activity in the cells sending the
signal through cis-
inhibition, such that Wnt signaling could indirectly attenuate Notch signaling
by promoting
Math] /D114 expression in the secretory lineage. Wnt signaling has multiple
roles during
differentiation of secretory cells, especially in the case of Paneth cells
(Bastide, Darido et al.
2007; Fevr, Robine et al. 2007). In line with this idea, the up-regulation of
several key
secretory genes due to Notch blockade was partially rescued by the LRP6
blocking antibody,
including Math], Hes] , Pax4, D111, D114 and Ngn3.
Regulation of Wnt signaling outputs by Notch signaling
The experiments described herein with the anti-LRP6 antibody point to a
differential
requirement for Wnt signaling in ISC self-renewal and secretory
differentiation. This may
reflect a functional difference between the LRP6 and LRP5 receptor although a
recent report
finds the activity of these molecules to be compensatory (Zhong, Baker et al.
2012). Wnt
signaling attenuation in these studies caused down-regulation of secretory
differentiation, while
leaving CBC stem cell activity intact. This suggests that lower levels of Wnt
signaling are
needed for stem cell maintenance and higher levels for secretory cell
differentiation. This
scenario is similar to the gradient of Wnt activity seen in hair follicle stem
cell maintenance
and differentiation (Blanpain and Fuchs 2006). However, ISCs are embedded in a
Wnt-rich
environment (Gregorieff, Pinto et al. 2005), such that Wnt activity, as
assessed by the Axin2/acz
reporter, is strongest at the crypt base and becomes weaker toward the villus
(Figure 1A-C).
Thus, based on these observations and the finding that the highest intensity
of nuclear NICD
occurs in CBCs and that high expression of the Notch target gene Olfm4 also
occurs in CBCs,
it was proposed that the lower level of Wnt signaling needed for IS C activity
is achieved
through the antagonistic activity of Notch signaling. In line with this
hypothesis, Notch
blockade caused an increase in Axin2Lacz expression throughout the crypt, with
a particular
increase in intensity at the crypt base (Figure 5F,J), along with aberrant
secretory cell
differentiation and a complete loss of ISC activity. The exact mechanism
underlying the
collaboration between Notch and Wnt signaling in maintenance of ISCs is still
unknown, but
the rescue experiments suggest that Notch signaling is dispensable for ISC
activity as long as
the Wnt signaling output approximates normal levels (Figure 7F). This notion
is supported by
104
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
published work showing that intestinal homeostasis, and presumably ISC
activity, remain intact
in Math] mutants when Notch activity is removed. Conversely, NICD-induced
progenitor
proliferation is dependent on intact Wnt signaling (Munoz-Descalzo, Tkocz et
al. 2011).
Notch/Wnt interaction in other contexts
The interaction between Wnt and Notch signaling described here may be a common
theme in stem cell biology. For example, deletion of the Notch] receptor in
mouse skin causes
inappropriate activation of Wnt/[3-catenin signaling in the epidermis and
impaired
differentiation in primary keratinocytes, as well as excess P-catenin
accumulation in the eye
epithelium leading to Wnt dependent hyper-proliferation (Nicolas, Wolfer et
al. 2003). In
cardiac progenitors, loss of Notch mimics a gain of function P-catenin
phenotype, and in mouse
embryonic stem cells, an antagonistic effect of Notch on Wnt signaling was
attributed to non-
canonical Notch receptor mediated degradation of 3-catenin (Kwon, Qian et al.
2009; Kwon,
Cheng et al. 2011). This work indicates that Notch signaling normally serves
as a natural brake
on the Wnt pathway, and that attenuation of Notch signaling releases the brake
and allows for
high levels of Wnt signaling. Thus, in certain contexts, it may be beneficial
to attenuate Notch
signaling in order to assist Wnt-mediated injury repair and stem cell-fueled
regeneration.
Finally, the interaction between Wnt and Notch signaling in ISCs has important
implications for the use of Notch pathway inhibitors. Intestinal goblet cell
metaplasia is a major
challenge in the development of therapies that block Notch signaling, such as
the y-secretase
inhibitors that hold promise for the treatment of Alzheimer disease or of
cancers that are
caused by mutations in the NOTCH pathway. The intestinal metaplasia disrupts
nutrient
absorption, and animals succumb due to severe weight loss under long term
Notch blockade.
By modulation of Wnt signaling, the intestinal metaplasia toxicity and the
lethality associated
with Notch blockade was overcome. These results suggest that layering Wnt
signaling
attenuation on top of y-secretase inhibition or other pathways that block
Notch signaling can
potentially overcome the intestinal toxicity associated with such treatments,
thus allowing for
long term dosing with such therapies.
In addition to the above experiments using the anti-LRP6 antibody, a decoy Wnt
receptor, Frizzled 8 CRD (FZD8CRD) (DeAlmeida, Miao et al. 2007) was also
tested to
determine whether it could similarly rescue the effect of Notch antibody
blockade. As with
anti-Lrp6 treatment alone, FZD8CRD treatment alone led to down-regulation of
Wnt signaling,
as assessed by Axin2Lacz, and secretory differentiation, as assessed by
Math1GFP (Figure 8).
Combined treatment with Notch antibodies and FZD8CRD led to complete rescue of
the
secretory metaplasia phenotype (Figure 7G-I), and importantly, this treatment
combination also
105
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
rescued the weight loss and lethality induced by Notch blocking antibodies
(Figure 71).
Because Notch signaling plays diverse roles in organ homeostasis and Notch/Wnt
interactions
may be prevalent in other systems, it cannot be concluded that rescue of
weight loss and
lethality is the result of secretory cell metaplasia suppression alone. Anti-
Lrp6 treatments in
combination with Notch antibodies gave similar results in terms of secretory
cell metaplasia
suppression, however these mice continued to lose weight at a similar rate
compared to
treatment with anti-Notch alone. Without intending to be bound by any
particular theory, it is
possible that the FZD8CRD acts less broadly than the LRP6 blockade, and
therefore this
reagent is able to rescue the effects in the intestine without causing other
problems for the
animal.
Although the foregoing invention has been described in some detail by way of
illustration and example for purposes of clarity of understanding, the
descriptions and
examples should not be construed as limiting the scope of the invention. The
disclosures of all
patent and scientific literature cited herein are expressly incorporated in
their entirety by
reference.
106
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
List of References
Andreu, P., S. Colnot, et al. (2005). "Crypt-restricted proliferation and
commitment to the Paneth cell
lineage following Apc loss in the mouse intestine." Development 132(6): 1443-
1451.
Andreu, P., G. Peignon, et al. (2008). "A genetic study of the role of the
Wnt/beta-catenin signalling in
Paneth cell differentiation." Dev Biol 324(2): 288-296.
Barker, N., J. H. van Es, et al. (2007). "Identification of stem cells in
small intestine and colon by
marker gene Lgr5." Nature 449(7165): 1003-1007.
Bastide, P., C. Darido, et al. (2007). "Sox9 regulates cell proliferation and
is required for Paneth cell
differentiation in the intestinal epithelium." J Cell Biol 178(4): 635-648.
Blanpain, C. and E. Fuchs (2006). "Epidermal stem cells of the skin." Annu Rev
Cell Dev Biol 22:
339-373.
Bourhis, E., Tam, C., Franke, Y., Bazan, J.F., Ernst, J., Hwang, J., Costa,
M., Cochran, A.G., and
Hannoush, R.N. (2010). Reconstitution of a frizzled8.Wnt3a.LRP6 signaling
complex reveals
multiple Wnt and Dkkl binding sites on LRP6. The Journal of biological
chemistry 285, 9172-
9179.
Cervantes, S., Yamaguchi, T.P., and Hebrok, M. (2009). Wnt5a is essential for
intestinal elongation in
mice. Developmental biology 326, 285-294.
de Lau, W., N. Barker, et al. (2011). "Lgr5 homologues associate with Wnt
receptors and mediate R-
spondin signalling." Nature 476(7360): 293-297.
DeAlmeida, V. I., L. Miao, et al. (2007). "The soluble wnt receptor
Frizzled8CRD-hFc inhibits the
growth of teratocarcinomas in vivo." Cancer Res 67(11): 5371-5379.
FarM, H.F., Van Es, J.H., and Clevers, H. (2012). Redundant sources of Wnt
regulate intestinal stem
cells and promote formation of Paneth cells. Gastroenterology 143, 1518-1529
e1517.
Fevr, T., S. Robine, et al. (2007). "Wnt/beta-catenin is essential for
intestinal homeostasis and
maintenance of intestinal stem cells." Mol Cell Biol 27(21): 7551-7559.
Fre, S., M. Huyghe, et al. (2005). "Notch signals control the fate of immature
progenitor cells in the
intestine." Nature 435(7044): 964-968.
Gong, Y., E. Bourhis, et al. (2010). "Wnt isoform-specific interactions with
coreceptor specify
inhibition or potentiation of signaling by LRP6 antibodies." PLoS One 5(9):
e12682.
Gregorieff, A., D. Pinto, et al. (2005). "Expression pattern of Wnt signaling
components in the adult
intestine." Gastroenterology 129(2): 626-638.
Kazanjian, A., T. Noah, et al. (2010). "Atonal homolog 1 is required for
growth and differentiation
effects of notch/gamma-secretase inhibitors on normal and cancerous intestinal
epithelial
cells." Gastroenterology 139(3): 918-928, 928 e911-916.
107
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
Kim, K.A., Zhao, J., Andarmani, S., Kakitani, M., Oshima, T., Binnerts, M.E.,
Abo, A., Tomizuka, K.,
and Funk, W.D. (2006). R-Spondin proteins: a novel link to beta-catenin
activation. Cell Cycle
5, 23-26.
Kim, T. H. and R. A. Shivdasani (2011). "Genetic evidence that intestinal
Notch functions vary
regionally and operate through a common mechanism of Mathl repression." J Biol
Chem
286(13): 11427-11433.
Korinek, V., N. Barker, et al. (1998). "Depletion of epithelial stem-cell
compartments in the small
intestine of mice lacking Tcf-4." Nat Genet 19(4): 379-383.
Kwon, C., P. Cheng, et al. (2011). "Notch post-translationally regulates beta-
catenin protein in stem
and progenitor cells." Nat Cell Biol 13(10): 1244-1251.
Kwon, C., L. Qian, et al. (2009). "A regulatory pathway involving Notchl/beta-
catenin/Isll determines
cardiac progenitor cell fate." Nat Cell Biol 11(8): 951-957.
Munoz-Descalzo, S., K. Tkocz, et al. (2011). "Modulation of the ligand-
independent traffic of Notch
by Axin and Apc contributes to the activation of Armadillo in Drosophila."
Development
138(8): 1501-1506.
Nicolas, M., A. Wolfer, et al. (2003). "Notchl functions as a tumor suppressor
in mouse skin." Nat
Genet 33(3): 416-421.
Pinto, D., A. Gregorieff, et al. (2003). "Canonical Wnt signals are essential
for homeostasis of the
intestinal epithelium." Genes Dev 17(14): 1709-1713.
Ridgway, J.B., Presta, L.G., and Carter, P. (1996). 'Knobs-into-holes'
engineering of antibody CH3
domains for heavy chain heterodimerization. Protein engineering 9, 617-621.
Sato, T., J. H. van Es, et al. (2011). "Paneth cells constitute the niche for
Lgr5 stem cells in intestinal
crypts." Nature 469(7330): 415-418.
Shi, F., Y. F. Cheng, et al. (2010). "Beta-catenin up-regulates Atohl
expression in neural progenitor
cells by interaction with an Atohl 3' enhancer." J Biol Chem 285(1): 392-400.
Simmons, L.C., Reilly, D., Klimowski, L., Raju, T.S., Meng, G., Sims, P.,
Hong, K., Shields, R.L.,
Damico, L.A., Rancatore, P., et al. (2002). Expression of full-length
immunoglobulins in
Escherichia coli: rapid and efficient production of aglycosylated antibodies.
Journal of
immunological methods 263, 133-147.
Spiess, C., Bevers, J., 3rd, Jackman, J., Chiang, N., Nakamura, G., Dillon,
M., Liu, H., Molina, P.,
Elliott, J.M., Shatz, W., et al. (2013). Development of a human IgG4
bispecific antibody for
dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines.
The Journal of
biological chemistry 288, 26583-26593.
Stanger, B. Z., R. Datar, et al. (2005). "Direct regulation of intestinal fate
by Notch." Proc Natl Acad
Sci U S A 102(35): 12443-12448.
van Es, J. H., A. Haegebarth, et al. (2012). "A critical role for the Wnt
effector Tcf4 in adult intestinal
homeostatic self-renewal." Mol Cell Biol 32(10): 1918-1927.
108
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
van Es, J. H., P. Jay, et al. (2005). "Wnt signalling induces maturation of
Paneth cells in intestinal
crypts." Nat Cell Biol 7(4): 381-386.
van Es, J. H., M. E. van Gijn, et al. (2005). "Notch/gamma-secretase
inhibition turns proliferative cells
in intestinal crypts and adenomas into goblet cells." Nature 435(7044): 959-
963.
VanDussen, K. L., A. J. Carulli, et al. (2012). "Notch signaling modulates
proliferation and
differentiation of intestinal crypt base columnar stem cells." Development
139(3): 488-497.
Wu, Y., C. Cain-Hom, et al. (2010). "Therapeutic antibody targeting of
individual Notch receptors."
Nature 464(7291): 1052-1057.
Yan, K. S., L. A. Chia, et al. (2012). "The intestinal stem cell markers Bmil
and Lgr5 identify two
functionally distinct populations." Proc Nat! Acad Sci U S A 109(2): 466-471.
Yang, Q., N. A. Bermingham, et al. (2001). "Requirement of Mathl for secretory
cell lineage
commitment in the mouse intestine." Science 294(5549): 2155-2158.
Zhong, Z., J. J. Baker, et al. (2012). "Lrp5 and Lrp6 play compensatory roles
in mouse intestinal
development." J Cell Biochem 113(1): 31-38.
Zhou, W. J., Z. H. Geng, et al. (2013). "Induction of intestinal stem cells by
R-spondin 1 and Slit2
augments chemoradioprotection." Nature 501(7465): 107-111.
109
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
Table of Sequences
SEQ Description Sequence
ID
NO
1 Human Jagl MRSPRTRGRS GRPLSLLLAL LCALRAKVCG ASGQFELEIL SMQNVNGELQ
NGNCCGGARN PGDRKCTRDE CDTYFKVCLK EYQSRVTAGG PCSFGSGSTP
precursor
VIGGNTFNLK ASRGNDRNRI VLPFSFAWPR SYTLLVEAWD SSNDTVQPDS
aa 1-33: signal IIEKASHSGM INPSRQWQTL KQNTGVAHFE YQIRVTCDDY YYGFGCNKFC
aa 34-1218: RPRDDFFGHY ACDQNGNKTC MEGWMGPECN RAICRQGCSP KHGSCKLPGD
mature CRCQYGWQGL YCDKCIPHPG CVHGICNEPW QCLCETNWGG QLCDKDLNYC
aa 34-1067: GTHQPCLNGG TCSNTGPDKY QCSCPEGYSG PNCEIAEHAC LSDPCHNRGS
CKETSLGFEC ECSPGWTGPT CSTNIDDCSP NNCSHGGTCQ DLVNGFKCVC
extracellular
PPQWTGKTCQ LDANECEAKP CVNAKSCKNL IASYYCDCLP GWMGQNCDIN
domain INDCLGQCQN DASCRDLVNG YRCICPPGYA GDHCERDIDE CASNPCLNGG
HCQNEINRFQ CLCPTGFSGN LCQLDIDYCE PNPCQNGAQC YNRASDYFCK
CPEDYEGKNC SHLKDHCRTT PCEVIDSCTV AMASNDTPEG VRYISSNVCG
PHGKCKSQSG GKFTCDCNKG FTGTYCHENI NDCESNPCRN GGTCIDGVNS
YKCICSDGWE GAYCETNIND CSQNPCHNGG TCRDLVNDFY CDCKNGWKGK
TCHSRDSQCD EATCNNGGTC YDEGDAFKCM CPGGWEGTTC NIARNSSCLP
NPCHNGGTCV VNGESFTCVC KEGWEGPICA QNTNDCSPHP CYNSGTCVDG
DNWYRCECAP GFAGPDCRIN INECQSSPCA FGATCVDEIN GYRCVCPPGH
SGAKCQEVSG RPCITMGSVI PDGAKWDDDC NTCQCLNGRI ACSKVWCGPR
PCLLHKGHSE CPSGQSCIPI LDDQCFVHPC TGVGECRSSS LQPVKTKCTS
DSYYQDNCAN ITFTFNKEMM SPGLTTEHIC SELRNLNILK NVSAEYSIYI
ACEPSPSANN EIHVAISAED IRDDGNPIKE ITDKIIDLVS KRDGNSSLIA
AVAEVRVQRR PLKNRTDFLV PLLSSVLTVA WICCLVTAFY WCLRKRRKPG
SHTHSASEDN TTNNVREQLN QIKNPIEKHG ANTVPIKDYE NKNSKMSKIR
THNSEVEEDD MDKHQQKARF AKQPAYTLVD REEKPPNGTP TKHPNWTNKQ
DNRDLESAQS LNRMEYIV
2 Murine Jagl MRSPRTRGRP GRPLSLLLAL LCALRAKVCG ASGQFELEIL SMQNVNGELQ
NGNCCGGVRN PGDRKCTRDE CDTYFKVCLK EYQSRVTAGG PCSFGSGSTP
VIGGNTFNLK ASRGNDRNRI VLPFSFAWPR SYTLLVEAWD SSNDTIQPDS
IIEKASHSGM INPSRQWQTL KQNTGIAHFE YQIRVTCDDH YYGFGCNKFC
RPRDDFFGHY ACDQNGNKTC MEGWMGPDCN KAICRQGCSP KHGSCKLPGD
CRCQYGWQGL YCDKCIPHPG CVHGTCNEPW QCLCETNWGG QLCDKDLNYC
GTHQPCLNRG TCSNTGPDKY QCSCPEGYSG PNCEIAEHAC LSDPCHNRGS
CKETSSGFEC ECSPGWTGPT CSTNIDDCSP NNCSHGGTCQ DLVNGFKCVC
PPQWTGKTCQ LDANECEAKP CVNARSCKNL IASYYCDCLP GWMGQNCDIN
INDCLGQCQN DASCRDLVNG YRCICPPGYA GDHCERDIDE CASNPCLNGG
HCQNEINRFQ CLCPTGFSGN LCQLDIDYCE PNPCQNGAQC YNRASDYFCK
CPEDYEGKNC SHLKDHCRTT TCEVIDSCTV AMASNDTPEG VRYISSNVCG
PHGKCKSQSG GKFTCDCNKG FTGTYCHENI NDCESNPCKN GGTCIDGVNS
YKCICSDGWE GAHCENNIND CSQNPCHYGG TCRDLVNDFY CDCKNGWKGK
TCHSRDSQCD EATCNNGGTC YDEVDTFKCM CPGGWEGTTC NIARNSSCLP
NPCHNGGTCV VNGDSFTCVC KEGWEGPICT QNTNDCSPHP CYNSGTCVDG
DNWYRCECAP GFAGPDCRIN INECQSSPCA FGATCVDEIN GYQCICPPGH
SGAKCHEVSG RSCITMGRVI LDGAKWDDDC NTCQCLNGRV ACSKVWCGPR
PCRLHKSHNE CPSGQSCIPV LDDQCFVRPC TGVGECRSSS LQPVKTKCTS
DSYYQDNCAN ITFTFNKEMM SPGLTTEHIC SELRNLNILK NVSAEYSIYI
ACEPSLSANN EIHVAISAED IRDDGNPVKE ITDKIIDLVS KRDGNSSLIA
AVAEVRVQRR PLKNRTDFLV PLLSSVLTVA WVCCLVTAFY WCVRKRRKPS
SHTHSAPEDN TTNNVREQLN QIKNPIEKHG ANTVPIKDYE NKNSKMSKIR
THNSEVEEDD MDKHQQKVRF AKQPVYTLVD REEKAPSGTP TKHPNWTNKQ
DNRDLESAQS LNRMEYIV
3 Human Jag2 MRAQGRGRLP RRLLLLLALW VQAARPMGYF ELQLSALRNV NGELLSGACC
DGDGRTTRAG GCGHDECDTY VRVCLKEYQA KVTPTGPCSY GHGATPVLGG
precursor
NSFYLPPAGA AGDRARARAR AGGDQDPGLV VIPFQFAWPR SFTLIVEAWD
aa 1-23: signal WDNDTTPNEE LLIERVSHAG MINPEDRWKS LHFSGHVAHL ELQIRVRCDE
aa 24-1238: NYYSATCNKF CRPRNDFFGH YTCDQYGNKA CMDGWMGKEC KEAVCKQGCN
mature LLHGGCTVPG ECRCSYGWQG RFCDECVPYP GCVHGSCVEP WQCNCETNWG
aa 24-1080: GLLCDKDLNY CGSHHPCTNG GTCINAEPDQ YRCTCPDGYS GRNCEKAEHA
CTSNPCANGG SCHEVPSGFE CHCPSGWSGP TCALDIDECA SNPCAAGGTC
extracellular
VDQVDGFECI CPEQWVGATC QLDANECEGK PCLNAFSCKN LIGGYYCDCI
domain PGWKGINCHI NVNDCRGQCQ HGGTCKDLVN GYQCVCPRGF GGRHCELERD
ECASSPCHSG GLCEDLADGF HCHCPQGFSG PLCEVDVDLC EPSPCRNGAR
CYNLEGDYYC ACPDDFGGKN CSVPREPCPG GACRVIDGCG SDAGPGMPGT
110
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
AASGVCGPHG RCVSQPGGNF SCICDSGFTG TYCHENIDDC LGQPCRNGGT
CIDEVDAFRC FCPSGWEGEL CDTNPNDCLP DPCHSRGRCY DLVNDFYCAC
DDGWKGKTCH SREFQCDAYT CSNGGTCYDS GDTFRCACPP GWKGSTCAVA
KNSSCLPNPC VNGGTCVGSG ASFSCICRDG WEGRTCTHNT NDCNPLPCYN
GGICVDGVNW FRCECAPGFA GPDCRINIDE CQSSPCAYGA TCVDEINGYR
CSCPPGRAGP RCQEVIGFGR SCWSRGTPFP HGSSWVEDCN SCRCLDGRRD
CSKVWCGWKP CLLAGQPEAL SAQCPLGQRC LEKAPGQCLR PPCEAWGECG
AEEPPSTPCL PRSGHLDNNC ARLTLHFNRD HVPQGTTVGA ICSGIRSLPA
TRAVARDRLL VLLCDRASSG ASAVEVAVSF SPARDLPDSS LIQGAAHAIV
AAITQRGNSS LLLAVTEVKV ETVVTGGSST GLLVPVLCGA FSVLWLACVV
LCVWWTRKRR KERERSRLPR EESANNQWAP LNPIRNPIER PGGHKDVLYQ
CKNFTPPPRR ADEALPGPAG HAAVREDEED EDLGRGEEDS LEAEKFLSHK
FTKDPGRSPG RPAHWASGPK VDNRAVRSIN EARYAGKE
4 Murine Jag2 MRARGWGRLP RRLLLLLVLC VQATRPMGYF ELQLSALRNV NGELLSGACC
DGDGRTTRAG GCGRDECDTY VRVCLKEYQA KVTPTGPCSY GYGATPVLGG
NSFYLPPAGA AGDRARARSR TGGHQDPGLV VIPFQFAWPR SFTLIVEAWD
WDNDTTPDEE LLIERVSHAG MINPEDRWKS LHFSGHVAHL ELQIRVRCDE
NYYSATCNKF CRPRNDFFGH YTCDQYGNKA CMDGWMGKEC KEAVCKQGCN
LLHGGCTVPG ECRCSYGWQG KFCDECVPYP GCVHGSCVEP WHCDCETNWG
GLLCDKDLNY CGSHHPCVNG GTCINAEPDQ YLCACPDGYL GKNCERAEHA
CASNPCANGG SCHEVPSGFE CHCPSGWSGP TCALDIDECA SNPCAAGGTC
VDQVDGFECI CPEQWVGATC QLDANECEGK PCLNAFSCKN LIGGYYCDCL
PGWKGINCQI NINDCHGQCQ HGGTCKDLVN GYQCVCPRGF GGRHCELEYD
KCASSPCRRG GICEDLVDGF RCHCPRGLSG LHCEVDMDLC EPSPCLNGAR
CYNLEGDYYC ACPEDFGGKN CSVPRDTCPG GACRVIDGCG FEAGSRARGV
APSGICGPHG HCVSLPGGNF SCICDSGFTG TYCHENIDDC MGQPCRNGGT
CIDEVDSFRC FCPSGWEGEL CDINPNDCLP DPCHSRGRCY DLVNDFYCAC
DDGWKGKTCH SREFQCDAYT CSNGGTCYDS GDTFRCACPP GWKGSTCTIA
KNSSCVPNPC VNGGTCVGSG DSFSCICRDG WEGRTCTHNT NDCNPLPCYN
GGICVDGVNW FRCECAPGFA GPDCRINIDE CQSSPCAYGA TCVDEINGYR
CSCPPGRSGP RCQEVVIFTR PCWSRGMSFP HGSSWMEDCN SCRCLDGHRD
CSKVWCGWKP CLLSGQPSDP SAQCPPGQQC QEKAVGQCLQ PPCENWGECT
AEEPLPPSTP CQPRSSHLDN NCARLTLRFN RDQVPQGTTV GAICSGIRAL
PATRAAAHDR LLLLLCDRAS SGASAVEVAM SFSPARDLPD SSLIQSTAHA
IVAAITQRGN SSLLLAVTEV KVETVVMGGS STGLLVPVLC SVFSVLWLAC
VVICVWWTRK RRKERERSRL PRDESTNNQW APLNPIRNPI ERPGGSGLGT
GGHKDILYQC KNFTPPPRRA GEALPGPAGH GAGGEDEEDE ELSRGDGDSP
EAEKFISHKF TKDPSCSLGR PACWAPGPKV DNRAVRSTKD VRRAGRE
Murine Jag 1 -DSL- ADLGSQFELE ILSMQNVNGE LQNGNCCGGV RNPGDRKCTR DECDTYFKVC
EGF 1 -4 (mouse LKEYQSRVTA GGPCSFGSGS TPVIGGNTFN LKASRGNDRN RIVLPFSFAW
PRSYTLLVEA WDSSNDTIQP DSIIEKASHS GMINPSRQWQ TLKQNTGIAH
Jagl antigen) FEYQIRVTCD DHYYGFGCNK FCRPRDDFFG HYACDQNGNK TCMEGWMGPD
CNKAICRQGC SPKHGSCKLP GDCRCQYGWQ GLYCDKCIPH PGCVHGTCNE
PWQCLCETNW GGQLCDKDLN YCGTHQPCLN RGTCSNTGPD KYQCSCPEGY
SGPNCEIAEH ACLSDPCHNR
GSCKETSSGF ECECSPGWTG PTCSTNIDDE FGLVPRGSGH HHHHH
6 human Jag 1 -DSL- QFELEILSMQ NVNGELQNGN CCGGARNPGD RKCTRDECDT YFKVCLKEYQ
EGF 1 -4 (human SRVTAGGPCS FGSGSTPVIG GNTFNLKASR GNDRNRIVLP FSFAWPRSYT
LLVEAWDSSN DTVQPDSIIE KASHSGMINP SRQWQTLKQN TGVAHFEYQI
Jagl antigen) RVTCDDYYYG FGCNKFCRPR DDFFGHYACD QNGNKTCMEG WMGPECNRAI
CRQGCSPKHG SCKLGDCRCQ YGWQGLYCDK CIPHPGCVHG ICNEPWQCLC
ETNWGGQLCD KDLNYCGTHQ PCLNGGTCSN TGPDKYQCSC PEGYSGPNCE
IAEHACLSDP CHNRGSCKET SLGFECECSP GWTGPTCSTN IDD
7 murine Jag2-DSL- ADLGSMGYFE LQLSALRNVN GELLSGACCD GDGRTTRAGG CGRDECDTYV
EGF1-4 (mouse RVCLKEYQAK VTPTGPCSYG YGATPVLGGN SFYLPPAGAA GDRARARSRT
GGHQDPGLVV IPFQFAWPRS FTLIVEAWDW DNDTTPDEEL LIERVSHAGM
Jag2 antigen) INPEDRWKSL HFSGHVAHLE LQIRVRCDEN YYSATCNKFC RPRNDFFGHY
TCDQYGNKAC MDGWMGKECK EAVCKQGCNL LHGGCTVPGE CRCSYGWQGK
FCDECVPYPG CVHGSCVEPW HCDCETNWGG LLCDKDLNYC GSHHPCVNGG
TCINAEPDQY LCACPDGYLG KNCERAEHAC ASNPCANGGS CHEVPSGFEC
HCPSGWNGPT CALDIDEEFG LVPRGSGHHH HHH
8 human Jag2-DSL- ARPMGYFELQ LSALRNVNGE LLSGACCDGD GRTTRAGGCG HDECDTYVRV
EGF 1 -4 (human CLKEYQAKVT PTGPCSYGHG ATPVLGGNSF YLPPAGAAGD RARARARAGG
DQDPGLVVIP FQFAWPRSFT LIVEAWDWDN DTTPNEELLI ERVSHAGMIN
Jag2 antigen) PEDRWKSLHF SGHVAHLELQ IRVRCDENYY SATCNKFCRP RNDFFGHYTC
DQYGNKACMD GWMGKECKEA VCKQGCNLLH GGCTVPGECR CSYGWQGRFC
DECVPYPGCV HGSCVEPWQC NCETNWGGLL CDKDLNYCGS HHPCTNGGTC
111
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
INAEPDQYRC TCPDGYSGRN CEKAEHACTS NPCANGGSCH EVPSGFECHC
PSGWSGPTCA LDIDEEFGLV PRGSGHHHHH H
9 Human Notchl MPPLLAPLLC LALLPALAAR GPRCSQPGET CLNGGKCEAA NGTEACVCGG
AFVGPRCQDP NPCLSTPCKN AGTCHVVDRR GVADYACSCA LGFSGPLCLT
precursor
PLDNACLTNP CRNGGTCDLL TLTEYKCRCP PGWSGKSCQQ ADPCASNPCA
(UniProtKB/Swi NGGQCLPFEA SYICHCPPSF HGPTCRQDVN ECGQKPGLCR HGGTCHNEVG
ss-Prot: SYRCVCRATH TGPNCERPYV PCSPSPCQNG GTCRPTGDVT HECACLPGFT
P46531.4) GQNCEENIDD CPGNNCKNGG ACVDGVNTYN CRCPPEWTGQ YCTEDVDECQ
LMPNACQNGG TCHNTHGGYN CVCVNGWTGE DCSENIDDCA SAACFHGATC
aa 1-18: signal HDRVASFYCE CPHGRTGLLC HLNDACISNP CNEGSNCDTN PVNGKAICTC
aa 19-2555: PSGYTGPACS QDVDECSLGA NPCEHAGKCI NTLGSFECQC LQGYTGPRCE
mature IDVNECVSNP CQNDATCLDQ IGEFQCICMP GYEGVHCEVN TDECASSPCL
aa 20-1426: EGF- HNGRCLDKIN EFQCECPTGF TGHLCQYDVD ECASTPCKNG AKCLDGPNTY
TCVCTEGYTG THCEVDIDEC DPDPCHYGSC KDGVATFTCL CRPGYTGHHC
like repeat domain ETNINECSSQ PCRHGGTCQD RDNAYLCFCL KGTTGPNCEI NLDDCASSPC
aa-13O7- 1732: DSGTCLDKID GYECACEPGY TGSMCNINID ECAGNPCHNG GTCEDGINGF
negative TCRCPEGYHD PTCLSEVNEC NSNPCVHGAC RDSLNGYKCD CDPGWSGTNC
regulatory region DINNNECESN PCVNGGTCKD MTSGYVCTCR EGFSGPNCQT NINECASNPC
(NRR) LNQGTCIDDV AGYKCNCLLP YTGATCEVVL APCAPSPCRN GGECRQSEDY
ESFSCVCPTG WQGQTCEVDI NECVLSPCRH GASCQNTHGG YRCHCQAGYS
GRNCETDIDD CRPNPCHNGG SCTDGINTAF CDCLPGFRGT FCEEDINECA
SDPCRNGANC TDCVDSYTCT CPAGFSGIHC ENNTPDCTES SCFNGGTCVD
GINSFTCLCP PGFTGSYCQH DVNECDSQPC LHGGTCQDGC GSYRCTCPQG
YTGPNCQNLV HWCDSSPCKN GGKCWQTHTQ YRCECPSGWT GLYCDVPSVS
CEVAAQRQGV DVARLCQHGG LCVDAGNTHH CRCQAGYTGS YCEDLVDECS
PSPCQNGATC TDYLGGYSCK CVAGYHGVNC SEEIDECLSH PCQNGGTCLD
LPNTYKCSCP RGTQGVHCEI NVDDCNPPVD PVSRSPKCFN NGTCVDQVGG
YSCTCPPGFV GERCEGDVNE CLSNPCDARG TQNCVQRVND FHCECRAGHT
GRRCESVING CKGKPCKNGG TCAVASNTAR GFICKCPAGF EGATCENDAR
TCGSLRCLNG GTCISGPRSP TCLCLGPFTG PECQFPASSP CLGGNPCYNQ
GTCEPTSESP FYRCLCPAKF NGLLCHILDY SFGGGAGRDI PPPLIEEACE
LPECQEDAGN KVCSLQCNNH ACGWDGGDCS LNFNDPWKNC TQSLQCWKYF
SDGHCDSQCN SAGCLFDGFD CQRAEGQCNP LYDQYCKDHF SDGHCDQGCN
SAECEWDGLD CAEHVPERLA AGTLVVVVLM PPEQLRNSSF HFLRELSRVL
HTNVVFKRDA HGQQMIFPYY GREEELRKHP IKRAAEGWAA PDALLGQVKA
SLLPGGSEGG RRRRELDPMD VRGSIVYLEI DNRQCVQASS QCFQSATDVA
AFLGALASLG SLNIPYKIEA VQSETVEPPP PAQLHFMYVA AAAFVLLFFV
GCGVLLSRKR RRQHGQLWFP EGFKVSEASK KKRREPLGED SVGLKPLKNA
SDGALMDDNQ NEWGDEDLET KKFRFEEPVV LPDLDDQTDH RQWTQQHLDA
ADLRMSAMAP TPPQGEVDAD CMDVNVRGPD GFTPLMIASC SGGGLETGNS
EEEEDAPAVI SDFIYQGASL HNQTDRTGET ALHLAARYSR SDAAKRLLEA
SADANIQDNM GRTPLHAAVS ADAQGVFQIL IRNRATDLDA RMHDGTTPLI
LAARLAVEGM LEDLINSHAD VNAVDDLGKS ALHWAAAVNN VDAAVVLLKN
GANKDMQNNR EETPLFLAAR EGSYETAKVL LDHFANRDIT DHMDRLPRDI
AQERMHHDIV RLLDEYNLVR SPQLHGAPLG GTPTLSPPLC SPNGYLGSLK
PGVQGKKVRK PSSKGLACGS KEAKDLKARR KKSQDGKGCL LDSSGMLSPV
DSLESPHGYL SDVASPPLLP SPFQQSPSVP LNHLPGMPDT HLGIGHLNVA
AKPEMAALGG GGRLAFETGP PRLSHLPVAS GTSTVLGSSS GGALNFTVGG
STSLNGQCEW LSRLQSGMVP NQYNPLRGSV APGPLSTQAP SLQHGMVGPL
HSSLAASALS QMMSYQGLPS TRLATQPHLV QTQQVQPQNL QMQQQNLQPA
NIQQQQSLQP PPPPPQPHLG VSSAASGHLG RSFLSGEPSQ ADVQPLGPSS
LAVHTILPQE SPALPTSLPS SLVPPVTAAQ FLTPPSQHSY SSPVDNTPSH
QLQVPEHPFL TPSPESPDQW SSSSPHSNVS DWSEGVSSPP TSMQSQIARI
PEAFK
Human Notch2 MPALRPALLW ALLALWLCCA APAHALQCRD GYEPCVNEGM CVTYHNGTGY
CKCPEGFLGE YCQHRDPCEK NRCQNGGTCV AQAMLGKATC RCASGFTGED
precursor
CQYSTSHPCF VSRPCLNGGT CHMLSRDTYE CTCQVGFTGK ECQWTDACLS
(UniProtKB/Swiss HPCANGSTCT TVANQFSCKC LTGFTGQKCE TDVNECDIPG HCQHGGTCLN
-Prot: Q04721.3); LPGSYQCQCP QGFTGQYCDS LYVPCAPSPC VNGGTCRQTG DFTFECNCLP
aa 1-25: signal GFEGSTCERN IDDCPNHRCQ NGGVCVDGVN TYNCRCPPQW TGQFCTEDVD
aa 26-2471: ECLLQPNACQ NGGTCANRNG GYGCVCVNGW SGDDCSENID DCAFASCTPG
STCIDRVASF SCMCPEGKAG LLCHLDDACI SNPCHKGALC DTNPLNGQYI
mature
CTCPQGYKGA DCTEDVDECA MANSNPCEHA GKCVNTDGAF HCECLKGYAG
aa 26-1412: EGF- PRCEMDINEC HSDPCQNDAT CLDKIGGFTC LCMPGFKGVH CELEINECQS
hkerepeatdonxnn NPCVNNGQCV DKVNRFQCLC PPGFTGPVCQ IDIDDCSSTP CLNGAKCIDH
aa ¨1422-1677: PNGYECQCAT GFTGVLCEEN IDNCDPDPCH HGQCQDGIDS YTCICNPGYM
GAICSDQIDE CYSSPCLNDG RCIDLVNGYQ CNCQPGTSGV NCEINFDDCA
negative
112
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
regulatory region SNPCIHGICM DGINRYSCVC SPGFTGQRCN IDIDECASNP CRKGATCING
(NRR) VNGFRCICPE GPHHPSCYSQ VNECLSNPCI HGNCTGGLSG YKCLCDAGWV
GINCEVDKNE CLSNPCQNGG TCDNLVNGYR CTCKKGFKGY NCQVNIDECA
SNPCLNQGTC FDDISGYTCH CVLPYTGKNC QTVLAPCSPN PCENAAVCKE
SPNFESYTCL CAPGWQGQRC TIDIDECISK PCMNHGLCHN TQGSYMCECP
PGFSGMDCEE DIDDCLANPC QNGGSCMDGV NTFSCLCLPG FTGDKCQTDM
NECLSEPCKN GGTCSDYVNS YTCKCQAGFD GVHCENNINE CTESSCFNGG
TCVDGINSFS CLCPVGFTGS FCLHEINECS SHPCLNEGTC VDGLGTYRCS
CPLGYTGKNC QTLVNLCSRS PCKNKGTCVQ KKAESQCLCP SGWAGAYCDV
PNVSCDIAAS RRGVLVEHLC QHSGVCINAG NTHYCQCPLG YTGSYCEEQL
DECASNPCQH GATCSDFIGG YRCECVPGYQ GVNCEYEVDE CQNQPCQNGG
TCIDLVNHFK CSCPPGTRGL LCEENIDDCA RGPHCLNGGQ CMDRIGGYSC
RCLPGFAGER CEGDINECLS NPCSSEGSLD CIQLTNDYLC VCRSAFTGRH
CETFVDVCPQ MPCLNGGTCA VASNMPDGFI CRCPPGFSGA RCQSSCGQVK
CRKGEQCVHT ASGPRCFCPS PRDCESGCAS SPCQHGGSCH PQRQPPYYSC
QCAPPFSGSR CELYTAPPST PPATCLSQYC ADKARDGVCD EACNSHACQW
DGGDCSLTME NPWANCSSPL PCWDYINNQC DELCNTVECL FDNFECQGNS
KTCKYDKYCA DHFKDNHCDQ GCNSEECGWD GLDCAADQPE NLAEGTLVIV
VLMPPEQLLQ DARSFLRALG TLLHTNLRIK RDSQGELMVY PYYGEKSAAM
KKQRMTRRSL PGEQEQEVAG SKVFLEIDNR QCVQDSDHCF KNTDAAAALL
ASHAIQGTLS YPLVSVVSES LTPERTQLLY LLAVAVVIIL FIILLGVIMA
KRKRKHGSLW LPEGFTLRRD ASNHKRREPV GQDAVGLKNL SVQVSEANLI
GTGTSEHWVD DEGPQPKKVK AEDEALLSEE DDPIDRRPWT QQHLEAADIR
RTPSLALTPP QAEQEVDVLD VNVRGPDGCT PLMLASLRGG SSDLSDEDED
AEDSSANIIT DLVYQGASLQ AQTDRTGEMA LHLAARYSRA DAAKRLLDAG
ADANAQDNMG RCPLHAAVAA DAQGVFQILI RNRVTDLDAR MNDGTTPLIL
AARLAVEGMV AELINCQADV NAVDDHGKSA LHWAAAVNNV EATLLLLKNG
ANRDMQDNKE ETPLFLAARE GSYEAAKILL DHFANRDITD HMDRLPRDVA
RDRMHHDIVR LLDEYNVTPS PPGTVLTSAL SPVICGPNRS FLSLKHTPMG
KKSRRPSAKS TMPTSLPNLA KEAKDAKGSR RKKSLSEKVQ LSESSVTLSP
VDSLESPHTY VSDTTSSPMI TSPGILQASP NPMLATAAPP APVHAQHALS
FSNLHEMQPL AHGASTVLPS VSQLLSHHHI VSPGSGSAGS LSRLHPVPVP
ADWMNRMEVN ETQYNEMFGM VLAPAEGTHP GIAPQSRPPE GKHITTPREP
LPPIVTFQLI PKGSIAQPAG APQPQSTCPP AVAGPLPTMY QIPEMARLPS
VAFPTAMMPQ QDGQVAQTIL PAYHPFPASV GKYPTPPSQH SYASSNAAER
TPSHSGHLQG EHPYLTPSPE SPDQWSSSSP HSASDWSDVT TSPTPGGAGG
GQRGPGTHMS EPPHNNMQVY A
11 Human Notch3 MGPGARGRRR RRRPMSPPPP PPPVRALPLL LLLAGPGAAA PPCLDGSPCA
NGGRCTQLPS REAACLCPPG WVGERCQLED PCHSGPCAGR GVCQSSVVAG
precursor
. TARFSCRCPR GFRGPDCSLP DPCLSSPCAH GARCSVGPDG RFLCSCPPGY
(UniProtKB/S wis s QGRSCRSDVD ECRVGEPCRH GGTCLNTPGS FRCQCPAGYT GPLCENPAVP
-Prot: Q9UM47.2) CAPSPCRNGG TCRQSGDLTY DCACLPGFEG QNCEVNVDDC PGHRCLNGGT
aa 1-39: signal CVDGVNTYNC QCPPEWTGQF CTEDVDECQL QPNACHNGGT CFNTLGGHSC
aa 40-2321: VCVNGWTGES CSQNIDDCAT AVCFHGATCH DRVASFYCAC PMGKTGLLCH
LDDACVSNPC HEDAICDTNP VNGRAICTCP PGFTGGACDQ DVDECSIGAN
mature
PCEHLGRCVN TQGSFLCQCG RGYTGPRCET DVNECLSGPC RNQATCLDRI
aa 40-1373: EGF- GQFTCICMAG FTGTYCEVDI DECQSSPCVN GGVCKDRVNG FSCTCPSGFS
hkerepeatdonxnn GSTCQLDVDE CASTPCRNGA KCVDQPDGYE CRCAEGFEGT LCDRNVDDCS
aa ¨1378- 1640: PDPCHHGRCV DGIASFSCAC APGYTGTRCE SQVDECRSQP CRHGGKCLDL
VDKYLCRCPS GTTGVNCEVN IDDCASNPCT FGVCRDGINR YDCVCQPGFT
negative
GPLCNVEINE CASSPCGEGG SCVDGENGFR CLCPPGSLPP LCLPPSHPCA
regulatory region HEPCSHGICY DAPGGFRCVC EPGWSGPRCS QSLARDACES QPCRAGGTCS
(NRR) SDGMGFHCTC PPGVQGRQCE LLSPCTPNPC EHGGRCESAP GQLPVCSCPQ
GWQGPRCQQD VDECAGPAPC GPHGICTNLA GSFSCTCHGG YTGPSCDQDI
NDCDPNPCLN GGSCQDGVGS FSCSCLPGFA GPRCARDVDE CLSNPCGPGT
CTDHVASFTC TCPPGYGGFH CEQDLPDCSP SSCFNGGTCV DGVNSFSCLC
RPGYTGAHCQ HEADPCLSRP CLHGGVCSAA HPGFRCTCLE SFTGPQCQTL
VDWCSRQPCQ NGGRCVQTGA YCLCPPGWSG RLCDIRSLPC REAAAQIGVR
LEQLCQAGGQ CVDEDSSHYC VCPEGRTGSH CEQEVDPCLA QPCQHGGTCR
GYMGGYMCEC LPGYNGDNCE DDVDECASQP CQHGGSCIDL VARYLCSCPP
GTLGVLCEIN EDDCGPGPPL DSGPRCLHNG TCVDLVGGFR CTCPPGYTGL
RCEADINECR SGACHAAHTR DCLQDPGGGF RCLCHAGFSG PRCQTVLSPC
ESQPCQHGGQ CRPSPGPGGG LTFTCHCAQP FWGPRCERVA RSCRELQCPV
GVPCQQTPRG PRCACPPGLS GPSCRSFPGS PPGASNASCA AAPCLHGGSC
RPAPLAPFFR CACAQGWTGP RCEAPAAAPE VSEEPRCPRA ACQAKRGDQR
CDRECNSPGC GWDGGDCSLS VGDPWRQCEA LQCWRLFNNS RCDPACSSPA
CLYDNFDCHA GGRERTCNPV YEKYCADHFA DGRCDQGCNT EECGWDGLDC
ASEVPALLAR GVLVLTVLLP PEELLRSSAD FLQRLSAILR TSLRFRLDAH
113
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
GQAMVFPYHR PSPGSEPRAR RELAPEVIGS VVMLEIDNRL CLQSPENDHC
FPDAQSAADY LGALSAVERL DFPYPLRDVR GEPLEPPEPS VPLLPLLVAG
AVLLLVILVL GVMVARRKRE HSTLWFPEGF SLHKDVASGH KGRREPVGQD
ALGMKNMAKG ESLMGEVATD WMDTECPEAK RLKVEEPGMG AEEAVDCRQW
TQHHLVAADI RVAPAMALTP PQGDADADGM DVNVRGPDGF TPLMLASFCG
GALEPMPTEE DEADDTSASI ISDLICQGAQ LGARTDRTGE TALHLAARYA
RADAAKRLLD AGADTNAQDH SGRTPLHTAV TADAQGVFQI LIRNRSTDLD
ARMADGSTAL ILAARLAVEG MVEELIASHA DVNAVDELGK SALHWAAAVN
NVEATLALLK NGANKDMQDS KEETPLFLAA REGSYEAAKL LLDHFANREI
TDHLDRLPRD VAQERLHQDI VRLLDQPSGP RSPPGPHGLG PLLCPPGAFL
PGLKAAQSGS KKSRRPPGKA GLGPQGPRGR GKKLTLACPG PLADSSVTLS
PVDSLDSPRP FGGPPASPGG FPLEGPYAAA TATAVSLAQL GGPGRAGLGR
QPPGGCVLSL GLLNPVAVPL DWARLPPPAP PGPSFLLPLA PGPQLLNPGT
PVSPQERPPP YLAVPGHGEE YPAAGAHSSP PKARFLRVPS EHPYLTPSPE
SPEHWASPSP PSLSDWSEST PSPATATGAM ATTTGALPAQ PLPLSVPSSL
AQAQTQLGPQ PEVTPKRQVL A
12 Human Notch4 MQPPSLLLLL LLLLLLCVSV VRPRGLLCGS FPEPCANGGT CLSLSLGQGT
CQCAPGFLGE TCQFPDPCQN AQLCQNGGSC QALLPAPLGL PSSPSPLTPS
precursor
FLCTCLPGFT GERCQAKLED PCPPSFCSKR GRCHIQASGR PQCSCMPGWT
(UniProtKB/Swiss GEQCQLRDFC SANPCVNGGV CLATYPQIQC HCPPGFEGHA CERDVNECFQ
-Prot: Q99466.2) DPGPCPKGTS CHNTLGSFQC LCPVGQEGPR CELRAGPCPP RGCSNGGTCQ
aa 1-23: signal LMPEKDSTFH LCLCPPGFIG PDCEVNPDNC VSHQCQNGGT CQDGLDTYTC
aa 24-2003: LCPETWTGWD CSEDVDECET QGPPHCRNGG TCQNSAGSFH CVCVSGWGGT
SCEENLDDCI AATCAPGSTC IDRVGSFSCL CPPGRTGLLC HLEDMCLSQP
mature
CHGDAQCSTN PLTGSTLCLC QPGYSGPTCH QDLDECLMAQ QGPSPCEHGG
aa 24-1171: EGF- SCLNTPGSFN CLCPPGYTGS RCEADHNECL SQPCHPGSTC LDLLATFHCL
likerepeatdomain CPPGLEGQLC EVETNECASA PCLNHADCHD LLNGFQCICL PGFSGTRCEE
DIDECRSSPC ANGGQCQDQP GAFHCKCLPG FEGPRCQTEV DECLSDPCPV
GASCLDLPGA FFCLCPSGFT GQLCEVPLCA PNLCQPKQIC KDQKDKANCL
CPDGSPGCAP PEDNCTCHHG HCQRSSCVCD VGWTGPECEA ELGGCISAPC
AHGGTCYPQP SGYNCTCPTG YTGPTCSEEM TACHSGPCLN GGSCNPSPGG
YYCTCPPSHT GPQCQTSTDY CVSAPCFNGG TCVNRPGTFS CLCAMGFQGP
RCEGKLRPSC ADSPCRNRAT CQDSPQGPRC LCPTGYTGGS CQTLMDLCAQ
KPCPRNSHCL QTGPSFHCLC LQGWTGPLCN LPLSSCQKAA LSQGIDVSSL
CHNGGLCVDS GPSYFCHCPP GFQGSLCQDH VNPCESRPCQ NGATCMAQPS
GYLCQCAPGY DGQNCSKELD ACQSQPCHNH GTCTPKPGGF HCACPPGFVG
LRCEGDVDEC LDQPCHPTGT AACHSLANAF YCQCLPGHTG QWCEVEIDPC
HSQPCFHGGT CEATAGSPLG FICHCPKGFE GPTCSHRAPS CGFHHCHHGG
LCLPSPKPGF PPRCACLSGY GGPDCLTPPA PKGCGPPSPC LYNGSCSETT
GLGGPGFRCS CPHSSPGPRC QKPGAKGCEG RSGDGACDAG CSGPGGNWDG
GDCSLGVPDP WKGCPSHSRC WLLFRDGQCH PQCDSEECLF DGYDCETPPA
CTPAYDQYCH DHFHNGHCEK GCNTAECGWD GGDCRPEDGD PEWGPSLALL
VVLSPPALDQ QLFALARVLS LTLRVGLWVR KDRDGRDMVY PYPGARAEEK
LGGTRDPTYQ ERAAPQTQPL GKETDSLSAG FVVVMGVDLS RCGPDHPASR
CPWDPGLLLR FLAAMAAVGA LEPLLPGPLL AVHPHAGTAP PANQLPWPVL
CSPVAGVILL ALGALLVLQL IRRRRREHGA LWLPPGFTRR PRTQSAPHRR
RPPLGEDSIG LKALKPKAEV DEDGVVMCSG PEEGEEVGQA EETGPPSTCQ
LWSLSGGCGA LPQAAMLTPP QESEMEAPDL DTRGPDGVTP LMSAVCCGEV
QSGTFQGAWL GCPEPWEPLL DGGACPQAHT VGTGETPLHL AARFSRPTAA
RRLLEAGANP NQPDRAGRTP LHAAVAADAR EVCQLLLRSR QTAVDARTED
GTTPLMLAAR LAVEDLVEEL IAAQADVGAR DKWGKTALHW AAAVNNARAA
RSLLQAGADK DAQDNREQTP LFLAAREGAV EVAQLLLGLG AARELRDQAG
LAPADVAHQR NHWDLLTLLE GAGPPEARHK ATPGREAGPF PRARTVSVSV
PPHGGGALPR CRTLSAGAGP RGGGACLQAR TWSVDLAARG GGAYSHCRSL
SGVGAGGGPT PRGRRFSAGM RGPRPNPAIM RGRYGVAAGR GGRVSTDDWP
CDWVALGACG SASNIPIPPP CLTPSPERGS PQLDCGPPAL QEMPINQGGE
GKK
13 Human-Notchl- mllvngshgg fnkehtskmv saivlyvlla aaahsafaad lgsdykdddd
NRR(uppercase )
kgsgVINGCK GKPCKNGGTC AVASNTARGF ICKCPAGFEG ATCENDARTC
GSLRCLNGGT CISGPRSPTC LCLGPFTGPE CQFPASSPCL GGNPCYNQGT
with Gp67 CEPTSESPFY RCLCPAKFNG LLCHILDYSF GGGAGRDIPP PLIEEACELP
secretion signal, ECQEDAGNKV CSLQCNNHAC GWDGGDCSLN FNDPWKNCTQ SLQCWKYFSD
N-terminal Flag GHCDSQCNSA GCLFDGFDCQ RAEGQCNPLY DQYCKDHFSD GHCDQGCNSA
tag, thrombin site, ECEWDGLDCA EHVPERLAAG TLVVVVLMPP EQLRNSSFHF LRELSRVLHT
NVVFKRDAHG QQMIFPYYGR EEELRKHPIK RAAEGWAAPD ALLGQVKASL
C-terminal Flag
LPGGSEGGRR RRELDPMDVR GSIVYLEIDN RQCVQASSQC FQSATDVAAF
tag (lower case) LGALASLGSL NIPYKIEAVQ SETVEPPPPA Qefglvprgs ghhhhhh
114
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
14 FLAG-Mouse MGGTAARLGA VILFVVIVGL HGVRGKDYKD DDDKLEVING
Notchl NRR-6His CRGKPCKNGG VCAVASNTAR GFICRCPAGF EGATCENDAR
TCGSLRCLNG GTCISGPRSP TCLCLGSFTG PECQFPASSP
CVGSNPCYNQ GTCEPTSENP FYRCLCPAKF NGLLCHILDY
SFTGGAGRDI PPPQIEEACE LPECQVDAGN KVCNLQCNNH
ACGWDGGDCS LNFNDPWKNC TQSLQCWKYF SDGHCDSQCN
SAGCLFDGFD CQLTEGQCNP LYDQYCKDHF SDGHCDQGCN
SAECEWDGLD CAEHVPERLA AGTLVLVVLL PPDQLRNNSF
HFLRELSHVL HTNVVFKRDA QGQQMIFPYY GHEEELRKHP
IKRSTVGWAT SSLLPGTSGG RQRRELDPMD IRGSIVYLEI
DNRQCVQSSS QCFQSATDVA AFLGALASLG SLNIPYKIEA
VKSEPVEPPL PSQGSGHHHH HH
15 FLAG-Human- KDDDDKGSGD VCPQMPCLNG GTCAVASNMP DGFICRCPPG FSGARCQSSC
Notch2-NRR- GQVKCRKGEQ CVHTASGPRC FCPSPRDCES GCASSPCQHG GSCHPQRQPP
YYSCQCAPPF SGSRCELYTA PPSTPPATCL SQYCADKARD GVCDEACNSH
6xHis ACQWDGGDCS LTMENPWANC SSPLPCWDYI NNQCDELCNT VECLFDNFEC
QGNSKTCKYD KYCADHFKDN HCNQGCNSEE CGWDGLDCAA DQPENLAEGT
LVIVVLMPPE QLLQDARSFL RALGTLLHTN LRIKRDSQGE LMVYPYYGEK
SAAMKKQRMT RRSLPGEQEQ EVAGSKVFLE IDNRQCVQDS DHCFKNTDAA
AALLASHAIQ GTLSYPLVSV VSESLTPERT EFGLVPRGSG HHHHHH
16 Mouse Notch2- ADVCPQKPCL NGGTCAVASN MPDGFICRCP PGFSGARCQS SCGQVKCRRG
NRR-FLAG EQCIHTDSGP RCFCLNPKDC ESGCASNPCQ HGGTCYPQRQ PPHYSCRCPP
SFGGSHCELY TAPTSTPPAT CQSQYCADKA RDGICDEACN SHACQWDGGD
CSLTMEDPWA NCTSTLRCWE YINNQCDEQC NTAECLFDNF ECQRNSKTCK
YDKYCADHFK DNHCDQGCNS EECGWDGLDC ASDQPENLAE GTLIIVVLLP
PEQLLQDSRS FLRALGTLLH TNLRIKQDSQ GALMVYPYFG EKSAAMKKQK
MTRRSLPEEQ EQEQEVIGSK IFLEIDNRQC VQDSDQCFKN TDAAAALLAS
HAIQGTLSYP LVSVFSELES PRNARRAGSG DYKDDDDKEN LYFQ
17 Human DLL1, MGSRCALALA VLSALLCQVW SSGVFELKLQ EFVNKKGLLG NRNCCRGGAG
rec ursor PPPCACRTFF RVCLKHYQAS VSPEPPCTYG SAVTPVLGVD SFSLPDGGGA
p
DSAFSNPIRF PFGFTWPGTF SLIIEALHTD SPDDLATENP ERLISRLATQ
RHLTVGEEWS QDLHSSGRTD LKYSYRFVCD EHYYGEGCSV FCRPRDDAFG
UniProtKB/Swiss- HFTCGERGEK VCNPGWKGPY CTEPICLPGC DEQHGFCDKP GECKCRVGWQ
Prot: 000548.2 GRYCDECIRY PGCLHGTCQQ PWQCNCQEGW GGLFCNQDLN YCTHHKPCKN
GATCTNTGQG SYTCSCRPGY TGATCELGID ECDPSPCKNG GSCTDLENSY
SCTCPPGFYG KICELSAMTC ADGPCFNGGR CSDSPDGGYS CRCPVGYSGF
NCEKKIDYCS SSPCSNGAKC VDLGDAYLCR CQAGFSGRHC DDNVDDCASS
PCANGGTCRD GVNDFSCTCP PGYTGRNCSA PVSRCEHAPC HNGATCHERG
HRYVCECARG YGGPNCQFLL PELPPGPAVV DLTEKLEGQG GPFPWVAVCA
GVILVLMLLL GCAAVVVCVR LRLQKHRPPA DPCRGETETM NNLANCQREK
DISVSIIGAT QIKNTNKKAD FHGDHSADKN GFKARYPAVD YNLVQDLKGD
DTAVRDAHSK RDTKCQPQGS SGEEKGTPTT LRGGEASERK RPDSGCSTSK
DTKYQSVYVI SEEKDECVIA TEV
18 Human DLL4, MAAASRSASG WALLLLVALW QQRAAGSGVF QLQLQEFINE RGVLASGRPC
EPGCRTFFRV CLKHFQAVVS PGPCTFGTVS TPVLGTNSFA VRDDSSGGGR
precursor
NPLQLPFNFT WPGTFSLIIE AWHAPGDDLR PEALPPDALI SKIAIQGSLA
VGQNWLLDEQ TSTLTRLRYS YRVICSDNYY GDNCSRLCKK RNDHFGHYVC
UniProtKB/Swiss- QPDGNLSCLP GWTGEYCQQP ICLSGCHEQN GYCSKPAECL CRPGWQGRLC
Prot: Q9NR61.1 NECIPHNGCR HGTCSTPWQC TCDEGWGGLF CDQDLNYCTH HSPCKNGATC
SNSGQRSYTC TCRPGYTGVD CELELSECDS NPCRNGGSCK DQEDGYHCLC
PPGYYGLHCE HSTLSCADSP CFNGGSCRER NQGANYACEC PPNFTGSNCE
KKVDRCTSNP CANGGQCLNR GPSRMCRCRP GFTGTYCELH VSDCARNPCA
HGGTCHDLEN GLMCTCPAGF SGRRCEVRTS IDACASSPCF NRATCYTDLS
TDTFVCNCPY GFVGSRCEFP VGLPPSFPWV AVSLGVGLAV LLVLLGMVAV
AVRQLRLRRP DDGSREAMNN LSDFQKDNLI PAAQLKNTNQ KKELEVDCGL
DKSNCGKQQN HTLDYNLAPG PLGRGTMPGK FPHSDKSLGE KAPLRLHSEK
PECRISAICS PRDSMYQSVC LISEERNECV IATEV
19 Human Frizzled7 MRDPGAAAPL SSLGLCALVL ALLGALSAGA GAQPYHGEKG ISVPDHGFCQ
PISIPLCTDI AYNQTILPNL LGHTNQEDAG LEVHQFYPLV KVQCSPELRF
(Fzd7), precursor
FLCSMYAPVC TVLDQAIPPC RSLCERARQG CEALMNKFGF QWPERLRCEN
FPVHGAGEIC VGQNTSDGSG GPGGGPTAYP TAPYLPDLPF TALPPGASDG
UniProtKB/Swiss- RGRPAFPFSC PRQLKVPPYL GYRFLGERDC GAPCEPGRAN GLMYFKEEER
Prot: 075084.2 RFARLWVGVW SVLCCASTLF TVLTYLVDMR RFSYPERPII FLSGCYFMVA
VAHVAGFLLE DRAVCVERFS DDGYRTVAQG TKKEGCTILF MVLYFFGMAS
SIWWVILSLT WFLAAGMKWG HEAIEANSQY FHLAAWAVPA VKTITILAMG
QVDGDLLSGV CYVGLSSVDA LRGFVLAPLF VYLFIGTSFL LAGFVSLFRI
RTIMKHDGTK TEKLEKLMVR IGVFSVLYTV PATIVLACYF YEQAFREHWE
115
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
RTWLLQTCKS YAVPCPPGHF PPMSPDFTVF MIKYLMTMIV GITTGFWIWS
GKTLQSWRRF YHRLSHSSKG ETAV
20 Human Frizzled8 MEWGYLLEVT SLLAALALLQ RSSGAAAASA KELACQEITV PLCKGIGYNY
(F d8) TYMPNQFNHD TQDEAGLEVH QFWPLVEIQC SPDLKFFLCS MYTPICLEDY
z , precursor
KKPLPPCRSV CERAKAGCAP LMRQYGFAWP DRMRCDRLPE QGNPDTLCMD
YNRTDLTTAA PSPPRRLPPP PPGEQPPSGS GHGRPPGARP PHRGGGRGGG
UniProtKB/Swiss- GGDAAAPPAR GGGGGGKARP PGGGAAPCEP GCQCRAPMVS VSSERHPLYN
Prot: Q9H461.1 RVKTGQIANC ALPCHNPFFS QDERAFTVFW IGLWSVLCFV STFATVSTFL
IDMERFKYPE RPIIFLSACY LFVSVGYLVR LVAGHEKVAC SGGAPGAGGA
GGAGGAAAGA GAAGAGAGGP GGRGEYEELG AVEQHVRYET TGPALCTVVF
LLVYFFGMAS SIWWVILSLT WFLAAGMKWG NEAIAGYSQY FHLAAWLVPS
VKSIAVLALS SVDGDPVAGI CYVGNQSLDN LRGFVLAPLV IYLFIGTMFL
LAGFVSLFRI RSVIKQQDGP TKTHKLEKLM IRLGLFTVLY TVPAAVVVAC
LFYEQHNRPR WEATHNCPCL RDLQPDQARR PDYAVFMLKY FMCLVVGITS
GVWVWSGKTL ESWRSLCTRC CWASKGAAVG GGAGATAAGG GGGPGGGGGG
GPGGGGGPGG GGGSLYSDVS TGLTWRSGTA SSVSYPKQMP LSQV
21 Human LRP5, MEAAPPGPPW PLLLLLLLLL ALCGCPAPAA ASPLLLFANR RDVRLVDAGG
precursor VKLESTIVVS GLEDAAAVDF QFSKGAVYWT DVSEEAIKQT YLNQTGAAVQ
NVVISGLVSP DGLACDWVGK KLYWTDSETN RIEVANLNGT SRKVLFWQDL
DQPRAIALDP AHGYMYWTDW GETPRIERAG MDGSTRKIIV DSDIYWPNGL
UniProtKB/Swiss- TIDLEEQKLY WADAKLSFIH RANLDGSFRQ KVVEGSLTHP FALTLSGDTL
Prot: 075197.2 YWTDWQTRSI HACNKRTGGK RKEILSALYS PMDIQVLSQE RQPFFHTRCE
EDNGGCSHLC LLSPSEPFYT CACPTGVQLQ DNGRTCKAGA EEVLLLARRT
DLRRISLDTP DFTDIVLQVD DIRHAIAIDY DPLEGYVYWT DDEVRAIRRA
YLDGSGAQTL VNTEINDPDG IAVDWVARNL YWTDTGTDRI EVTRLNGTSR
KILVSEDLDE PRAIALHPVM GLMYWTDWGE NPKIECANLD GQERRVLVNA
SLGWPNGLAL DLQEGKLYWG DAKTDKIEVI NVDGTKRRTL LEDKLPHIFG
FTLLGDFIYW TDWQRRSIER VHKVKASRDV IIDQLPDLMG LKAVNVAKVV
GTNPCADRNG GCSHLCFFTP HATRCGCPIG LELLSDMKTC IVPEAFLVFT
SRAAIHRISL ETNNNDVAIP LTGVKEASAL DFDVSNNHIY WTDVSLKTIS
RAFMNGSSVE HVVEFGLDYP EGMAVDWMGK NLYWADTGTN RIEVARLDGQ
FRQVLVWRDL DNPRSLALDP TKGYIYWTEW GGKPRIVRAF MDGTNCMTLV
DKVGRANDLT IDYADQRLYW TDLDTNMIES SNMLGQERVV IADDLPHPFG
LTQYSDYIYW TDWNLHSIER ADKTSGRNRT LIQGHLDFVM DILVFHSSRQ
DGLNDCMHNN GQCGQLCLAI PGGHRCGCAS HYTLDPSSRN CSPPTTFLLF
SQKSAISRMI PDDQHSPDLI LPLHGLRNVK AIDYDPLDKF IYWVDGRQNI
KRAKDDGTQP FVLTSLSQGQ NPDRQPHDLS IDIYSRTLFW TCEATNTINV
HRLSGEAMGV VLRGDRDKPR AIVVNAERGY LYFTNMQDRA AKIERAALDG
TEREVLFTTG LIRPVALVVD NTLGKLFWVD ADLKRIESCD LSGANRLTLE
DANIVQPLGL TILGKHLYWI DRQQQMIERV EKTTGDKRTR IQGRVAHLTG
IHAVEEVSLE EFSAHPCARD NGGCSHICIA KGDGTPRCSC PVHLVLLQNL
LTCGEPPTCS PDQFACATGE IDCIPGAWRC DGFPECDDQS DEEGCPVCSA
AQFPCARGQC VDLRLRCDGE ADCQDRSDEA DCDAICLPNQ FRCASGQCVL
IKQQCDSFPD CIDGSDELMC EITKPPSDDS PAHSSAIGPV IGIILSLFVM
GGVYFVCQRV VCQRYAGANG PFPHEYVSGT PHVPLNFIAP GGSQHGPFTG
IACGKSMMSS VSLMGGRGGV PLYDRNHVTG ASSSSSSSTK ATLYPPILNP
PPSPATDPSL YNMDMFYSSN IPATARPYRP YIIRGMAPPT TPCSTDVCDS
DYSASRWKAS KYYLDLNSDS DPYPPPPTPH SQYLSAEDSC PPSPATERSY
FHLFPPPPSP CTDSS
22 Human LRP6, MGAVLRSLLA CSFCVLLRAA PLLLYANRRD LRLVDATNGK ENATIVVGGL
EDAAAVDFVF SHGLIYWSDV SEEAIKRTEF NKTESVQNVV VSGLLSPDGL
precursor
ACDWLGEKLY WTDSETNRIE VSNLDGSLRK VLFWQELDQP RAIALDPSSG
FMYWTDWGEV PKIERAGMDG SSRFIIINSE IYWPNGLTLD YEEQKLYWAD
UniProtKB/Swiss- AKLNFIHKSN LDGTNRQAVV KGSLPHPFAL TLFEDILYWT DWSTHSILAC
Prot: 075581.2 NKYTGEGLRE IHSDIFSPMD IHAFSQQRQP NATNPCGIDN GGCSHLCLMS
PVKPFYQCAC PTGVKLLENG KTCKDGATEL LLLARRTDLR RISLDTPDFT
DIVLQLEDIR HAIAIDYDPV EGYIYWTDDE VRAIRRSFID GSGSQFVVTA
QIAHPDGIAV DWVARNLYWT DTGTDRIEVT RLNGTMRKIL ISEDLEEPRA
IVLDPMVGYM YWTDWGEIPK IERAALDGSD RVVLVNTSLG WPNGLALDYD
EGKIYWGDAK TDKIEVMNTD GTGRRVLVED KIPHIFGFTL LGDYVYWTDW
QRRSIERVHK RSAEREVIID QLPDLMGLKA TNVHRVIGSN PCAEENGGCS
HLCLYRPQGL RCACPIGFEL ISDMKTCIVP EAFLLFSRRA DIRRISLETN
NNNVAIPLTG VKEASALDFD VTDNRIYWTD ISLKTISRAF MNGSALEHVV
EFGLDYPEGM AVDWLGKNLY WADTGTNRIE VSKLDGQHRQ VLVWKDLDSP
RALALDPAEG FMYWTEWGGK PKIDRAAMDG SERTTLVPNV GRANGLTIDY
AKRRLYWTDL DTNLIESSNM LGLNREVIAD DLPHPFGLTQ YQDYIYWTDW
SRRSIERANK TSGQNRTIIQ GHLDYVMDIL VFHSSRQSGW NECASSNGHC
116
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
SHLCLAVPVG GFVCGCPAHY SLNADNRTCS APTTFLLFSQ KSAINRMVID
EQQSPDIILP IHSLRNVRAI DYDPLDKQLY WIDSRQNMIR KAQEDGSQGF
TVVVSSVPSQ NLEIQPYDLS IDIYSRYIYW TCEATNVINV TRLDGRSVGV
VLKGEQDRPR AVVVNPEKGY MYFTNLQERS PKIERAALDG TEREVLFFSG
LSKPIALALD SRLGKLFWAD SDLRRIESSD LSGANRIVLE DSNILQPVGL
TVFENWLYWI DKQQQMIEKI DMTGREGRTK VQARIAQLSD IHAVKELNLQ
EYRQHPCAQD NGGCSHICLV KGDGTTRCSC PMHLVLLQDE LSCGEPPTCS
PQQFTCFTGE IDCIPVAWRC DGFTECEDHS DELNCPVCSE SQFQCASGQC
IDGALRCNGD ANCQDKSDEK NCEVLCLIDQ FRCANGQCIG KHKKCDHNVD
CSDKSDELDC YPTEEPAPQA TNTVGSVIGV IVTIFVSGTV YFICQRMLCP
RMKGDGETMT NDYVVHGPAS VPLGYVPHPS SLSGSLPGMS RGKSMISSLS
IMGGSSGPPY DRAHVTGASS SSSSSTKGTY FPAILNPPPS PATERSHYTM
EFGYSSNSPS THRSYSYRPY SYRHFAPPTT PCSTDVCDSD YAPSRRMTSV
ATAKGYTSDL NYDSEPVPPP PTPRSQYLSA EENYESCPPS PYTERSYSHH
LYPPPPSPCT DSS
23 Anti-Notchl QVQLQQSGAE LMKPGASVKI SCKAAGYTMR GYWIEWIKQR PGHGLEWIGQ
antibody 52M51 ILPGTGRTNY NEKFKGKATF TADTSSNTAN MQLSSLTSED SAVYYCARFD
GNYGYYAMDY WGQGSSVTVS SA
heavy chain
variable region
24 52M51 light chain QAVVTQESAL TTSPGETVTL TCRSSTGAVT TSNYANWVQE KPDHLFTGLI
variable region GGTNNRAPGV PARFSGSLIG DKAALTITGA QTEDEAIYFC ALWYSNHWVF
GGGTKLTVLG
25 52M51H4L3 QVQLVQSGAE VKKPGASVKI SCKVSGYTLR GYWIEWVRQA PGKGLEWIGQ
heav chain ILPGTGRTNY NEKFKGRVTM TADTSTDTAY MELSSLRSED TAVYYCARFD
y
GNYGYYAMDY WGQGTTVTVS SA
variable region
26 52M51H4L3 light SGVDSQAVVT QEPSLTVSPG GTVTLTCRSS TGAVTTSNYA NWFQQKPGQA
chain variable PRTLIGGTNN RAPGVPARFS GSLLGGKAAL TLSGAQPEDE AEYYCALWYS
NHWVFGGGTK LTVLG
region
27 52M51 HVR-H1 RGYWIE
28 52M51 HVR-H2 QILPGTGRTNYNEKFKG
29 52M51 HVR-H3 FDGNYGYYAMDY
30 52M51 HVR-L1 RSSTGAVTTSNYAN
31 52M51 HVR-L2 GTNNRAP
32 52M51 HVR-L3 ALWYSNHWVFGGGTKL
33 Anti-Notch2/3 EVQLVESGGG LVQPGGSLRL SCAASGFTFS SSGMSWVRQA PGKGLEWVSV
anfibody59R5 IASSGSNTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARSI
FYTTWGQGTL VTVSS
heavy chain
variable region
34 59R5 light chain DIVLTQSPAT LSLSPGERAT LSCRASQSVR SNYLAWYQQK
PGQAPRLLIY
variable region GASSRATGVP ARFSGSGSGT DFTLTISSLE PEDFAVYYCQ QYSNFPITFG
QGTKVEIKR
35 59R5 HVR-H1 SSSGMS
36 59R5 HVR-H2 VIASSGSNTYYADSVK
37 59R5 HVR-H3 SIFYTT
38 59R5 HVR-L1 RASQSVRSNYL
39 59R5 HVR-L2 GASSRA
40 59R5 HVR-L3 QQYSNFPI
41 Anti-Notchl A-2 EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYWIHWVRQA
PGKGLEWVAR
antibod heavy INPPNRSNQY ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCARGS
y
GFRWVMDYWG QGTLVTVSS
chain variable
region
42 A-2 light chain DIQMTQSPSS LSASVGDRVT ITCRASQDVS TAVAWYQQKP
GKAPKLLIYS
variable region ASFLYSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ FYTTPSTFGQ
GTKVEIKR
43 A, A-1, A-2, A-3 GFTFSSYWIH
HVR-H1
44 A HVR-H2 ARINPSNGSTNYADSVKG
45 A-1 HVR-H2 ARINPSNGSAHYADSVKG
46 A-2 HVR-H2 ARINPSNRSNQYADSVKG
117
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
47 A-3 HVR-H2 ARINPSNGSTRYADSVKG
48 A, A-1, A-2, A- RGSGFRWVMDY
3HVR-H3
49 A, A-1, A-2, A- RASQDVSTAVA
3HVR-L1
50 A, A-1, A-2, A- SASFLYS
3HVR-L2
51 A HVR-L3 QQSYTTPPT
52 A-1 HVR-L3 QQSYTTPAT
53 A-2 HVR-L3 QQFYTTPST
54 A-3 HVR-L3 QQSFSTPAT
55 Anti-Notch2 D-3 EVQLVESGGG LVQPGGSLRL SCAASGYTFS SYGMSWVRQA
PGKGLEWVSY
antibody heavy IYPYSGATYY ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCARHS
GYYRISSAMD VWGQGTLVTV SA
chain variable
region
56 D-3 light chain DIQMTQSPSS LSASVGDRVT ITCRASQNIK RFLAWYQQKP
GKAPKLLIYG
variable region ASTRESGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YYRSPHTFGQ
GTKVEIKR
57 D HVR-Hl GYSFTSYGMS
58 D-1, D-2, D-3 GYTFSSYGMS
HVR-Hl
59 D, D-1, D-2, D-3 SYIYPYSGATYYADSVKG
HVR-H2
60 D, D-1, D-2, D-3 HSGYYRISSAMDV
HVR-H3
61 D HVR-Ll RASQSISSYLA
62 D-1 HVR-Li RASQSNRRFLA
63 D-2 HVR-Li RASQSVRSFLA
64 D-3 HVR-Ll RASQNIKRFLA
65 D, D-1 HVR-L2 GASSRAS
66 D-2 HVR-L2 RASIRAS
67 D-3 HVR-L2 GASTRES
68 D HVR-L3 QQYYSSPLT
69 D-1 HVR-L3 QQYYISPLT
70 D-2 HVR-L3 QQYYISPWT
71 D-3 HVR-L3 QQYYRSPHT
72 Anti-Notch3 NRR EVQLVESGGG LVQPGGSLKL SCAASGFTFS HYYMSWVRQT PEKRLEWVAY
256-A4 antibody ISNGGGRTDY PDSVKGRFTI SRDNAKNTLH LQMSSLKSED TAMYYCTRLD
YFGGSPYFDY WGQGTTLTVS SA
heavy chain
variable region
73 256-A4 light chain EIVLTQSPAI TAASLGQKVT ITCSASSSVS YMHWYQQKSG
TSPKPWIYEI
variable region SKLASGVPPR FSGSGSGTSY SLTISSMEAE DAAIYYCQQW NYPLITFGSG
TKLEIKRADA APTV
74 256-A4, 256-A8 GFTFSHYYMS
HVR-Hl
75 256-A4 HVR-H2 ISNGGGRTD
76 256-A8 HVR-H2 YINSGGGRTD
77 256-A4 HVR-H3 RLDYFGGSPYFDY
78 256-A8 HVR-H3 LDYYGGSPYFDY
79 256-A4, 256-A8 SASSSVSYMH
HVR-Li
80 256-A4, 256-A8 EISKLAS
HVR-L2
81 256-A4, 256-A8 QQWNYPLIT
HVR-L3
118
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
82 Anti-Notch3 SDVQLQESGP GLVKPSQSLS LTCSVTGYSI TSGYYWNWIR QFPGNKLEWM
255A-71 antibody GFISYDGSNN YNPSLKNRIS ITRDTSKNQF FLKLNSVTTE DTATFYCATL
YYDYDGNYFD YWGQGTTLTV SSA
heavy chain
variable region
83 255A-71 light CDIQMTQTTS SLSASLGDRV TISCRTSQDI SNYLNWYQQK PDGTVKLLIY
chain variable YTSRLHSGVP SRFSGSGSGT DYSLTISNLE QEDIATYFCQ QGNALPLTFG
PGTKLELKRA DAAPTV
region
84 255A-71 HVR- GYSITSGYYWNW
H1
85 255A-71 HVR-H2 ISYDGSNNYN
86 255A-71 HVR-H3 LYYDYDGNYFDY
87 255A-71 HVR-Li RTSQDISNYLN
88 255A-71 HVR-L2 YTSRLHS
89 255A-71 HVR-L3 QQGNALPT
90 Anti-Notch3 CQVQLQQSGD DLVKPGASVK LSCKASGYTF TSYWINWIKQ RPGQGLEWIG
255A-77 antibody HIGPGSGSTY YNEIFKGKAT LTVDTSSSTA YIQLSSLSSE DSAVYFCVLT
RYFYAMDYWG QGTSVTVSSA
heavy chain
variable region
91 255A-77 light DIVMTQSPSS LAVTAGEKVT MRCKSSQSLL WSVNQNNYLS WYQQKQGQPP
chain variable KLLIYGASIR ESWVPDRFTG SGSGTDFTLT ISNVHVEDLA VYYCQHNHGS
FLPLTFGAGT KLELKRADAA
region PTV
92 255A-77 HVR- GYTFTSYWIN
H1
93 255A-77 HVR-H2 HIGPGSGSTYYN
94 255A-77 HVR-H3 TRYFYAMDY
95 255A-77 HVR-Li KSSQSLLWSVNQNNYL
96 255A-77 HVR-L2 GAS IRES
97 255A-77 HVR-L3 QHNHGSFLPLT
98 Anti-Notch3 256- SQVQLQQSGA ELAKPGTSVK MACKASGYTF TTHWMNWVKQ RPGQGLEWIG
Al3 antibody TINPSNDFTD CNQKFKDKAI LTADKSSSTA YMQLSSLTSE DSAIYYCASG
LTARAWFAYW GQGTLVTVSA A
heavy chain
variable region
99 256-A13 light RATISCRASQ SVTTSNYSYM HWFQQKPGQP PKLLIKYASN LDSGVPARFS
chain variable GSGSGTDFTL NIHPVEEEDT ATFYCQHSWE IPYTFGGGTN LEIKRADAAP
TV
region
100 256-A13 HVR- GYTFTTHWMNW
H1
101 256-A13 HVR-H2 INPSNDFTDCN
102 256-A13 HVR-H3 TARAWFAY
103 256-A13 HVR-Ll RASQSVTTSNYSYMH
104 256-A13 HVR-L2 YASNLDSG
105 256-A13 HVR-L3 QHSWEIPYT
106 Anti-Jagged A-2 EVQLVESGGG LVQPGGSLRL SCAASGFTFS NYGIHWVRQA
PGKGLEWVGW
antibody heavy ITGNGGYSDY ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCARAG
SWFAYWGQGT LVTVSS
chain variable
region
107 Anti-Jagged A-2 DIQMTQSPSS LSASVGDRVT ITCRASQDVS TAVAWYQQKP
GKAPKLLIYS
antibody light ASFLYSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SYTTPPTFGQ
GTKVEIK
chain variable
region
108 Anti-Jagged A-2 GFTFSNYGIH
HVR-Hl
109 Anti-Jagged A-2 WITGNGGYSDYADSVKG
HVR-H2
119
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
110 Anti-Jagged A-2 AGSWFAY
HVR-H3
111 Anti-Jagged A-2 RASQDVSTAVA
HVR-L1
112 Anti-Jagged A-2 SASFLYS
HVR-L2
113 Anti-Jagged A-2 QQSYTTPPT
HVR-L3
114 Anti-Jagged B-3 EVQLVESGGG LVQPGGSLRL SCAASGFTFT SYDIHWVRQA
PGKGLEWVGG
antibody heavy ISPADGDTDY ANSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCARND
YDVRFVGSGM DYWGQGTLVT VSS
chain variable
region
115 Anti-Jagged B-3 DIQMTQSPSS LSASVGDRVT ITCRASQDVS TAVAWYQQKP
GKAPKLLIYS
antibody light ASFLYSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SFTAPPTFGQ
GTKVEIK
chain variable
region
116 Anti-Jagged B-3 GFTFTSYDIH
HVR-H1
117 Anti-Jagged B-3 GISPADGDTDYANSVKG
HVR-H2
118 Anti-Jagged B-3 NDYDVRFVGSGMDY
HVR-H3
119 Anti-Jagged B-3 RASQDVSTAVA
HVR-L1
120 Anti-Jagged B-3 SASFLYS
HVR-L2
121 Anti-Jagged B-3 QOSFTAPPT
HVR-L3
122 Anti-Jagged Cl EVQLVESGGG LVQPGGSLRL SCAASGFTFT NSDIHWVRQA
PGKGLEWVGG
antibody heavy ITPADGYTDY ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCARSY
WSSSPGSAFD YWGQGTLVTV SS
chain variable
region
123 Anti-Jagged Cl DIQMTQSPSS LSASVGDRVT ITCRASQDVS TAVAWYQQKP
GKAPKLLIYS
antibody light ASFLYSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SYISPSTFGQ
GTKVEIK
chain variable
region
124 Anti-Jagged Cl GFTFTNSDIH
HVR-H1
125 Anti-Jagged Cl GITPADGYTDYADSVKG
HVR-H2
126 Anti-Jagged Cl SYWSSSPGSAFDY
HVR-H3
127 Anti-Jagged Cl RASQDVSTAVA
HVR-L1
128 Anti-Jagged Cl SASFLYS
HVR-L2
129 Anti-Jagged Cl QQSYISPST
HVR-L3
130 Anti-Jagged 4D11 EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSS
antibody heavy IDPEGRQTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDI
GGRSAFDYWG QGTLVTVSS
chain variable
region
131 4D11 light chain DIQMTQSPSS LSASVGDRVT ITCRASQSIS SYLNWYQQKP
GKAPKLLIYA
variable region ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TVVAPPLFGQ
GTKVEIKR
120
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
132 Anti-Jagged 64R7 QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV
antibod heavy ISYDGSNKYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDK
y
YDIPDAFDIW GQGTLVTVSS
chain variable
region
133 64R7 antibody DIRMTQSPSS LSASVGDRVT ITCRASQGIS NDLAWYQQKP GKVPRLLIYA
light chain TSTLQSGVPS RFSGSGSATD FTLTISSLQP EDVATYYCQQ SYNAPITFGQ
GTRLEIK
variable region
134 64R7 HVR-H1 SYAMH
135 64R7 HVR-H2 VISYDGSNKYYADSVKG
136 64R7 HVR-H3 DKYDIPDAFDI
137 64R7 HVR-L1 RASQGISNDLA
138 64R7 HVR-L2 ATSTLQS
139 64R7 HVR-L3 QQSYNAPI
140 Anti-Jagged QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAA
133R0201 IYPDSSNKYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDK
YDIPDAFDIW GQGTLVTVS
antibody heavy
chain variable
region
141 Anti-Jagged DIRMTQSPSS LSASVGDRVT ITCRASQGIS NDLAWYQQKP GKVPRLLIYA
133R0201 TSTLQSGVPS RFSGSGSATD FTLTISSLQP EDVATYYCQQ SYNAPITFGQ
GTRLEIK
antibody light
chain variable
region
142 133R0201 HVR- SYAMH
H1
143 133R0201 HVR- AIYPDSSNKYYADSVKG
H2
144 133R0201 HVR- DKYDIPDAFDI
H3
145 133R0201 HVR- RASQGISNDLA
Li
146 133R0201 HVR- ATSTLQS
L2
147 133R0201 HVR- QQSYNAPT
L3
148 Anti-Jagged QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAA
133R0203 ISPEASNKYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDK
YDIPDAFDIW GQGTLVTVS
antibody heavy
chain variable
region
149 Anti-Jagged DIRMTQSPSS LSASVGDRVT ITCRASQGIS NDLAWYQQKP GKVPRLLIYA
133R0203 TSTLQSGVPS RFSGSGSATD FTLTISSLQP EDVATYYCQQ SYNAPITFGQ
GTRLEIK
antibody light
chain variable
region
150 133R0203 HVR- SYAMH
H1
151 133R0203 HVR- AISPEASNKYYADSVKG
H2
152 133R0203 HVR- DKYDIPDAFDI
H3
153 133R0203 HVR- RASQGISNDLA
Li
154 133R0203 HVR- ATSTLQS
121
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
L2
155 133R0203 HVR- QQSYNAPT
L3
156 Anti-Jagged QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAA
133R0205 IYPASSNKYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDK
YDIPDAFDIW GQGTLVTVS
antibody heavy
chain variable
region
157 Anti-Jagged DIRMTQSPSS LSASVGDRVT ITCRASQGIS NDLAWYQQKP GKVPRLLIYA
133R0205 TSTLQSGVPS RFSGSGSATD FTLTISSLQP EDVATYYCQQ SYNAPITFGQ
GTRLEIK
antibody light
chain variable
region
158 133R0205 HVR- SYAMH
H1
159 133R0205 HVR- AIYPASSNKYYADSVKG
H2
160 133R0205 HVR- DKYDIPDAFDI
H3
161 133R0205 HVR- RASQGISNDLA
Li
162 133R0205 HVR- ATSTLQS
L2
163 133R0205 HVR- QQSYNAPT
L3
164 Anti-Jagged QVQLKQSGAE LVRPGTSVKL SCKTSGYIFT SYWIHWVKQR SGQGLEWIAR
64M51 antibody IYPGIGSTYY NEKFKDKATL TADKSSSTAY MQLSSLKSED SAVYFCAKNG
GFFDYWGQGT TLTVSS
heavy chain
variable region
165 Anti-Jagged DIVLTQSPAS LAVSLGQRAT ISCRASESVD SYGNSFMHWY QQKPGQPPKL
64M51 antibody LIYRASNLES GIPARFSGSG SRTDFTLTIN PVEADDVATY YCQQSNEDPW
TFGGGTKLEI K
light chain
variable region
166 64M51 HVR-H1 SYNTH
167 64M51 HVR-H2 RIYPGIGSTYYNEKFKD
168 64M51 HVR-H3 NGGFFDY
169 64M51 HVR-L1 RASESVDSYGNSFMH
170 64M51 HVR-L2 RASNLES
171 64M51 HVR-L3 QQSNDPWT
172 Anti-Jagged QVQLQESGPG LVKPSGTLSL TCTVSGDSIS SSNWWSWVRQ PPGQGLEWIG
64R1B antibody EIFHGENTNY NPSLKSRVTI SVDKSKNQIS LNLTSATAAD TAVYYCARNP
GIGAAKFDSW GQGTLVTVSS
heavy chain
variable region
173 Anti-Jagged DIVMTQTPLS LSVTPGQPAS ISCKSSQSLL HSDGKTYLYW YLQKPGQPPQ
64R1B antibody LLIYEVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCMQHIDFP
FTFGQGTKLE IK
light chain
variable region
174 64R1B HVR-Hl SSNWWS
175 64R1B HVR-H2 EIFHGENTNYNPSLKS
176 64R1B HVR-H3 NPGIGAAKFDS
177 64R1B HVR-Ll KSSQSLLHSDGKTYLY
178 64M51 HVR-L2 EVSNRFS
179 64M51 HVR-L3 MQHIDFP
180 Anti-DLL4 EVQLVESGGG LVQPGGSLRL SCAASGFTFT DNWISWVRQA PGKGLEWVGY
122
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
antibody ISPNSGFTYY ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCARDN
YW26.82 heavy FGGYFDYWGQ GTLV
chain variable
region
181 YW26.82 light DIQMTQSPSS LSASVGDRVT ITCRASQDVS TAVAWYQQKP GKAPKLLIYS
chain variable ASFLYSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SYTGTVTFGQ
GTKVEIKR
region
182 YW26.82 HVR- GFTFTDNWIS
H1
183 YW26.82 HVR- GYISPNSGFTYYADSVKG
H2
184 YW26.82 HVR- VYYCARDNFGGYFDY
H3
185 YW26.82 HVR- RASQDVSTAVA
Li
186 YW26.82 HVR- SASFLYS
L2
187 YW26.82 HVR- QQSYTGTVT
L3
188 Anti-DLL4 QVQLVQSGAE VKKPGASVKI SCKASGYSFT AYYIHWVKQA PGQGLEWIGY
anfibod ISSYNGATNY NQKFKGRVTF TTDTSTSTAY MELRSLRSDD TAVYYCARDY
y
DYDVGMDYWG QGTLVTVSS
demcizumab
(OMP-21M18)
heavy chain
variable region
189 demcizumab light DIVMTQSPDS LAVSLGERAT ISCRASESVD NYGISFMKWF QQKPGQPPKL
chain variable LIYAASNQGS GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQQSKEVPW
TFGGGTKVEI K
region
190 demcizumab TAYYIH
HVR-H1
191 demcizumab YISSYNGATNYNQKFKG
HVR-H2
192 demcizumab RDYDYDVGMDY
HVR-H3
193 demcizumab RASESVDNYGISFMK
HVR-L1
194 demcizumab AASNQGS
HVR-L2
195 demcizumab QQSKEVPWTFGG
HVR-L3
196 aLRP6 EVQLVESGGG LVQPGGSLRL SCAASGFTFG YYYISWVRQA PGKGLEWVAE
YW211.31.62 ISPYSGSTYY ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCALRA
RPPIRLHPRG SVMDYWGQ
antibody heavy
chain variable
region
197 aLRP6 DIQMTQSPSS LSASVGDRVT ITCRASQDVS TAVAWYQQKP GKAPKLLIYS
YW211.31.62 ASFLYSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SYTTPPTFGQ
GTKVEIKR
light chain
variable region
198 aLRP6 YYYIS
YW211.31.62
HVR-H1
199 aLRP6 EISPYSGSTYYADSVKG
YW211.31.62
123
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
HVR-H2
200 aLRP6 RARPPIRLHPRGSV
YW211.31.62
HVR-H3
201 aLRP6 RASQDVSTAVA
YW211.31.62
HVR-L1
202 aLRP6 SASFLYS
YW211.31.62
HVR-L2
203 aLRP6 QQSYTTPPT
YW211.31.62
HVR-L3
204 aLRP6 YW210.09 EVQLVESGGG LVQPGGSLRL SCAASGFTFT NSYIHWVRQA PGKGLEWVGW
antibod heavy ITPYGGYTNY ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCARGS
y
GHVNAVKNYG YVMDYWGQ
chain variable
region
205 aLRP6 YW210.09 DIQMTQSPSS LSASVGDRVT ITCRASQDVS TAVAWYQQKP GKAPKLLIYS
light chain ASFLYSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SYTTPPTFGQ
GTKVEIKR
variable region
206 aLRP6 YW210.09 NSYI
HVR-H1
207 aLRP6 YW210.09 WITPYGGYTNYADSVK
HVR-H2
208 aLRP6 YW210.09 GSGHVNAVKNYGYV
HVR-H3
209 aLRP6 YW210.09 RASQDVSTAVA
HVR-L1
210 aLRP6 YW210.09 SASFLYS
HVR-L2
211 aLRP6 YW210.09 QQSYTTPPT
HVR-L3
212 aLRP5 P6C.51.61 EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVSR
ISSNGGSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARWI
antibody heavy
PQSYPFASYK SGFDYWGQ
chain variable
region
213 aLRP5 P6C.51.61 DIQMTQSPSS LSASVGDRVT ITCRASQVMG YYLAWYQQKP GKAPKLLIYD
light chain ASSLESGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YYSYPFTFGQ
GTKVEIKR
variable region
214 aLRP5 P6C.51.61 GFTFSSYAMH
HVR-H1
215 aLRP5 P6C.51.61 SR ISSNGGSTYY ADSVKG
HVR-H2
216 aLRP5 P6C.51.61 WIPQSYPFASYK SGFDY
HVR-H3
217 aLRP5 P6C.51.61 RASQVMG YYLA
HVR-L1
218 aLRP5 P6C.51.61 DASSLES
HVR-L2
219 aLRP5 P6C.51.61 QQ YYSYPFT
HVR-L3
220 aLRP 7E5C8 QVQLKESGPG LVASSQSLSI TCTVSGFSLS RYSVHWVRQP PGKGLEWLGM
antibod heavy IWGGGSTDYN SALKSRLGIS KDNSKSQVFL KMNSLQTDDT AMYYCAGTGS
y
WFAYWGQGTL VTVSA
chain variable
124
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
region
221 aLRP antibody DIQMTQSPAS LSASVGETVT ITCRASGNIH NYLAWYQQKQ GKSPQLLVYN
7E5C8 light chain AKTLADGVPS RFSGSGSGTQ YSLKINSLQP EDFGSYYCQH FWSTPWTFGG
GTKLEIK
variable region
222 Anti-Fzd antibody EVQLVESGGG LVQPGGSLRL SCAASGFTFS HYTLSWVRQA
PGKGLEWVSV
Vantict umab ISGDGSYTYY ADSVKGRFTI SSDNSKNTLY LQMNSLRAED TAVYYCARNF
IKYVFANWGQ GTLVTVSS
(18R5) heavy
chain variable
region
223 Vantictumab light DIELTQPPSV SVAPGQTARI SCSGDNIGSF YVHWYQQKPG
QAPVLVIYDK
chain variable SNRPSGIPER FSGSNSGNTA TLTISGTQAE DEADYYCQSY ANTLSLVFGG
GTKLTVLG
region
224 Vantictumab GFTFSHYTLS
HVR-H1
225 Vantictumab VISGDGSYTYYADSVKG
HVR-H2
226 Vantictumab NFIKYVFAN
HVR-H3
227 Vantictumab SGDNIGSFYVH
HVR-L1
228 Vantictumab DKSNRPSG
HVR-L2
229 Vantictumab QSYANTLSL
HVR-L3
230 Anti-Fzd antibody EVQLVESGGG LVQPGGSLRL SCAASGFTFS SFNMFWVRQA
PGKGLEWVAG
B9L9.3 heavy IDDDGSYPNY GSAVKGRATI SRDNSKNTLY LQMNSLRAED TAVYYCAKSG
YGGSWGGYIA DDIDAWGQGT LVTVSS
chain variable
region
231 B9L9.3 light chain ELTQPPSVSV SPGQTARITC SGDGSYAGSY YYGWYQQKPG
QAPVTLIYYN
variable region NKRPSGIPER FSGSLSGSTN TLTISGVQAE DEADYYCGSA DNSGAAFGGG
TKLTVL
232 B9L9.3 HVR-H1 SFNMF
233 B9L9.3 HVR-H2 GIDDDGSYPNYGSAVKG
234 B9L9.3 HVR-H3 SGYGGSWGGYIADDIDA
235 B9L9.3 HVR-L1 SGDGSYAGSYYYG
236 B9L9.3 HVR-L2 YNNKRPS
237 B9L9.3 HVR-L3 GSADNSGAA
238 Fzd7 ECD CQPISIPLCT DIAYNQTILP NLLGHTNQED AGLEVHQFYP LVKVQCSPEL
RFFLCSMYAP VCTVLDQAIP PCRSLCERAR QGCEALMNKF GFQWPERLRC
ENFPVHGAGE IC
239 Fzd8 ECD CQEITVPLCK GIGYNYTYMP NQFNHDTQDE AGLEVHQFWP LVEIQCSPDL
KFFLCSMYTP ICLEDYKKPL PPCRSVCERA KAGCAPLMRQ YGFAWPDRMR
CDRLPEQGNP DT
240 54F28 Fzd8-Fc ASAKELACQE ITVPLCKGIG YNYTYMPNQF NHDTQDEAGL EVHQFWPLVE
IQCSPDLKFF LCSMYTPICL EDYKKPLPPC RSVCERAKAG CAPLMRQYGF
AWPDRMRCDR LPEQGNPDTL CMDYNRTDLT TEPKSSDKTH TCPPCPAPEL
LGGPSVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV
HNAKTKPREE QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK
TISKAKGQPR EPQVYTLPPS RDELTKNQVS LTCLVKGFYP SDIAVEWESN
GQPENNYKTT PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN
HYTQKSLSLS PGK
241 Anti-Notch QVQLQQSGAE LMKPGASVKI SCKATGYTFS NYWMEWVKQR PGHGLEWIGE
N248A antibody ILPGRGRTNY NENFKGKATF TADTSSNTVY MQLNSLTSED SAVYYCARFH
SSAYYYTMDY WGQRTSVTVS S
heavy chain
variable region
242 N248A antibody QAVVTQESAL TTSPGETVTL TCRSSTGAVT TSNYANWVQE
KPDHLFTGLI
li ht chain GGTNNRAPGI PARFSGSLIG DKAALTITGA QTEDEAIYFC ALWYSNHWVF
g
GGGTKLTVL
125
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
variable region
243 N248A HVR-H1 NYWME
244 N248A HVR-H2 EILPGRGRTNYNENFK
245 N248A HVR-H3 FHSSAYYYTMDY
246 N248A HVR-L1 RSSTGAVTTSNYAN
247 N248A HVR-L2 GTNNRAP
248 N248A HVR-L3 ALWYSNHWV
249 Anti-DLL/VEGF QVQLVQSGAE VKKPGASVKI SCKASGYSFT AYYIHWVKQA PGQGLEWIGY
219R45-MB- ISNYNRATNY NQKFKGRVTF TTDTSTSTAY MELRSLRSDD TAVYYCARDY
DYDVGMDYWG QGTLVTVSS
21R83 heavy
chain variable
region (anti-DLL
arm)
250 219R45-MB- DIVMTQSPDS LAVSLGERAT ISCRASESVD NYGISFMKWF QQKPGQPPKL
21R83 light chain LIYAASNQGS GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQQSKEVPW
TFGGGTKVEI K
variable region
(anti-DLL arm)
251 219R45-MB- TAYYIH
21R83 HVR-H1
252 219R45-MB- YISNYNRATNYNQKFK
21R83 HVR-H2
253 219R45-MB- RDYDYDVGMDY
21R83 HVR-H3
254 219R45-MB- RASESVDNYGISFMK
21R83 HVR-L1
255 219R45-MB- AASNQGS
21R83 HVR-L2
256 219R45-MB- QQSKEVPWTFGG
21R83 HVR-L3
257 decoy Wnt MEWGYLLEVT SLLAALAVLQ RSSGAAAASA KELACQEITV PLCKGIGYNY
TYMPNQFNHD TQDEAGLEVH QFWPLVEIQC SPDLKFFLCS MYTPICLEDY
receptor, KKPLPPCRSV CERAKAGCAP LMRQYGFAWP DRMRCDRLPE QGNPDTLCMD
Frizzled 8 CRD YNRTDLESGG GGVTDKTHTC PPCPAPELLG GPSVFLFPPK PKDTLMISRT
(FZD8CRD) PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL
TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE
EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL
YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K
258 J1-183D HVR-H1 DYAIH
sequence
259 J1-183D_VH and NTYYGDSKYNQKFKD
VH_l HVR-H2
sequence
260 J1-183D_VH_2, NTYYGDSKYAQKFQG
VH_3, and VH_4
HVR-H2 sequence
261 J1-183D HVR-H3 GYDGFAY
sequence
262 J1-183D HVR-L1 RTSENIYSYLT
sequence
263 J1-183D_VL and NAKILAAGV
_VL_1 HVR-L2
sequence
264 J1-183D_VL_2 NAKTLASGV
HVR-L2 sequence
265 J1-183D_VL_3 NAKILDSGV
HVR-L2 sequence
266 J1-183D_VL_4 HAKILDSGV
126
CA 02952315 2016-12-13
WO 2016/007775 PCT/US2015/039790
HVR-L2 sequence
267 J1-183D HVR-L3 QHHYD I PWT
sequence
268 J1-183D_VL light MSVP TQVLGL LL LWLTDARCD I QL TQSPAS LSASVGETVTF
TCRTSEN IYSYLT
chain sequence WYQQKQGKSPQL LVYNAK I LAAGVPSRF SGYGSGTQF S LK
INSLQPEDFGTYYC
QHHYD I PWTF GGGTKLE IKRT
269 J1-183D_VL_1 light MSVP TQVLGL LL LWLTDARCD I QMTQSP SS LSASVGDRVT I
TCRTSEN IYSYLT
chain sequence WYQQKPGKAPKL LVYNAK I LAAGVPSRF SGSGSGTDFTLT I S
SLQPEDFATYYC
QHHYD I PWTF GGGTKLE IKRT
270 J1-183D_VL_2 light MSVP TQVLGL LL LWLTDARCD I QMTQSP SS LSASVGDRVT I
TCRTSEN IYSYLT
chain sequence WYQQKPGKAPKLL I YNAKTLASGVPSRF SGSGSGTDFTL
T I SS LQPE DFATYYCQHHYD IPWTFGGGTKLE IKRT
271 J1-183D_VL_ 3 MSVP TQVLGL LL LWLTDARCD I QMTQSP SS LSASVGDRVT I
TCRTSEN IYSYLT
light chain sequence WYQQKPGKAPKLL I YNAK I L DSGVPSRF SGSGSGTDFTLT I S
SLQPEDFATYYC
QHHYD I PWTF GGGTKLE IKRT
272 J1-183D_VL_4 light MSVP TQVLGL LL LWLTDARCD I QMTQSP SS LSASVGDRVT I
TCRTSEN IYSYLT
chain sequence WYQQKPGKAPKLL I YHAK I L DSGVPSRF SGSGSGTDFTLT I S
SLQPEDFATYYC
QHHYD I PWTF GGGTKLE IKRT
273 J1-183D_VH heavy MEWSWVFLFF LSVT TGVHSQVQLQQPGTELVRPGVSVK I SCKVSGYAF
TDYAIH
chain sequence WIMQSHAKSLEWIG I INTYYGDSKYNQKFKDKATMTVDKS SNTAYMELARLT
SE
DSAIYYCARGYDGFAYWGQGTLVTVSSASTKGP
274 J1-183D_VH_1 MEWSWVFLFFLSVTTGVHSQVQLVQSGAELKKPGASVKVSCKVSGYAF TDYAIH
heavy chain WI RQAPGQGLEWMG I INTYYGDSKYNQKFKDRVTMTVDKS TS TAYMEL SS
LRSE
sequence DTAVYYCARGYDGFAYWGQGTLVTVS SAS TKGP
275 J1-183D_VH_2 MEWSWVFLFFLSVTTGVHSQVQLVQSGAELKKPGASVKVSCKVSGYAF TDYAIH
heavy chain WI RQAPGQGLEWMG I INTYYGDSKYAQKFQGRVTMTVDTS TS TAYMEL SS
LRSE
sequence DTAVYYCARGYDGFAYWGQGTLVTVS SAS TKGP
276 J1-183D_VH_3 MEWSWVFLFFLSVTTGVHSQVQLVQSGAELKKPGASVKVSCKVSGYAF TDYAIH
heavy chain WVRQAPGQGLEWMG I INTYYGDSKYAQKFQGRVTMTVDTS TS TAYMEL SS
LRSE
sequence DTAVYYCARGYDGFAYWGQGTLVTVS SAS TKGP
277 J1-183D_VH_4 MEWSWVFLFFLSVTTGVHSQVQLVQSGAEVKKPGASVKVSCKASGYTF TDYAIH
heavy chain WVRQAPGQGLEWMG I INTYYGDSKYAQKFQGRVTMTVDTS TS TAYMEL SS
LRSE
sequence DTAVYYCARGYDGFAYWGQGTLVTVS SAS TKGP
278 J1-65D HVR-Hl DYEMH
279 J1-65D_VH and QPGGGGTAYNQKFKG
VH_l HVR-H2
280 J1-65D_VH_2 QPGGGGTAYAQKFKG
HVR-H2
281 J1-65D_VH_3 and QPGGGGTAYAQKFQG
VH_4 HVR-H2
282 J1-65D HVR-H3 RGYDDYPFAY
283 J1-65D_VL, VL_1, RASGNIHNYLA
VL_2, and VL_3
HVR-L1
284 J1-65D_VL_4 RASQGIHNYLA
HVR-L1
285 J1-65D_VL HVR- NAKTLADD I
L2
286 J1-65D_VL_1 NAKTLADDV
HVR-L2
287 J1-65D_VL_2, NAKTLADAV
VL_3, and VL_4
HVR-L2
288 J1-65D_VL, VL_1, QHFWSAPWT
VL_2, and VL_3
HVR-L3
289 J1-65D_VL_4 QQFWSAPWT
HVR-L3
290 J1-65D_VL MSVP TQVLGL LL LWLTDARCD I QLQSPASL SASVGE TVT I
TCRASGNIHNYLAW
light chain sequence YQQKQGKSPQLLVYNAKTLADD IP SRF SGSGSGTQYSLKINS LQPE DF GS
YYCQ
HFWSAPWTFGGGTKLE IKRT
127
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
291 J1-65D_VL_1 light
MSVPTQVLGLLLLWLTDARCDIQMTQSPSSLSASVGDRVTITCRASGNIHNYLA
chain sequence WYQQKPGKAPKLLIYNAKTLADDVPSRFSGSGSGTDYTLTISSLQPEDFATYYC
QHFWSAPWTFGGGTKLEIKRT
292 J1-65D_VL_2 light
MSVPTQVLGLLLLWLTDARCDIQMTQSPSSLSASVGDRVTITCRASGNIHNYLA
chain sequence WYQQKPGKAPKLLIYNAKTLADAVPSRFSGSGSGTDYTLTISSLQPEDFATYYC
QHFWSAPWTFGGGTKLEIKRT
293 J1-65D_VL_31ight MSVPTQVLGLLLLWLTDARCDIQMTQSPSSLSASVGDRVTITCRASGNIHNYLA
chain sequence WYQQKPGKAPKLLIYNAKTLADAVPSRFSGSGSGTDYTLTISSLQPEDFATYYC
QHFWSAPWTFGQGTKLEIKRT
294 J1-65D_VL_ 4 light
MSVPTQVLGLLLLWLTDARCDIQMTQSPSSLSASVGDRVTITCRASQGIHNYLA
chain sequence WYQQKPGKAPKLLIYNAKTLADAVPSRFSGSGSGTDYTLTISSLQPEDFATYYC
QQFWSAPWTFGQGTKLEIKRT
295 J1-65D_VH heavy
MEWSWVFLFFLSVTTGVHSQVQLQQPGAELVRPGASVKLSCKALGYTFTDYEMH
chain sequence WVKETPVHGLEWIGAIQPGGGGTAYNQKFKGKATLTADKSSSTAYMELSSLTSE
DSAVYYCTRRGYDDYPFAYWGQGTLVTVSSASTKGP
296 J1-65D_VH_1 MEWSWVFLFFLSVTTGVHSQVQLVQSGAELKKPGSSVKVSCKASGYTFTDYEMH
heavy chain WVRQAPGQGLEWMGAIQPGGGGTAYNQKFKGRVTLTADKSTSTAYMELSSLRSE
sequence DTAVYYCTRRGYDDYPFAYWGQGTLVTVSSASTKGP
297 J1-65D_VH_2 MEWSWVFLFFLSVTTGVHSQVQLVQSGAELKKPGSSVKVSCKASGYTFTDYEMH
heavy chain WVRQAPGQGLEWMGAIQPGGGGTAYAQKFKGRVTLTADKSTSTAYMELSSLRSE
sequence DTAVYYCTRRGYDDYPFAYWGQGTLVTVSSASTKGP
298 J1-65D_VH_3 MEWSWVFLFFLSVTTGVHSQVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEMH
heavy chain WVRQAPGQGLEWMGAIQPGGGGTAYAQKFQGRVTLTADKSTSTAYMELSSLRSE
sequence DTAVYYCTRRGYDDYPFAYWGQGTLVTVSSASTKGP
299 J1-65D_VH_ 4 MEWSWVFLFFLSVTTGVHSQVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEMH
heavy chain WVRQAPGQGLEWMGAIQPGGGGTAYAQKFQGRVTITADKSTSTAYMELSSLRSE
sequence DTAVYYCTRRGYDDYPFAYWGQGTLVTVSSASTKGP
300 131R010 HVR H1 KASGYTFT DYS
301 131R010 HVR H2 IYPSNGDS
302 131R010 HVR H3 ATYF ANNFDY
303 131R010FIVRL1 QSVD YDGDSYM
304 131R010FIVRL2 AASNLES
305 131R010FIVRL3 QQSNEDPLT
306 131R010 heavy QVQLVQSGAE VKKPGASVKV SCKASGYTFT DYSIHWVRQA PGQGLEWIGY
chain variable IYPSNGDSGY NQKFKNRVTM TRDTSTSTAY MELSRLRSED TAVYYCATYF
region ANNFDYWGQG TTLTVSS
307 131R010 light chain DIQMTQSPSS LSASVGDRVT ITCKASQSVD YDGDSYMNWY
QQKPGKAPKL
variable region LIYAASNLES GVPSRFSGSG SGTDFTLTIS PVQAEDFATY YCQQSNEDPL
TFGAGTKLEL KRT
308 89M5 HVR-H1 TGYTMH
309 89M5 HVR-H2 GINPNNGGTTYNQNFKG
310 89M5 HVR-H3 KEFSDGYYFFAY
311 89M5 HVR-L1 KASQDVIFAVA
312 89M5 HVR-L2 WASTRHT
313 89M5 HVR-L3 QQHYSTPW
314 89M5 heavy chain EVQLQQSGPE LVKPGASVKI SCKTSGYTFT GYTMHWVRQS
HGKTLEWIGG
variable region INPNNGGTTY NQNFKGKATL TVEKSSTTAY LELRSLTSED SALYYCARKE
FSDGYYFFAY WGQGTLVTVS A
315 89M5 light chain DIVMTQSHKF MSTSVGDRVN ITCKASQDVI FAVAWYQQKP
GQSPKLLIYW
variable region ASTRHTGVPD RFTGSVSGTD YTLTISSVQA EDLALYYCQQ HYSTPWTFGG
GTKLEIK
316 130M23 HVR-H1 SSYAMS
317 130M23 HVR-H2 SISSGGSTYYPDSVKG
318 130M23 HVR-H3 RGGDPGVYNGDYEDAMDY
319 130M23 HVR-L1 KASQDVSSAVA
320 130M23 HVR-L2 WASTRHT
321 130M23 HVR-L3 QQHYSTP
322 130M23 heavy EVKLVESGGG LVKPGGSLKF SCAASGFSFS SYAMSWVRQT PEKRLEWVAS
chain variable ISSGGSTYYP DSVKGRFTIS RDNVRNILYL QMSSLASEDT AMYFCARGGD
region PGVYNGDYED AMDYWGQGTS VTVSS
128
CA 02952315 2016-12-13
WO 2016/007775
PCT/US2015/039790
323 130M23 light chain DIVMTQSHKF MSTSVGDRVS ITCKASQDVS SAVAWYQQKP
GQSPKLLIYW
variable region ASTRHTGVPD RFTNSGSGTD YTLTISSVQA EDLALYYCQQ HYSTPWTFGG
GTKLEIK
129
